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Cardiovascular disease is the leading cause of death worldwide. In 2012, an estimated 
18.2 million people died from cardiovascular diseases (ischemic heart disease, stroke and 
hypertensive heart disease), representing 30% of all global deaths.1 With increasing age, 
mortality from cardiovascular disease increases exponentially (Figure 1).2-4 Moreover, as 
populations age due to worldwide population growth and increasing longevity, annual 
cardiovascular disease mortality is projected to raise even further.5
In the Netherlands, on average, 57 women and 50 men die every day from cardio-
vascular diseases: 32 (56%) of these women and 15 (30%) of these men are aged 85 years 
and older.6 The majority of cardiovascular deaths in old age is caused by ischemic heart 
disease in men and stroke and heart failure in women.6 The greatest amount of cardio-
vascular mortality took place in the 1970s and since then, cardiovascular mortality has 
declined.7 Between 1980 and 2012, the standardized mortality rate decreased by 43% 
in men and women aged 85 years and over.6 The decline in fatality rates reflects the 
improvements in treatment strategies in the past decades. More people (both young 
and old), will continue to survive their acute cardiovascular event. As a result, there is 
a projected increase in prevalence of cardiovascular disease over the coming decades, 
especially for coronary heart disease. This also applies for other common diseases in old 
age, such as diabetes and osteoarthritis (Figure 2).
However, this increase in survival rates of acute cardiovascular events is also asso-
ciated with a loss of functional status and quality of life. Disability-adjusted life-years 
(DALYs) reflect the ‘burden of disease’. It is a time-based measure that combines years 
of life lost due to premature mortality and years of life lost due to time lived in a state of 



































Figure 1. Number of cardiovascular (CV) and non-cardiovascular (non-CV) deaths per 100,000 persons in 




den of disease resulting in 282,834 DALYs, compared to 194,312 DALYs for diabetes and 
123,509 DALYs for osteoarthritis (Figure 2).9,10 From age 65 years onward, cardiovascular 
disease causes the highest number of DALYs, followed by cancer.11
In conclusion, cardiovascular disease has a large impact in old age and will probably 
have an even greater impact in the future.
Prevention oF CardiovasCular disease in old age
Prevention of cardiovascular disease aims to prevent the development of cardiovascular 
disease in individuals without a history of cardiovascular disease (primary prevention), 
and recurrences and complications in those with established disease (secondary 
prevention). Besides advice concerning a healthy lifestyle (such as smoking cessation, 
healthy diet, weight control and exercise), a regimen of statins, blood pressure-lowering 
and antiplatelet agents (the latter only in secondary prevention) may significantly re-
duce the risk of death from cardiovascular disease in people at high cardiovascular risk. 
Eligible for prevention are those with a 10-year cardiovascular risk equal to or above 
20%, and those who have survived a previous cardiovascular event.12,13
There is evidence that blood pressure-lowering agents and statins, although less 
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Figure 2. Predicted increase in prevalence and impact of the five most common diseases in the Dutch 
population between 2010 and 2030
Source: Ned Tijdschr Geneeskd. 2014;158:A78198 and Nationaal Kompas Volksgezondheid9
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prevention of (especially) stroke and heart failure in persons aged 80 years and over.14 
Statin therapy is safe and effective in older people to reduce the risk for cardiovascular 
events, whereas no effect was found on all-cause mortality.15 However, no clinical trials 
have addressed the prevention of coronary events using statins in people aged 85 years 
and older.16
When taking into account the current threshold to start preventive medication in 
individuals with a 10-year cardiovascular (absolute) risk equal or above 20%, then vir-
tually all persons aged 75 years and over are eligible for preventive medication when 
applying traditional risk scores, i.e. the age-related absolute risk. This means that older 
people may be prescribed preventive medication based on predominantly age-related 
absolute risk. Indeed, some have suggested that preventive cardiovascular treatment 
should be offered to everyone over a specified age, without measuring other risk 
factors.17 Others have different opinions and suggest, for example, to start preventive 
medication in persons with the highest relative risk.
The evidence that i) preventive medication is beneficial up to old age on the one 
hand, and that ii) adverse drug-drug interactions and potential clinically significant 
adverse effects lead to poorer quality of life on the other, can argue both in favour and 
also against starting preventive cardiovascular medication in old age. This dilemma was 
reflected by the debate in the Journal of American Geriatric Society regarding whether 
or not to start statin therapy.18,19 Either way, physicians are often reluctant to start pre-
ventive medication in order to avoid either polypharmacy or overmedication, not only 
in apparently healthy older people but also in vulnerable older people.
CardiovasCular risk PrediCtion in old age
To help physicians decide whether to advise preventive medication to their older pa-
tients, prediction of those at highest or lowest (relative) risk is of pivotal importance. 
This also emphasizes the need for risk stratification in old age. Relatively easy methods 
to distinguish high-risk patients from low-risk patients may, therefore, contribute to 
better targeting of preventive strategies of cardiovascular disease in old age.
The most important independent predictor for cardiovascular disease is age: as we 
get older, our risk of cardiovascular disease increases.20 Increasing age is a proxy for 
the aging process of the body, including blood vessels and organs such as the heart. 
In middle age, many other risk predictors for cardiovascular disease are known, such as 
high blood pressure, high cholesterol level, smoking, obesity and a history of diabetes, 
all of which are very common.21-24
Chapter 1
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Cardiovascular risk models in old age
Because the risk for cardiovascular disease is considered to be multifactorial, risk factors 
are considered in conjunction when developing clinical risk scores. Clinical cardiovas-
cular risk scores, such as the Framingham Risk Score25 and the Systematic Coronary Risk 
Evaluation (SCORE),26 are used worldwide to select those at high cardiovascular risk.
Their accuracy to predict risk of cardiovascular outcomes declines with advancing 
age, because the individual risk predictors have a different predictive value in old age 
compared to middle age.27-32 Between age 70 and 80 years, classical cardiovascular risk 
factors appear to reverse their association with clinical outcomes, such that they no 
longer predict adverse events but, rather, predict good health outcomes. High blood 
pressure, high cholesterol and obesity are no longer risk factors for mortality and, in 
some studies, are even associated with better survival in old age.27-32 These paradoxical 
observations have also been referred to as ‘reverse epidemiology’, ‘inverse epidemiol-
ogy’ or ‘risk factor paradox’. Therefore, in older people, established classic risk factors 
and corresponding risk scores (e.g. the Framingham Risk Score and the SCORE risk func-
tion) do not qualify for adequate risk prediction. The Leiden 85-plus Study showed that 
the Framingham Risk Score in no way predicts cardiovascular risk in persons aged 85 
years and over.33
Emerging cardiovascular risk factors
In old age there is a lack of good cardiovascular risk predictors, as the classical cardiovas-
cular risk factors tend to lose their predictive value. Therefore, there is a need to identify 
new cardiovascular risk factors. In addition, the classical cardiovascular risk factors age, 
current cigarette smoking, hypertension, family history of premature coronary heart 
disease, low high density lipoprotein (HDL) levels and high low density lipoprotein (LDL) 
levels, when present, cannot explain the total variation in cardiovascular risk. Other 
factors, yet to be identified, might also influence cardiovascular risk. There has been 
intensive research to identify new cardiovascular risk factors in middle age, in order to 
improve cardiovascular risk prediction. These so-called ‘emerging risk factors’34 can be 
divided into serological biomarkers, and (imaging) tests for subclinical atherosclerotic 
disease.
1. Serological emerging risk factors
Little is known about the use of serological emerging risk factors in old age. Much 
research has focused on predominantly middle-aged populations. Several lipid risk 
factors have been studied in middle-aged adults. Lipoprotein(a) has an independent 
predictive power to predict coronary heart disease risk.35 However, several prospec-
tive studies do not confirm this independent prediction.36 Although apolipoprotein B 
13
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has been proposed as an alternative to LDL cholesterol as a risk factor, there is limited 
evidence to support this additional value on cardiovascular risk prediction.37 Low apo-
lipoprotein A-I is associated with an increased cardiovascular risk, but the independent 
predictive power of apolipoprotein A-I remains unclear.37,38 Inflammatory markers such 
as C-reactive protein, interleukin-6 and lipoprotein-associated phospholipase A2 have 
been studied as separate markers, but also in combination with other emerging risk 
factors. In older persons, lipoprotein-associated phospholipase A2 is a potential bio-
marker for vascular events.39 C-reactive protein was included in multiple risk models and 
found to be one of the best predictors of cardiovascular events among the emerging 
risk factors in middle age.40,41 A higher level of high sensitivity C-reactive protein is as-
sociated with higher cardiovascular risk; however, it minimally enhances cardiovascular 
disease prediction beyond established vascular risk factors in older age.42 This might be 
explained by the decreasing predictive value of C-reactive protein with age.43,44 Several 
hemostatic/thrombosis factors are associated with coronary heart disease risk in middle 
age. For example, a high level of fibrinogen associates with increased risk for coronary 
events.45,46 Other hemostatic/thrombosis factors have been mentioned, such as tissue 
plasminogen activator, D-dimer, von Willebrand factor, factor V Leiden and protein C.46 
Sensitive troponin T, a marker for myocardial damage, is associated with cardiovascular 
events both in men and women.41 However, the evidence in old age is lacking for most 
of these factors. Moderately elevated amino acid homocysteine levels are associated 
with increased risk of first,47,48 as well as recurrent myocardial infarction.49 It has also 
been shown that homocysteine is predictive of cardiovascular events in old age.33,50 
Recent study showed that high homocysteine levels not only identify older persons 
at high risk for coronary heart disease and mortality, but also identify those with the 
highest absolute risk reduction by statin treatment and the lowest number needed to 
treat to prevent coronary heart disease.51 It is unknown whether there is an underlying 
biological pathway to explain the predictive value of homocysteine. Evidently, risk pre-
diction based on homocysteine is valid up to high age. However, general practitioners 
(or physicians in general) might be reluctant to order a blood test for homocysteine 
since the causal relationship between homocysteine and cardiovascular disease is not 
clear for moderately elevated homocysteine levels. The neuro-humoral factor N-terminal 
pro-brain natriuretic peptide (NT-proBNP) is also a strong predictor in risk models with 
emerging risk factors in middle age.40,41 NT-proBNP might also be relevant in cardiovas-
cular risk prediction in old age. Therefore, NT-proBNP might be a promising serological 
marker in old age.
2. (Imaging) tests for subclinical atherosclerotic disease
Advanced subclinical atherosclerotic disease is associated with a greater risk for major 
coronary events, up to the very old. The ankle-brachial blood pressure index is a simple 
Chapter 1
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and non-invasive test to confirm lower extremity peripheral arterial disease. A lower 
ankle-brachial blood pressure index is associated with a higher risk of mortality in old 
age.52 Imaging techniques are also used to test for atherosclerotic plaque burden, in-
cluding the coronary calcium score53 and carotid artery intima media thickness.54 The 
calcium score can be useful in cardiovascular risk prediction; a score of zero excludes 
coronary artery disease. Because atherosclerosis increases with age, the likelihood a 
person has a low calcium score decreases with advancing age. Therefore, use of the 
calcium score in older patients (>65 years) is generally not recommended.55 The sever-
ity of the intimal medial thickness of the carotid arteries correlates with risk for major 
coronary events.56
In conclusion, for many of the emerging risk factors the association with cardiovas-
cular disease has been studied, both separately and in combination.40,41,46,57,58 However, 
their optimal use in routine screening and risk stratification, especially in old age, remains 
to be determined. In addition, many of these new risk factors, especially the imaging 
techniques, are costly and time consuming, and not easily available in primary care. 
Moreover, use of the calcium score is generally not recommended in old age. Therefore, 
we could argue that cardiovascular risk prediction in old age, especially in primary care, 
should be based on easily accessible risk predictors.
Promising ways to PrediCt CardiovasCular risk in old age
Blood pressure measurements; single versus multiple measurements
Average (systolic) blood pressure is part of all cardiovascular risk scores used in daily 
practice25,26,59-61 and considered to be the key or most important blood pressure mo-
dality when determining risk of cardiovascular disease. Although these risk scores 
are validated for people up to age 65-75 years, in daily practice they are also applied 
to older people. However, until now, data on the association between blood pres-
sure and mortality in very old age are conflicting.28,29,62-64 In a large meta-analysis of 
observational data from 61 studies,62 both high systolic and diastolic blood pressure 
were independently predictive of cardiovascular mortality (stroke and coronary heart 
disease) in all age groups. However, this association attenuated considerably with age. 
In contrast, observational studies in exclusively very older populations have shown 
that low, and not high blood, pressure is associated with increased mortality in very 
old age.28,29,63,64 Besides mortality, low blood pressure is also associated with morbidity, 
such as a decreased cognitive function,65 decreased renal function,66 grip strength67 
and increased depressive and anxiety symptoms.68,69 Thus, in very old age, low blood 
pressure changes from a favorable to an unfavorable predictive factor. The etiological 
mechanisms behind this association are not yet completely unravelled.
15
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Systolic blood pressure rises with age until age 75 years,28,70 then decreases in very old 
age.28,63,70,71 Although a decreasing trend in systolic blood pressure in very old age is 
associated with an increased mortality risk, data from these studies are not consis-
tent.28,63,70-72 There is limited information about the clinical significance and predictive 
value of decreasing systolic blood pressure in the individual over time
Blood pressure not only rises with age up to the very old, it also varies over time 
within individuals, resulting in variability in blood pressure.73,74 Studies in middle-aged 
persons suggest that this variability in blood pressure (assessed across multiple visits) 
is itself a predictor of incident cardiovascular disease75-77 and may have an important 
additional role in increasing the risk of vascular events, in particular stroke. In addition, 
the adverse effects of variability in blood pressure may extend beyond stroke. In a 
population-based study of adults in the USA, higher levels of visit-to-visit variability in 
systolic blood pressure was associated with increased all-cause mortality.76
It is still unknown whether the use of multiple blood pressure measurements ex-
pressed in the trends or variability in blood pressure have any clinical significance in old 
age with regard to prediction of mortality and morbidity. Selection of high risk blood 
pressure patterns in old age could be an important and easily available step in the suc-
cessful prediction of mortality and cardiovascular morbidity in this age group.
N-terminal pro-brain natriuretic peptide
Ventricular myocytes release prohormone pro-brain natriuretic peptide (BNP) in reac-
tion to ventricular wall stress and hypoxia.78,79 Pro-BNP is then split into the active BNP 
and inactive NT-proBNP. NT-proBNP is known to increase with age, even in the absence 
of heart failure or cardiovascular disease,80 and is mainly cleared through renal excre-
tion.81 NT-proBNP is a diagnostic sensitive, but not highly specific, biomarker for heart 
failure, but also a prognostic marker for incident cardiovascular morbidity and mortal-
ity in middle-aged82,83 and older persons.84,85 Also, it was part of multiple panels of 
biomarkers tested to improve risk stratification for (death from) cardiovascular disease 
beyond risk stratification on a model based only on established risk factors, mainly in a 
middle-aged population.41,46,57 However, the optimal use of NT-proBNP in risk stratifica-
tion in old age remains to be determined.
In conclusion, in cardiovascular risk prediction in old age there is a need for inex-
pensive and easy to use risk factors that not only distinguish high-risk from low-risk 




aim and outline oF this thesis
Aim
The general aim of this thesis is to study classical and new cardiovascular risk predic-
tors in old age, in order to optimize risk stratification and subsequent prevention of 
cardiovascular disease in older persons.
Study populations
PROspective Study of Pravastatin in the Elderly at Risk (PROSPER)
The PROspective Study of Pravastatin in the Elderly at Risk (PROSPER) is a randomized, 
double-blind, placebo-controlled trial, designed to investigate the effect of pravastatin 
in prevention of vascular events in older persons. Between December 1997 and May 1999 
a total of 5804 individuals were screened and enrolled in Scotland, Ireland and the Neth-
erlands. Men and women aged 70-82 years were recruited if they had either pre-existing 
vascular disease (including stable angina, intermittent claudication, stroke, transient isch-
emic attack, myocardial infarction, and vascular surgery) or raised risk of such disease be-
cause of one or more major cardiovascular risk factors, defined as hypertension, cigarette 
smoking, or diabetes mellitus. Individuals with poor cognitive function (Mini-Mental State 
Examination score <24 points) were excluded. The primary outcome of the study was the 
combined endpoint of definite or suspected death from coronary heart disease, non-fatal 
myocardial infarction, and fatal or non-fatal stroke during a mean follow-up of 3.2 years. 
At baseline, and every 3 months thereafter, participants were reviewed with a maximum 
follow-up of 4 years. A 12-lead electrocardiogram was recorded annually. Cognition tests 
and disability assessment were assessed every year.
Leiden 85-plus Study
The Leiden 85-plus Study is a population based prospective follow-up study. All inhabit-
ants of the city of Leiden, the Netherlands, turning 85 years old between September 
1997 and September 1999 were invited to participate. Of the 705 people that were eli-
gible to participate in the study, a total of 599 (87%) people gave informed consent and 
were enrolled. No exclusion criteria were used. Participants were visited at baseline and 
yearly thereafter by a research nurse at their place of residence until the age of 90 was 
reached or the participant died. During these visits, information on sociodemographic 
characteristics was collected and participants underwent face-to-face interviews, blood 
samples were drawn, and biometrical measurements and electrocardiography were 
taken. The participant’s general practitioner (or, if applicable, nursing home physician) 
was interviewed annually about the participant’s medical history, and the pharmacist 
provided detailed information on all medication used by each participant. Mortality 
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data were obtained from the municipal registry. Causes of death were classified into 
standardized ICD10 codes based on complete death certificates.
Brief description of chapters
This thesis is divided in two parts.
Part 1 Multiple blood pressure measurements in cardiovascular risk prediction in old age
Chapters 2 and 3 focus on visit-to-visit blood pressure variability. Chapter 2 describes 
the association between visit-to-visit variability in blood pressure and cardiovascular 
disease in older persons in the PROSPER study. In Chapter 3 an attempt was made to 
identify biological factors associated with visit-to-visit variability in blood pressure 
to help elucidate the biological mechanisms underlying high levels of visit-to-visit-
variability in blood pressure in older persons.
Chapters 4 and 5 focus on blood pressure trends. Chapter 4 describes whether the 
absence or presence of heart failure influences the prognostic value of low systolic 
blood pressure with regard to mortality in the oldest old in the Leiden 85-plus Study. 
There is limited information about the clinical significance of decreasing systolic blood 
pressure in the individual over time. Therefore, in Chapter 5, the association between 
blood pressure trends and mortality in the oldest old is investigated.
Part 2 N-terminal pro-brain natriuretic peptide levels in cardiovascular risk prediction in 
old age
The second part of this thesis focuses on the use of NT-proBNP levels in older patients 
as a prognostic instrument for cardiovascular mortality and morbidity, and evaluates 
the added value of NT-proBNP in the prediction of treatment effect in old age. The use 
of NT-proBNP in the prediction of the treatment effect in secondary prevention is evalu-
ated in Chapter 6. Chapter 7 describes whether an increase in NT-proBNP levels over 
time is still associated with cardiac disease and mortality in very old age and the effect 
of the change in renal function on this association.
By addressing these questions, this thesis will contribute to improved clinical 
management of cardiovascular risk in old age. In addition, the studies can contribute 
to adequate communication regarding cardiovascular risks and treatment benefits, and 
shared decision-making between physicians (general practitioners) and patients by 
providing evidence-based information on cardiovascular risk factors and the predicted 
treatment effect. In this way, this thesis will contribute to the prevention of one of the 
most important diseases worldwide with its related high disease burden and mortality 
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Variability in blood pressure predicts cardiovascular disease in young- and middle-aged 
subjects, but relevant data for older individuals are sparse. We analysed data from the 
PROspective Study of Pravastatin in the Elderly at Risk (PROSPER) study of 5804 partici-
pants aged 70–82 years with a history of, or risk factors for cardiovascular disease. Visit-to-
visit variability in blood pressure (standard deviation) was determined using a minimum 
of five measurements over 1 year; an inception cohort of 4819 subjects had subsequent 
in-trial 3 years follow-up; longer-term follow-up (mean 7.1 years) was available for 1808 
subjects. Higher systolic blood pressure variability independently predicted long-term 
follow-up vascular and total mortality (hazard ratio per 5 mmHg increase in standard 
deviation of systolic blood pressure = 1.2, 95% confidence interval 1.1–1.4; hazard ratio 1.1, 
95% confidence interval 1.1–1.2, respectively). Variability in diastolic blood pressure asso-
ciated with increased risk for coronary events (hazard ratio 1.5, 95% confidence interval 
1.2–1.8 for each 5 mmHg increase), heart failure hospitalisation (hazard ratio 1.4, 95% 
confidence interval 1.1–1.8) and vascular (hazard ratio 1.4, 95% confidence interval 1.1–1.7) 
and total mortality (hazard ratio 1.3, 95% confidence interval 1.1–1.5), all in long-term 
follow-up. Pulse pressure variability was associated with increased stroke risk (hazard 
ratio 1.2, 95% confidence interval 1.0–1.4 for each 5 mmHg increase), vascular mortal-
ity (hazard ratio 1.2, 95% confidence interval 1.0–1.3) and total mortality (hazard ratio 
1.1, 95% confidence interval 1.0–1.2), all in long-term follow-up. All associations were 
independent of respective mean blood pressure levels, age, gender, in-trial treatment 
group (pravastatin or placebo) and prior vascular disease and cardiovascular disease risk 
factors. Our observations suggest variability in diastolic blood pressure is more strongly 
associated with vascular or total mortality than is systolic pressure variability in older 
high-risk subjects.
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introduCtion
In daily practice and all major clinical guidelines,1-5 ‘usual’ or average blood pressure is 
considered to be the key or most important measure determining risk of cardiovascular 
disease (CVD); reductions in average blood pressure are generally thought to account 
for the benefits of antihypertensive drugs.1-9 However, recently Rothwell et al.10 has ques-
tioned the usual blood-pressure hypothesis, suggesting that visit-to-visit variability in 
blood pressure (assessed across multiple visits) may have an important additional role 
in increasing risk of vascular events, and in particular stroke. Visit-to-visit variability in 
blood pressure is increased in cohorts at high risk of stroke.11,12 A secondary analysis of 
several randomised controlled trials found that visit-to-visit variability in systolic blood 
pressure and episodic hypertension were strong predictors of stroke, independent of 
mean systolic blood pressure.13 In addition the adverse effects of variable blood pres-
sure may stretch beyond stroke. In a population-based study of US adults, higher levels 
of visit-to-visit variability in systolic blood pressure were associated with increased 
all-cause mortality.14
However the risks associated with visit-to-visit variability of blood pressure in older 
age are less clear; some investigators have suggested such associations with visit-to-
variability in systolic blood pressure may decrease with advancing age.13 Therefore, we 
aimed to establish whether visit-to-visit variability in blood pressure in older patients 
is associated with increased risk of incident CVD. We performed an analysis of the PRO-
spective Study of Pravastatin in the Elderly at Risk (PROSPER) cohort.15
methods
Study design
Details of the design and outcome of PROSPER have been Published elsewhere.15-17 
Between December 1997 and May 1999 a total of 5804 individuals were screened and 
enrolled in Scotland, Ireland and the Netherlands. Men and women aged 70–82 years 
were recruited if they had either pre-existing vascular disease (coronary, cerebral, or 
peripheral) or raised risk of such disease because of smoking, hypertension or diabetes. 
Plasma total cholesterol was required to be 4.0–9.0 mmol/L and triglyceride concen-
trations  ≤6.0 mmol/L. Individuals with poor cognitive function (Mini-Mental State 
Examination score <24 points) were excluded. The level of blood pressure was not part 
of the inclusion or exclusion criteria. The institutional ethics review boards of all centres 
approved the protocol and all participants gave written informed consent. The protocol 




Sitting blood pressure was measured once at baseline and at follow-up visits every three 
months during the randomised phase of the trial (mean follow-up 3.2 years) with a fully 
automatic electronic sphygmomanometer (Omron M4®) by trained research nurses.
Outcomes and follow-up
The outcomes for this study were incidence of cardiovascular events, including definite 
or suspected death from coronary heart disease or non-fatal myocardial infarction 
(CHD/MI), fatal or non-fatal stroke, heart failure hospitalisation, vascular mortality and 
total mortality.
All in-trial endpoints were assessed by the PROSPER Endpoints Committee, which 
was blinded to study medication. For this study the in-trial outcomes occurring over a 
maximum of 3 years (mean 2.3 years), following one year of blood pressure observations 
(i.e. five blood pressure measurements) were analysed. This follow-up was considered 
‘short-term’.
Routine health data on morbidity and mortality for the Scottish sub-group (in-
cluding post-trial follow-up) were obtained from the Information Services Division, 
a division of National Services Scotland, part of National Health Service Scotland. The 
data obtained included the Scottish Morbidity Records (SMR) - SMR00 outpatient at-
tendances; SMR01 general acute inpatient and day case discharges; SMR04 psychiatric 
admissions, residents and discharges; SMR06 cancer registrations, and General Register 
Office for Scotland death registrations. The outcomes for the Scottish sub-group were 
followed up over a maximum of 9.3 years (mean 7.1), following two years of blood pres-
sure observations (with nine blood pressure measurements). This was considered the 
‘long-term follow-up’.
Statistical analysis
Baseline summary characteristics are reported as means with standard deviations (SD) 
for continuous variables and as numbers with percentage (%) for categorical variables. 
Variability of blood pressure was quantified using the standard deviation (SD) and the 
coefficient of variation (SD/mean; CV). The results for SD and CV were qualitatively the 
same; therefore the results for SD are presented. F-tests were used to test the difference 
in blood pressure variability between participants receiving pravastatin and those re-
ceiving placebo. The association of visit-to-visit variability in blood pressure in relation 
to the different endpoints was assessed separately for short- and long-term follow-up, 
the latter restricted to the Scottish sub-cohort. For short-term follow-up blood pressure 
variability was calculated from measurements made at visits 1 to 5 (0–12 months). In 
the Scottish sub-cohort which, in addition, has longer-term follow-up, blood pressure 
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variability was calculated from measurements made from visit 1 to 9 (0–24 months). 
Participants who had a CVD event during the blood pressure variability measurement 
period (0–12 months for short-term follow-up and 0–24 months for long-term follow-
up) were excluded from relevant analysis. Participants with one or more missing blood 
pressure measurements, including those who died during the blood pressure vari-
ability measurement period, were excluded from the analyses. The agreement in blood 
pressure variability was assessed for the short-term inception cohort by analysing the 
Spearman Rank Correlation between the first three blood pressure measurements and 
the last two measurements. For the long-term Scottish sub-cohort, agreement in blood 
pressure variability was assessed by analysing the Spearman Rank Correlation between 
the first five blood pressure measurements and the last four measurements.
The associations between measures of blood pressure variability and time to oc-
currence of clinical outcomes were assessed using Cox proportional hazards models. 
Measures of blood pressure variability used were standard deviations and these were 
split into quarters of their distributions and hazard ratios (HRs) and corresponding 95% 
confidence intervals were calculated in relation to the lowest quarter of SD (referent); 
homogeneity across the quartiles was assessed using a general test of heterogeneity.
Analyses were adjusted for country (short-term analyses only), randomized treat-
ment group (pravastatin or placebo) and the respective mean blood pressure measure 
during the period blood pressure variability was assessed (mean systolic blood pressure 
for systolic blood pressure variability; mean diastolic blood pressure for diastolic blood 
pressure variability and mean pulse pressure for pulse pressure variability) (Model 1). 
A second model (Model 2) included additional adjustment for age, gender, smoking 
status, and prior histories of diabetes, hypertension, cardiovascular disease, cerebro-
vascular disease or peripheral vascular disease, as well as body mass index (BMI), high 
density lipoprotein cholesterol (HDL) and low density lipoprotein cholesterol (LDL). The 
results for Models 1 and 2 were qualitatively the same; therefore the results for Model 2 
are presented in the main tables.
We performed a number of sensitivity analyses, including using continuous values 
of the blood pressure variability measurements to evaluate the influence of the split-
ting the blood pressure variability measurements by quartiles. In this case continuous 
measures of variability of blood pressure were reported as HRs per 5 mmHg increase 
in SD of systolic and diastolic blood pressure and pulse pressure. HRs for one SD differ-
ence in baseline blood pressure, mean blood pressure and blood pressure variability, 
for systolic and diastolic blood pressure and pulse pressure were calculated. Further 
subgroup analyses were conducted for gender, the use of antihypertensive medication 
at baseline, baseline blood pressure above and below the median and for patients with/




Of the initial cohort of 5804 PROSPER participants, 5054 were alive and had a full blood 
pressure profile up to 12 months (five measurements); 235 of these participants were 
excluded from analyses as having had a CVD event during this period, giving 4819 
participants as an inception cohort to be included in the short-term (in trial) follow-
up analyses (Figure 1). For the long-term follow-up (including post-trial) analyses only 
the Scottish sub-cohort was eligible (n =2520); 625 of these participants were excluded 





























Assessment of eligibility 
n=23770 





Not included or refused n=16714 
Not included or refused n=1252  
Exclusion participants with events in the 
measurement period (0-12 months) n=235 
Missing full blood pressure profile  
(0-12 months) n=750  
Short-term (in trial) follow-
up n=4819 
Long-term follow-up  
n= 1808 
Missing long-term follow-up 
data (i.e. Ireland and the 
Netherlands) n=3284 
Missing full blood pressure 
profile n=625 
Exclusion participants with 
events in the measurement 
period (0-24 months) n=87 
Figure 1. Flow chart
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ments); an additional 87 of these participants were excluded as they had a CVD event 
during this period, giving 1808 Scottish participants to be included in the inception 
cohort for the long-term follow-up analyses (Figure 1).
Table 1 presents the baseline characteristics for the participants in the short- and 
long-term follow-up. Of the 4819 participants in the short-term follow-up 2339 (48.5%) 
were men, the mean age was 75.2 years (SD 3.3) and 2086 (43.3%) had a history of cardio-
vascular disease. Of the 1808 participants in the long-term follow-up 876 (48.5%) were 
men, the mean age was 75.2 years (SD 3.4) and 865 (47.8%) had a history of cardiovascular 
disease.
We initially examined whether there was a difference in variability in blood pressure 
between participants receiving pravastatin and those receiving placebo. There was 
no significant difference for short-term and long-term follow up, systolic and diastolic 




Long-term (Scottish sub-cohort) 
(n=1808)
Continuous variates (mean, SD)
Age (years) 75.2 (3.3) 75.2 (3.4)
Systolic blood pressure (mmHg) 154.7 (21.6) 153.7 (20.8)
Diastolic blood pressure (mmHg) 83.9 (11.4) 82.9 (10.8)
Pulse pressure (mmHg) 70.8 (18.1) 70.9 (17.7)
Body mass index (kg/m2) 26.9 (4.2) 26.8 (4.1)
Alcohol (units per week)* 5.3 (9.4) 4.6 (8.2)
Total cholesterol (mmol/L) 5.7 (0.9) 5.7 (1.0)
Low-density lipoprotein cholesterol (mmol/L) 3.8 (0.8) 3.8 (0.8)
High-density lipoprotein cholesterol (mmol/L) 1.3 (0.4) 1.3 (0.4)
Triglycerides (mmol/L) 1.5 (0.7) 1.6 (0.7)
Mini-Mental State Examination (pts) 28.1 (1.5) 28.3 (1.4)
Barthel index (pts) 13.7 (1.0) 13.8 (0.8)
Instrumental activities of daily-living (pts) 19.8 (0.7) 19.8 (0.6)
Categorical variates (n, %)
Men 2339 (48.5) 876 (48.5)
Current smoker 1262 (26.2) 472 (26.1)
History of diabetes mellitus 492 (10.2) 144 (8.0)
History of hypertension 3016 (62.6) 1077 (59.6)
History of cardiovascular disease† 2086 (43.3) 865 (47.8)
SD Standard deviation.
*1 unit = 60 ml distilled spirits, 170 ml wine or 300 ml beer.
†Any of stable angina, intermittent claudication, stroke, transient ischemic attack, myocardial infarction, peripheral arte-
rial disease surgery, or amputation for vascular disease more than 6 months before study entry.
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blood pressure and pulse pressure (range of p-values 0.288–0.868); therefore, data from 
both groups were combined; however all subsequent analyses were adjusted for ran-
domized treatment group because of the effect of the pravastatin on CVD outcomes.
Blood pressure variability was reproducible for short-term and long-term follow 
up, for systolic and diastolic blood pressure and pulse pressure (p-value <0.0001). The 
Spearman Rank Correlation was higher when more blood pressure measurements were 
added in the model.
Visit-to-visit variability in systolic blood pressure
Across the first five blood pressure measurements in the short-term follow-up cohort 
the mean SD for variability of systolic blood pressure was 13.6 mmHg. The mean SD 
for variability of systolic blood pressure across the first nine blood pressure measure-
ments in the long-term follow-up cohort was 14.1 mmHg. Table 2 shows the results of 
the time-to-event analyses for the different quartiles of SD of systolic blood pressure for 
all endpoints in the short-term and long-term follow-up.
In the long-term follow-up, risk of vascular and total mortality increased across 
quartiles for SD of systolic blood pressure in the fully adjusted model. SD of systolic 
blood pressure per 5 unit change (mmHg) was associated with coronary events (HR 1.1, 
95% CI 1.0–1.3); vascular mortality (HR 1.2, 95% CI 1.1–1.4) and total mortality (HR 1.1, 95% 
CI 1.1– 1.2) in the long-term follow-up. The predictive value of visit-to-visit variability in 
systolic blood pressure was similar in all subgroup analyses, including in participants 
with and without the use of antihypertensive medication (data not shown).
Visit-to-visit variability in diastolic blood pressure
Across the first five measurements in the whole cohort the mean SD of diastolic blood 
pressure was 7.3 mmHg. The mean SD of diastolic blood pressure across the first nine 
measurements in the Scottish sub-cohort was 7.4 mmHg. Table 3 shows the results of 
the time-to-event analyses for the different quartiles of diastolic blood pressure for all 
endpoints in the short-term and long-term follow-up. In both short-term and long-term 
follow-up, high visit-to-visit variability in diastolic blood pressure was associated with 
increased risk of coronary events, heart failure hospitalisation and vascular and total 
mortality. The HRs for heart failure hospitalization and coronary events in the long-term 
follow-up were 1.9 (95% CI 1.3–2.8) for the highest quarter versus lowest quarter of SD of 
diastolic blood pressure and 1.8 (95% CI 1.3–2.6), respectively in the fully adjusted model 
(Table 3). SD of diastolic blood pressure per 5 unit change (mmHg) predicted coronary 
events (HR 1.1, 95% CI 1.0–1.3) and heart failure hospitalization (HR 1.3, 95% CI 1.1–1.6) in 
the short-term follow-up. In the long-term follow-up SD of diastolic blood pressure per 
5 unit change predicted coronary events (HR 1.5, 95% CI 1.2–1.8); heart failure hospitalisa-
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tion (HR 1.4, 95% CI 1.1–1.8); vascular mortality (HR 1.4, 95% CI 1.1–1.7) and total mortality 
(HR 1.3, 95% CI 1.1– 1.5).
Variability in diastolic blood pressure was more predictive for coronary events in male 
participants (p for interaction = 0.008) and for vascular mortality in male participants 
and participants with systolic blood pressure below median (p for interaction = 0.043 
and 0.028, respectively) in long-term follow-up.

















































































































































Data are presented as Hazard Ratios and 95% Confidence Intervals.
Adjustment for randomized treatment, country (short-term follow-up only), mean systolic blood pressure, age, gender, 
current smoker, histories of diabetes, hypertension, cardiovascular disease, cerebrovascular disease & peripheral vascular 
disease, body mass index, high-density lipoprotein and low-density lipoprotein.
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Visit-to-visit variability in pulse pressure
Across the first five measurements in the whole cohort the mean SD of pulse pressure 
was 12.2 mmHg. Across the first nine measurements in the Scottish sub-cohort the mean 
SD of pulse pressure was 12.6 mmHg.
Table 4 shows the results of the time-to-event analyses for the different quartiles of 
pulse pressure for all endpoints in the short-term and long-term follow-up. In the short-
term follow-up, there was no association between the SD of pulse pressure and the risk 
of CVD events or mortality. In the long-term follow-up, high visit-to-visit variability in 

















































































































































Data are presented as Hazard Ratios and 95% Confidence Intervals.
Adjustment for randomized treatment, country (short-term follow-up only), mean diastolic blood pressure, age, gender, 
current smoker, histories of diabetes, hypertension, cardiovascular disease, cerebrovascular disease & peripheral vascular 
disease, body mass index, high-density lipoprotein and low-density lipoprotein.
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pulse pressure was associated with increased risk of stroke (HR for the highest quartile 
versus lowest quartile 1.6, 95% CI 1.1–2.4); vascular and total mortality (HR 1.3, 95% CI 
1.0–1.8 and HR 1.3, 95% CI 1.1–1.6 respectively). When the analyses were repeated for the 
continuous values of pulse pressure, SD of pulse pressure per 5 unit change (mmHg) 
predicted stroke (HR 1.2, 95% CI 1.0–1.4), vascular mortality (HR 1.2, 95% CI 1.0–1.3) and 
total mortality (HR 1.1, 95% CI 1.0–1.2) in the long-term follow-up. Variability in pulse 
pressure was more predictive for total mortality in participants with systolic blood pres-
sure below the median (p for interaction =0.024).
table 4. Hazard Ratio’s for the endpoints associated with quartiles of the standard deviation (SD) of pulse 
pressure
Short-term follow-up (n=4819)












































































































































Data are presented as Hazard Ratios and 95% Confidence Intervals.
Adjustment for randomized treatment, country (short-term follow-up only), mean pulse pressure, age, gender, current 
smoker, histories of diabetes, hypertension, cardiovascular disease, cerebrovascular disease & peripheral vascular disease, 




Table 5 shows the result of the analyses with one SD difference in baseline, mean and 
variability in blood pressure in the long-term Scottish cohort. One SD difference in 
baseline systolic and diastolic blood pressure, but not pulse pressure, was associated 
with an increased risk of stroke. One SD difference in mean systolic and diastolic blood 
pressure and pulse pressure was associated with an increased risk of stroke.
One SD difference in variability in systolic and diastolic blood pressure predicted an 
increased risk of vascular and total mortality, but was not associated with an increased 
risk of stroke.
In the analyses with one SD difference in baseline, mean and variability in blood 
pressure in the short-term follow-up cohort, one SD difference in variability in diastolic 
blood pressure predicted an increased risk in coronary events and heart failure hos-
pitalisation (HR 1.11, 95% CI 1.01–1.21 and 1.20, 95% CI 1.05–1.38, respectively), no other 
associations were found (data not shown).
disCussion
This study shows that in older subjects visit-to-visit variability in systolic blood pressure, 
diastolic blood pressure and pulse pressure are associated with an increased long-term 
risk for cardiovascular and total mortality. In addition variability in diastolic blood pres-
sure was predictive of coronary events and heart failure hospitalisation; variability in 
systolic blood pressure was predictive of heart failure hospitalisations. Variability in 
pulse pressure (but not diastolic blood pressure or systolic blood pressure) was some-
what associated with long-term stroke risk. These associations were independent of 
respective mean blood pressure values, the use of antihypertensive medication and 
other risk factors. The association of intra-individual variability in blood pressure mea-
surements with adverse clinical outcomes was first recognized in the early 1990s.18-21 
Subsequent studies have investigated the predictive value of visit-to-visit variability in 
blood pressure in middle-aged people.19,22-25 In contrast the present study population 
consists of an older population (aged ≥70 years) with high risk of vascular events and 
deaths. Therefore, the present study gives new insight into the clinical significance of 
blood pressure variability with regard to morbidity and mortality in later life. It has been 
suggested that the association between increased variability in blood pressure and the 
risk of stroke is strongest in younger age groups.10,13
The reliability of blood pressure variability increased with the number of measure-
ments included, this is in line with previous research in younger age groups.10,13 It is 
possible that our measures of blood pressure variability, although based on a reason-
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ably large number of individual measurements, may still have underestimated the true 
magnitude of effect of variability on clinical outcomes.
The association between visit-to-visit variability in systolic blood pressure and 
increased total mortality found in older persons in this present study is generally in 
line with previous research in younger age-groups.13,14 Visit-to-visit variability in systolic 
table 5. Hazard Ratio’s for the endpoints associated with one SD change in each blood pressure parameter 
(a-c) for the long-term follow-up (n=1808)
a. Systolic blood pressure







Outcomes HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
Coronary events 1.1 (0.9-1.2) 0.390 1.2 (1.0-1.32) 0.030 1.1 (1.0-1.3) 0.044
Fatal / non-fatal stroke 1.2 (1.0-1.3) 0.030 1.2 (1.1-1.4) 0.003 1.1 (1.0-1.3) 0.084
Heart failure hospitalisation 1.1 (0.9-1.2) 0.514 1.1 (0.9-1.2) 0.426 1.1 (1.0-1.3) 0.135
Vascular mortality 1.1 (1.0-1.2) 0.082 1.2 (1.1-1.3) 0.005 1.2 (1.1-1.4) >0.001
Total mortality 1.0 (1.0-1.1) 0.255 1.1 (1.0-1.2) 0.056 1.1 (1.1-1.2) >0.001
b. Diastolic blood pressure







Outcomes HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
Coronary events 1.0 (0.9-1.1) 0.989 1.0 (0.9-1.1) 0.939 1.2 (1.1-1.4) 0.001
Fatal / non-fatal stroke 1.2 (1.0-1.3) 0.019 1.2 (1.1-1.4) 0.008 1.1 (1.0-1.2) 0.141
Heart failure hospitalisation 0.9 (0.8-1.0) 0.181 0.9 (0.8-1.0) 0.060 1.2 (1.0-1.3) 0.014
Vascular mortality 1.0 (0.9-1.2) 0.558 1.0 (1.0-1.2) 0.234 1.2 (1.1-1.3) 0.003
Total mortality 1.0 (1.0-1.1) 0.465 1.0 (1.0-1.1) 0.459 1.1 (1.1-1.2) >0.001
c. Pulse pressure







Outcomes HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
Coronary events 1.1 (0.9-1.2) 0.314 1.2 (1.1-1.4) 0.006 1.1 (1.0-1.2) 0.199
Fatal / non-fatal stroke 1.1 (0.9-1.2) 0.284 1.2 (1.0-1.3) 0.031 1.2 (1.0-1.3) 0.018
Heart failure hospitalisation 1.1 (1.0-1.3) 0.118 1.2 (1.0-1.3) 0.043 1.1 (0.9-1.2) 0.271
Vascular mortality 1.1 (1.0-1.2) 0.094 1.2 (1.1-1.3) 0.005 1.2 (1.0-1.3) 0.008
Total mortality 1.0 (1.0-1.1) 0.375 1.1 (1.0-1.2) 0.053 1.1 (1.0-1.2) 0.008
Data are presented as Hazard Ratios and 95% Confidence Intervals.
Adjustment for randomized treatment, mean systolic blood pressure (a), mean diastolic blood pressure (b) and mean pulse 
pressure (c), age, gender, current smoker, histories of diabetes, hypertension, cardiovascular disease, cerebrovascular dis-
ease & peripheral vascular disease, body mass index, high-density lipoprotein and low-density lipoprotein.
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blood pressure has also been claimed to be a predictor of stroke10,13,24,26 and coronary 
events,13,27 however in the present study visit-to-visit variability in systolic blood pres-
sure was not associated with an increased risk of stroke or coronary events. In contrast, 
sensitivity analyses in this present study showed that one SD difference in baseline and 
mean systolic and diastolic blood pressure was associated with an increased risk of 
stroke.
In our cohort, variability in pulse pressure was the only measure that was associated 
with an increased risk of stroke, albeit modestly so; systolic blood pressure variability 
may be a more powerful predictor of stroke in younger cohorts; Rothwell et al.13 found 
an adjusted HR for stroke of 12.1 (95% CI 7.4–19.7; highest vs. lowest decile) in a popula-
tion aged 40–79 years. Such differences between our study and other cohorts might 
be caused by higher mean systolic blood pressure levels in our older cohort. However 
there was no meaningful difference in average blood pressure between our study and 
other relevant cohorts (e.g. mean systolic blood pressure 150 mmHg in the UK-TIA and 
164 mmHg at baseline and 148 mmHg on treatment in the ASCOT-BPA13 compared to 
154/155 mmHg in the present study).
In previous research, in predominantly younger populations compared to the pres-
ent study, no associations were present between visit-to-visit variability in diastolic 
blood pressure and all-cause mortality and CVD.13,14,27 In contrast, our data suggest 
that in older subjects diastolic blood pressure variability is more strongly associated 
with coronary events and vascular or total mortality than is systolic pressure variability, 
especially in male subjects and those with systolic blood pressure below median. The 
mechanisms for why diastolic blood pressure variability should be more strongly associ-
ated with risk in elderly remain uncertain but could speculatively include a bigger drop 
off in diastolic blood pressure as marker of risk. In addition, it is also not clear why such 
associations appear to be significantly stronger in men compared to women. Clearly, 
our results suggest these issues merit further study.
The present study reveals some differences in the association between variability 
in the different blood pressure measurement and outcomes and shows some differ-
ences with previous research. One of the major differences between the present study 
and previous research is the age of the participants. Although the present study was 
not aimed to investigate etiological mechanisms behind the observed associations, it 
is tempting to hypothesize that the mechanisms involved in the association between 
variability in blood pressure and stroke are different in younger and older persons. In 
previous studies, greater variability in blood pressure was related to older age and pulse 
pressure,13,14 which both correlate with arterial stiffness. Arterial stiffness may play a role 
in the found associations between variability in blood pressure and CVD events. While 
variability increases with age, the association with CVD events is not found to increase 
correspondingly with similar analysis. The variability in systolic blood pressure found 
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in the present study was indeed higher than the variability in systolic blood pressure 
found in younger populations (mean SD of systolic blood pressure 14.1 mmHg vs. 7.7 
mmHg14), while the associated risk for total mortality was not higher. This could indicate 
that there might be more competing mechanisms in older persons than in younger 
persons.
This study has a number of strengths. Blood pressure was not part of the inclusion 
or exclusion criteria for the PROSPER trial. Therefore, people with the full range of 
baseline blood pressure and variability in blood pressure were included. The estima-
tion of visit-to-visit variability should be reasonably reliable because of the frequency 
of measurements. The large sample size allowed us to conduct several subgroup 
analyses and investigating different outcomes. However a limitation of this study is 
that long-term follow-up was not assessed in the total PROSPER trial population and it 
was only available for the Scottish sub-cohort. Another potential limitation is that the 
participants were randomized to an intervention (pravastatin vs. placebo), however, we 
found no difference in variability in blood pressure between randomized groups and all 
analyses were adjusted for the randomized treatment. Third, we had no data on the use 
of antihypertensive medications during the follow-up after the randomized control trial 
ended. PROSPER was not designed to assess the effect of blood pressure on outcomes 
and the accuracy of measurement of blood pressure was reduced. By not having the 
perfect blood pressure measurement we may have underestimated the true effect of 
variability in blood pressure on clinical outcomes.
The present study aimed only to establish whether there is an association between 
of visit-to-visit variability in blood pressure and adverse CVD outcomes in older pa-
tients; however if these associations are causal the results may have implications in 
the management and treatment of blood pressure in the older population. Besides the 
aim of lowering the usual level of blood pressure in hypertensive patients, it is possible 
that additional benefit might be obtained from reducing variability in blood pressure. 
In a recent meta-analysis it was suggested that the use of calcium channel blockers 
and non-loop diuretics results in less systolic blood pressure variability than the use of 
ACE inhibitors and angiotensin 2 receptor antagonists. Calcium channel blockers have 
shown to reduce visit-to-visit variability compared with placebo.28 However, currently it 
is not certain whether differential effects of various antihypertensives on variability in 
blood pressure will also lead to clinical gains.
In conclusion, in older subjects at risk of CVD events variability in systolic blood 
pressure is predictive for the risk of heart failure hospitalisations and cardiovascular and 
total mortality; variability in diastolic blood pressure is predictive for the risk of coronary 
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Visit-to-visit variability in blood pressure is an independent predictor of cardiovascular 
disease. This study investigates biological correlates of intra-individual variability in 
blood pressure in older persons.
Methods
Nested observational study within the PROspective Study of Pravastatin in the Elderly 
at Risk (PROSPER) among 3,794 male and female participants (range 70–82 years) with a 
history of, or risk factors for cardiovascular disease. Individual visit-to-visit variability in 
systolic and diastolic blood pressure and pulse pressure (expressed as 1 SD in mm Hg) 
was assessed using nine measurements over 2 years. Correlates of higher visit-to-visit 
variability were examined at baseline, including markers of inflammation, endothelial 
function, renal function and glucose homeostasis.
Results
Over the first 2 years, the mean intra-individual variability (1 SD) was 14.4 mm Hg for 
systolic blood pressure, 7.7 mm Hg for diastolic blood pressure, and 12.6 mm Hg for 
pulse pressure. After multivariate adjustment a higher level of interleukin-6 at baseline 
was consistently associated with higher intra-individual variability of blood pressure, 
including systolic, diastolic, and pulse pressure. Markers of endothelial function (Von 
Willebrand factor, tissue plasminogen activator), renal function (glomerular filtration 
rate) and glucose homeostasis (blood glucose, homeostatic model assessment index) 
were not or to a minor extent associated with blood pressure variability.
Conclusion
In an elderly population at risk of cardiovascular disease, inflammation (as evidenced 
by higher levels of interleukin-6) is associated with higher intra-individual variability in 
systolic, diastolic, and pulse pressure.
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Blood pressure varies over time within individuals, resulting in variability in blood pres-
sure.1-4 Until the 1990s variability in blood pressure was merely regarded as a random 
phenomenon and an obstacle to determine the usual blood pressure.1,5-7 Usual or 
average blood pressure was considered to be the main determinant in the cause of 
cardiovascular disease and accounting for the benefits of antihypertensive drugs. 1,5-7 
However, recent data suggest that variability in blood pressure assessed across several 
visits (i.e., visit-to-visit variability) is reproducible and not a random phenomenon,8,9 and 
that visit-to-visit variability in blood pressure itself is a predictor of incident cardiovas-
cular disease.10-18 Long-term visit-to-visit variability in systolic blood pressure has been 
claimed to be associated with increased risk of stroke,10,12-14 coronary events10,15,18 and 
all-cause mortality,11,17,18 all in middle-aged persons. In older age, visit-to-visit variability 
blood pressure is associated with an increased long-term risk for cardiovascular and 
total mortality and cognitive decline.16,19 In addition, variability in diastolic blood pres-
sure is predictive of coronary events and heart failure hospitalization.16
Higher visit-to-visit variability in blood pressure might result from biological factors. 
Possible mechanisms underlying high levels of visit-to-visit-variability of blood pressure 
include impaired baroreceptor function,5,20 arterial stiffness,11,21 impaired endothelial 
function,22,23 inflammation,21,24,25 and renal impairment.26 Identifying factors associated 
with intra-individual variability in blood pressure may help elucidate the underlying 
mechanisms. It is unknown which factors correlate most strongly with variability of 
blood pressure in older people. We hypothesized that inflammation, impaired endo-
thelial function, renal function, and glucose metabolism might be important biological 
pathways underlying visit-to-visit variability of blood pressure in older age, based on 
previous studies on correlates of higher variability of blood pressure in middle-aged 
populations.10,21-26 We tested these hypotheses in 3,794 subjects participating in the 
PROspective Study of Pravastatin in the Elderly at Risk (PROSPER).27
methods
Study design
Details of the design and outcome of PROSPER have been published elsewhere.27-29 In 
short, between December 1997, and May 1999 a total of 5,804 individuals were screened 
and enrolled in Scotland (n = 2,520), Ireland (n = 2,184) and the Netherlands (n = 1,100). 
Men and women aged 70–82 years were recruited if they had either pre-existing vascu-
lar disease (coronary, cerebral, or peripheral) or increased risk of such disease because 
of smoking, hypertension, or diabetes. Their plasma total cholesterol was required 
to be 4.0–9.0 mmol/L and their triglyceride concentrations  ≤6.0 mmol/L. Individuals 
with poor cognitive function (Mini-Mental State Examination score  <24 points) were 
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excluded. Blood pressure was not part of the inclusion or exclusion criteria. In total, 
5,804 participants were randomized to either placebo or pravastatin; 2,913 assigned 
placebo and 2,891 assigned pravastatin.27 During the pre-randomization visits, baseline 
participant characteristics were collected.28 The institutional ethics review boards of all 
centers approved the protocol, and all participants gave written informed consent.
Blood pressure measurements
Sitting blood pressure was measured once at baseline and at follow-up visits every 3 
months during the trial (mean follow-up 3.2 years) with a fully automatic electronic 
sphygmomanometer (Omron M4).
Biomarkers
Markers of inflammation. Saved biobank of baseline K2EDTA samples were used to as-
say interleukin-6 in 2007 using a high-sensitivity enzyme-linked immunosorbent assay 
(R&D Systems) with inter- and intra-assay coefficients of variation of <6% and sensitivity 
of  <0.16 pg/mL.30 High sensitivity C-reactive protein levels were measured on stored 
K2EDTA (at −80 °C) baseline samples by automated particle-enhanced immunoturbi-
dimetric assay (Roche UK, Welwyn Garden City, UK), with inter- and intra-assay coef-
ficients of variation of <3% and a lower limit of sensitivity of 0.1 mg/L.31 The laboratory 
participates in a national external quality control for highsensitivity C-reactive protein. 
All laboratory analyses were conducted by technicians blind to the identity of samples.
Markers of endothelial function. In baseline blood samples from the biobank (stored 
at <80 °C) tissue plasminogen activator antigen was measured in citrated plasma us-
ing an enzyme-linked immunosorbent assay (Biopool AB) and VonWillebrand factor 
antigen level was measured in citrated plasma using an enzyme-linked immunosorbent 
assay with rabbit antihuman polyclonal antibodies (Dako).32
Markers of renal function. Baseline serum creatinine levels were measured at central 
laboratories, one in each of the three participating countries. Glomerular filtration rate 
was estimated using the Modification of Diet in Renal Disease equation33:
eGFR=186 x serum creatinine level (mg dl)(-1.154) x age(-0.203) x 0.742 (if female)
Markers of glucose metabolism. Body mass index and detailed medical history was 
collected at baseline. Fasting glucose levels were assessed at baseline, using routine 
methods.29 Diabetes at baseline was defined by self-reported history, a fasting blood 
glucose concentration of 7.0 mmol/L or greater or a blood glucose measurement of 
11.1 mmol/L or greater when fasting status was uncertain, or self-reported use of anti-
diabetic drugs (any oral hypoglycemic agent or insulin). Data on fasting glucose and 
fasting insulin levels were used to calculate the degree of insulin resistance according 
to homeostatic model assessment (HOMA).34 The HOMA score was calculated using 
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the HOMA index34 by dividing the product of fasting levels of glucose and insulin by a 
constant.
Statistical analysis
Variability of blood pressure was defined as the SD of the mean per person over 9 visits 
(0–24 months). Variability was assessed for systolic blood pressure, diastolic blood pres-
sure and pulse pressure. Participants with one or more missing blood pressure measure-
ments in the first 24 months (n = 1,403); those who had a cardiovascular event in the 
measurement period (0–24 months, n = 316) and those with atrial fibrillation (n = 4) were 
excluded. A total of 487 participants had missing data for one or more of the biomark-
ers and were also excluded (some participants had more than one exclusion criteria) 


















Assessment of eligibility 
n=23770 





Not included or refused n=16714 
Not included or refused n=1252  
Exclusion participants with missing 
blood pressure measurements 
(n=1403); and/or a cardiovascular 
event (n=316) in the measurement 
period (0-24 months) and/or atrial 
fibrillation (n=4) 
Included in the analysis 
n= 3794 
Exclusion participants with missing 
data for the characteristics (n=487) 
Figure  1. Flow chart
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of variation (SD/ mean). The results for SD and coefficient of variation were qualitatively 
the same; therefore the results for SD are presented.
F-tests were used to test the variability in blood pressure variability between partici-
pants receiving pravastatin and those receiving placebo. Variability variables were split 
into quartiles. Baseline characteristics were calculated by quartile of SD of variability 
variables; they are reported as mean with SD for continuous variables and as numbers 
with percentage (%) for categorical variables. The association between the character-
istics at baseline (independent variable) with the variability variables (dependent vari-
able) was assessed using linear regression. The distribution of the variables C-reactive 
protein and interleukin-6 was skewed, therefore, these variables were log-transformed.
The markers of inflammation, endothelial function, renal function, and glucose me-
tabolism were first analyzed separately, and then combined. The initial “minimally ad-
justed” regression model included adjustment for country and randomized treatment. 
In a subsequent model adjustment for age, gender, current smoking, average blood 
pressure during follow-up (systolic and diastolic blood pressure and pulse pressure), 
history of cardiovascular disease, history of hypertension, total cholesterol, high-density 
lipoprotein, and low-density lipoprotein was made. In the final model, the multivariable 
analysis, all biomarkers were combined to determine the subset of characteristics that 
were independently associated with variability in blood pressure. The beta’s from the 
linear regression analyses for the variables C-reactive protein and interleukin-6 are not 
easy to interpret as these variables were log-transformed. Therefore, the change in SD 
per doubling of these variables was calculated. In addition, the R-squared values for 
the models were calculated. In an additional analysis we excluded interleukin-6 from 
the final model to assess what effect this would have on the parameter estimates of the 
other variables.
A change in antihypertensive drug treatment could have influenced the SD in blood 
pressure. We therefore performed a sensitivity analysis in all participants that remained 
on the same antihypertensive treatment throughout the first 24 months.
results
Table 1 presents the baseline characteristics for the participants. Of the 3,794 partici-
pants 1,810 (47.7%) were men, the mean age was 75.2 years (SD 3.3) and 1,603 (42.3%) had 
a history of cardiovascular disease. The mean intra-individual SD of 9 measurements of 
systolic blood pressure was 14.4 mm Hg; the mean SD of diastolic blood pressure was 
7.7 mm Hg and the mean SD of pulse pressure was 12.6 mm Hg. There was no significant 
difference in variability in blood pressure between participants receiving pravastatin 
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and those receiving placebo (P values 0.31, 0.92, 0.15); therefore, data from both groups 
were combined and all analyses were adjusted for treatment.
Biological correlates of systolic blood pressure variability
Table  2 shows the baseline characteristics per quartile of variability in systolic blood 
pressure. Higher levels of C-reactive protein, interleukin-6 and creatinine and lower 
estimated glomerular filtration rate, all at baseline, were associated with higher quar-
tiles of intra-individual variability of systolic blood pressure in the minimally adjusted 
analysis. Baseline levels of Von Willebrand Factor and tissue plasminogen activator were 
not associated with intra-individual variability in systolic blood pressure, nor was there 
an association between the glucose metabolism characteristics and intra-individual 
variability in systolic blood pressure.
table 1. Characteristics of study participants (n=3,794)
Characteristic
Categorical variates (n, %)
Men 1,810 (47.7%)





History of cardiovascular diseasea 1,603 (42.3%)
History of hypertension 2,412 (63.6%)
Continuous variates (mean, SD)
Age (years) 75.21 (3.32)
Average systolic blood pressure (mmHg) 153.78 (16.32)
Variability in systolic blood pressure (mmHg) 14.38 (5.11)
Average diastolic blood pressure (mmHg) 83.25 (7.54)
Variability in diastolic blood pressure (mmHg) 7.68 (2.97)
Average pulse pressure (mmHg) 70.53 (12.96)
Variability in pulse pressure (mmHg) 12.64 (4.56)
Baseline total cholesterol (mmol/L) 5.69 (0.90)
Baseline Low-density lipoprotein cholesterol (mmol/L) 3.79 (0.80)
Baseline High-density lipoprotein cholesterol (mmol/L) 1.28 (0.35)
a Any of stable angina, intermittent claudication, stroke, transient ischemic attack, myocardial infarction, peripheral arterial 
disease surgery, or amputation for vascular disease more than 6 months before study entry.
Chapter 3
52
Biological correlates of diastolic blood pressure variability
Table 3 shows the baseline characteristics per quartile of variability in diastolic blood 
pressure. Higher levels of C-reactive protein and interleukin-6, were associated with 
higher quartiles of intra-individual variability of diastolic blood pressure. In contrast 
to systolic blood pressure variability, higher estimated glomerular filtration rate was 
associated with a higher variability in diastolic blood pressure. Higher levels of tissue 
plasminogen activator, higher body mass index and higher level of HOMA were all as-
sociated with higher variability in diastolic blood pressure in the minimally adjusted 
analysis.
table 2. Baseline biomarkers by quartile of intra-individual systolic blood pressure variability (measured as 
SD of 9 measurements over 24 months)
















































































































































Mean and corresponding SDs and numbers and corresponding percentage.
Abbreviation: HOMA, homeostatic model assessment.
aAdjusted for randomised treatment code and country by linear regression. P for trend across quartiles.
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Biological correlates of pulse pressure variability
Higher levels of C-reactive protein (P < 0.001), interleukin-6 (P < 0.001) and tissue plas-
minogen activator at baseline (P < 0.01) were also associated with higher variability of 
pulse pressure in the minimally adjusted analyses (Supplementary Table 1). Moreover, 
lower estimated glomerular filtration rate (P < 0.001), higher body mass index (P < 0.001) 
and higher level of HOMA at baseline (P  <  0.01) were also associated higher intra-
individual variability in pulse pressure.
Adjusted multivariable analysis
In the adjusted multivariable analysis, the association between higher levels of interleu-
kin-6 and higher variability of systolic and diastolic blood pressure and pulse pressure 
remained significant (all P < 0.01) (Table 4). Every doubling of interleukin-6 was associ-
table 3. Baseline biomarkers by quartile of intra-individual diastolic blood pressure variability (measured as 
SD of 9 measurements over 24 months)














































































































































Mean and corresponding SDs and numbers and corresponding percentage.
Abbreviation: HOMA, homeostatic model assessment.
aAdjusted for randomised treatment code and country by linear regression. P for trend across quartiles.
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ated with 0.26 higher intra-individual SD (i.e., variability) systolic blood pressure and 0.21 
(higher intra-individual SD diastolic blood pressure. R-squared value for the adjusted 
multivariate model was 8.2% for systolic blood pressure variability and 4.8% for diastolic 
blood pressure, and 8.2% for pulse pressure variability.
Table 5 shows that there was no independent association between tissue plasmino-
gen activator and variability in systolic and diastolic blood pressure in the adjusted mul-
tivariable analysis. A higher level of tissue plasminogen activator was associated with 
higher pulse pressure variability, every point higher of tissue plasminogen activator was 
associated with 0.05 (95% CI 0.01–0.09) higher SD pulse pressure. R-squared value for the 
adjusted multivariable analysis was 8.0%.
The associations between renal function and variability in blood pressure disap-
peared when adjusted for age, gender, current smoking, average blood pressure during 
follow-up (systolic and diastolic blood pressure and pulse pressure), history of cardio-
vascular disease, history of hypertension, and cholesterol in the multivariable analysis.
The association between body mass index and pulse pressure variability remained 
significant in the multivariable analysis (parameter estimate 0.06, 95% CI 0.02–0.10). R-
squared value for the multivariate model was 8.0%. 
In the final step of the analysis, all biomarkers were included in the same adjusted 
multivariable model. In this model, only higher levels of interleukin-6 were associated 
with higher variability of systolic and diastolic blood pressure and pulse pressure (all 
P <  0.02). Every doubling of interleukin-6 was associated with 0.24 higher SD systolic 
blood pressure, 0.19 higher SD diastolic blood pressure and 0.23 higher SD pulse pres-
sure. Moreover, every point higher of body mass index was associated with a 0.045 (95% 
CI 0.004, 0.087) higher SD pulse pressure. The R-squared value for this adjusted multi-
variable model including all biomarkers was 9.0% for systolic blood pressure variability, 
5.0% for diastolic blood pressure variability and 8.7% for pulse pressure variability.
table 4. Change in intra-individual SD (of 9 measurements over 24 months) systolic and diastolic blood 
pressure per doubling of C-reactive protein and interleukin-6, multivariable analysis per pathway































aAdjusted for country and treatment by linear regression; P value calculated by linear regression.
bAdjusted for age, gender, country, treatment, current smoking, average SBP over 2 years for variability in SBP and average 
DBP over 2 years for variability in DBP, history of cardiovascular disease, history of hypertension, total, HDL- and LDL- cho-
lesterol by linear regression; P value calculated by linear regression.
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In an additional analysis we excluded interleukin-6 from the final multivariable 
model. In this model, higher level of C-reactive protein was associated with higher sys-
tolic and diastolic blood pressure variability as well as higher pulse pressure variability 
(all P < 0.01).
In a sensitivity analysis we explored the effect of excluding those participants 
(n  =  1,816) with a change in antihypertensive drug treatment (defined as a change in 
listed antihypertensive drugs), and repeating the analysis for only those participants 
(n = 1,978) who remained on the same antihypertensive drugs throughout the first 24 
months; in these analyses there was no material change in the relationships observed 
in the whole cohort.
disCussion
This study shows that higher interleukin-6 levels are associated with visit-to-visit vari-
ability in systolic and diastolic blood pressure as well as pulse pressure in an older 
population at high risk for cardiovascular disease. In addition, higher body mass index 
was associated with higher visit-to- visit variability in pulse pressure. These associations 
were independent of various cardiovascular risk factors and average blood pressure 
and remained present when all participants that had a change in antihypertensive drug 
treatment were excluded.
Previously it has already been suggested that visit-to-visit variability in blood 
pressure is not a random phenomenon.8 Several underlying mechanisms have been 
proposed with regard to higher levels of visit-to-visit variability in blood pressure.8,35,36 
Some have suggested that higher blood pressure variability might identify people with 
subclinical inflammation.25 In animal models, variability of blood pressure has been 
associated with higher levels of C-reactive protein.21,24 In the present study elevated 
interleukin-6 was indeed associated with variability in systolic and diastolic blood 
pressure as well as pulse pressure. In contrast, elevated C-reactive protein was not inde-
pendently associated with higher visit-to-visit variability in blood pressure, in line with 
other studies.11 However, when we excluded interleukin-6 from the final multivariable 
analysis, higher level of C-reactive protein became associated with higher variability in 
systolic and diastolic blood pressure as well as pulse pressure. This effect is biologically 
plausible; adjusting for interleukin-6 implies adjusting in the causal pathway, since in-
terleukin-6 stimulates the production of C-reactive protein. Interleukin-6 and C-reactive 
protein were measured at baseline, prior to the measure of variability, therefore, we 
could not assess causal relationships. We hypothesis that subclinical inflammation may 
lead to higher blood pressure variability and as a result, is associated with higher risk 
of cardiovascular disease. Another explanation is that subclinical inflammation itself 
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causes higher risk of cardiovascular disease and higher blood pressure variability. 
Higher blood pressure variability could then be regarded as a marker of the association 
between subclinical inflammation and cardiovascular disease.
Recent evidence in a small sample of African Americans indicates that higher blood 
pressure variability is linked with endothelial injury, decreased endothelial functioning 
and disturbances in vascular smooth muscle functioning.22,23 It has been suggested that 
tissue plasminogen activator, which is synthesized mainly in the vascular endothelium, 
is a marker for endothelial function, with higher levels of tissue plasminogen activator 
indicating endothelial dysfunction.37-39 In our study, the associations between tissue 
plasminogen activator and blood pressure variability was only observed for pulse pres-
sure variability in the adjusted analysis. The evidence suggesting that impaired endo-
thelial function underlies the higher blood pressure variability presented in our study is 
therefore only limited and less convincing as compared to the inflammation pathway. 
We have previously shown that, pulse pressure variability was somewhat associated 
with long-term stroke risk in an older population at risk for cardiovascular disease, 
while systolic and diastolic blood pressure variability where not.16 This could indicate 
that different underlying mechanism might play a role. Endothelial injury, resulting 
in endothelial dysfunction could be a result of variability in pulse pressure. Whether 
higher levels of tissue plasminogen activator are just a marker of higher variability of 
pulse pressure or a true mediator in the relation between variability in pulse pressure 
and cardiovascular disease is uncertain. The association between estimated glomerular 
filtration rate and blood pressure variability disappeared when adjusted for age, gen-
der, current smoking, average blood pressure, history of cardiovascular disease, history 
of hypertension, and cholesterol. This could indicate that impaired renal function does 
not underlie high levels of visit-to-visit-variability of blood pressure. The previously 
observed association between history of diabetes and blood pressure variability10 was 
not replicated in our study. We only found a low parameter estimate between body 
mass index and variability in pulse pressure, suggesting that glucose metabolism might 
not be relevant in an older population at risk for cardiovascular disease. Furthermore, 
it has been suggested that higher blood pressure variability may be a manifestation 
of baroreflex regulation of blood pressure.5,20 However, decreased heart rate variability 
is associated with an increased risk of mortality in a previous study,40 suggesting that 
heart rate variability does not play a role in the association between variability in blood 
pressure and mortality.
Another explanation may lie in cognitive decline. Both interleukin-6 levels41 and 
C-reactive protein levels42 and blood pressure variability19 have been associated with 
cognitive decline. A common explanation may be that either cardiovascular burden, 
as measured in an increased level of interleukin-6 and C-reactive protein as well as 
increased blood pressure variability cause cognitive decline. Conversely, cognitive 
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decline may cause increased inflammatory markers (as a result of altered lifestyle, such 
as eating) and blood pressure variability.
The differences found in the associations between the different biomarkers and 
the variability in systolic and diastolic blood pressure and pulse pressure might reflect 
the differences in the associations with cardiovascular disease which were previously 
shown.16
Identifying inflammation as a factor associated with intra-individual variability in 
blood pressure and excluding other factors such as glucose, may help elucidate the 
underlying mechanisms of intra-individual variability in blood pressure. The model 
explains up to 9% of the variability in blood pressure, this modest fit could be consid-
ered to be a weakness of the study, despite small P values that reflect the large sample 
size. However, since we have only one baseline measure of biomarkers, this could be an 
underestimation of the true association due to regression dilution bias. We argue that 
part of the observed association could also be attributed to the fact that blood pressure 
was measured once every 3 months and the time of the day could vary between these 
measurements. The season of measurement could also influence the variability in blood 
pressure. This exogenous introduced variability however is unlikely to be of any effect 
on the influence of blood pressure variability on the pathogenesis of cardiovascular 
disease. Inflammation is one of the possible biological pathways of higher variability in 
blood pressure not explained by these exogenous factors. Other potential biological 
mechanisms remain unknown up to now. The change in drugs used as antihypertensive 
treatment could have influenced the blood pressure variability. This is, however, not 
expected to influence the association between interleukin-6 and blood pressure vari-
ability. The results did not materially changed when all participant that had a change in 
antihypertensive drug treatment (defined as a change in listed antihypertensive drugs) 
were excluded. It would be interesting to know if baseline variability in blood pressure 
predicts subsequent changes in inflammation biomarkers using longitudinal data. 
Metabolomics might also be a potential direction for further research to explore novel 
mechanisms of blood pressure variability.
This study was embedded in the PROSPER trial, a large double-blinded randomized 
placebo-controlled trial in older persons. This landmark clinical trial with older partici-
pants was performed following guidelines of good clinical practice. Blood pressure was 
not part of the inclusion or exclusion criteria for the PROSPER trial, therefore, people 
with the full range of baseline blood pressure and variability in blood pressure were 
included. The estimation of visit-to-visit variability should be reasonably reliable be-
cause of the frequency of measurements (nine measurements). The large sample size is 
another strength of this study. This study has certain limitations. A potential limitation 
is that the participants were randomized to an intervention (pravastatin vs. placebo), 
however, we found no difference in variability in blood pressure between both ran-
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domized groups and all analyses were adjusted for the randomized treatment. Second, 
given the cross-sectional design of the study, we cannot conclude whether variability 
in blood pressure lead to subclinical inflammation, or vice versa. Third, we were lacking 
measures of baroreflex sensitivity, therefore this potential biological mechanism under-
lying individual variability in blood pressure in older persons could not be analyzed in 
this study. In addition, some of the associations between variability in blood pressure 
and baseline biomarkers may not be linear, however, we do not have sufficient power in 
our data to explore this fully. The trend or slope of blood pressure over time may have 
influenced the SD of blood pressure and thus can be considered as a potential con-
founding variable. The analysis was not adjusted for the trend or slope in blood pressure 
as we believe that this is beyond the scope of this paper. The final analysis were adjusted 
for randomized treatment code, country, age, gender, current smoking, average blood 
pressure, history of cardiovascular disease, history of hypertension, and cholesterol. 
One could argue that when adjusting for all these additional variables one might have 
introduced confounding instead of the intended adjustment for confounding. The step 
wise analysis approach was chosen to provide the most transparent results. Finally, 
there was no correction for multiple testing. These corrections could have resulted 
in type II errors and therefore prematurely discarding potentially useful observations 
which may help to elucidate the underlying mechanisms of intra-individual variability 
in blood pressure.
For the interpretation of the results it is important to note that the excluded patients 
are intrinsically different due to the criteria used for selection. The excluded patients 
include those with events in the measurement period (0–24 months, n = 316) and there-
fore differed in a systematic manner. They likely include the “sicker” patients. Another of 
our criteria is the requirement to have blood pressure measured at each of the nine time 
points during the 24 months. This excludes the non-attenders.
In conclusion, in this study of older population at risk, higher levels of interleukin-6 
were independently associated with visit-to-visit variability in systolic and diastolic 
blood pressure and pulse pressure. Additional research is needed to confirm these 
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 aPPendix
supplemental table 1. Baseline biomarkers by quartile of intra-individual pulse pressure variability (mea-
sured as SD of 9 measurements over 24 months)
















































































































































Mean and corresponding SDs and numbers and corresponding percentage.
Abbreviation: HOMA, homeostatic model assessment.
aAdjusted for randomised treatment code and country by linear regression. P for trend across quartiles.
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To investigate whether low systolic blood pressure is predictive for increased mortality 
risk in 90-year-old subjects without heart failure, defined by low levels of NT-proBNP, as 
well as in 90-year-old subjects with high levels of NT-proBNP.
Methods and results
This study was embedded in the Leiden 85-plus Study, an observational population-
based prospective study. All 90-year-old participants (n = 267) were included between 
2002 and 2004 and followed up for mortality for at least 5 years. Differences in mortal-
ity risks were compared between participants with low systolic blood pressure (≤150 
mmHg) and high systolic blood pressure (>150 mmHg) within strata of low NT-proBNP 
(<284 pg/mL for women and >306 pg/mL for men = lowest tertile) vs. high NT-proBNP 
(middle and highest tertile) at age 90 years. During maximal follow-up of 7.2 years, 212 
participants (79%) died. Among participants with low NT-proBNP, low systolic blood 
pressure gave a two-fold increased risk (hazard ratio 2.0, 95% confidence interval 1.1–3.4) 
compared with participants with high systolic blood pressure. For participants with 
high NT-proBNP, low systolic blood pressure provided a 1.7 increased mortality risk (95% 
confidence interval 1.2–2.3) compared with high systolic blood pressure.
Conclusion
Low systolic blood pressure is predictive for increased mortality risk in 90-year-old 
subjects, irrespective of the NT-proBNP level. Therefore, the absence or presence of 
heart failure as determined by NT-proBNP does not influence the prognostic value of 
low systolic blood pressure with regard to mortality in the oldest old.
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Low blood pressure, heart failure and increased mortality
introduCtion
High systolic blood pressure is an established risk factor for cardiovascular disease and 
mortality in middle-aged persons. In contrast, observational data on the predictive 
relationship between systolic blood pressure and mortality in very old age are less 
consistent.1-4 One large meta-analysis showed that high systolic blood pressure predicts 
increased mortality risk in all age groups, but also that this relationship was consid-
erably attenuated with age.1 Others, especially observational studies in exclusively 
elderly populations, have shown that not high, but low systolic blood pressure predicts 
increased mortality.2-4 To date, it remains unknown which mechanism(s) are responsible 
for this ‘inversion of risk prediction’.
A plausible explanation is that (subclinical) heart failure may, at least in part, underlie 
this ‘inversion of risk prediction’.2,4-7 Prolonged and uncontrolled hypertension can lead 
to heart failure that might lower blood pressure.8 Indeed, patients with heart failure 
tend to have lower blood pressure values. Our group previously reported that very old 
subjects with low systolic blood pressure have an impaired cardiac function.5 Therefore, 
we hypothesized that in very old subjects without heart failure, low systolic blood pres-
sure is not predictive for increased mortality risk compared with those with high systolic 
blood pressure, but, instead, still follows the usual pattern (low systolic blood pressure 
associated with low risk, and high systolic blood pressure associated with high risk).
Diagnosing heart failure in old age is challenging. Symptoms and signs in combina-
tion with NT-proBNP reliably identify the presence or absence of heart failure in the 
vast majority of patients.9 NT-proBNP alone is a sensitive but not highly specific marker 
of heart failure. The negative predictive value of low levels of NT-proBNP is robust, and 
low levels of NT-proBNP are reported to exclude heart failure.10-12 Also, within the Leiden 
85-plus Study, it was shown that low NT-proBNP levels exclude echocardiographic ab-
normalities in very old age.13
The present study investigates the predictive relationship between systolic blood 
pressure and mortality in a population-based cohort of nonagenarians without heart 




The Leiden 85-plus Study is a prospective population-based study in 85-year-old inhab-
itants of the city of Leiden (The Netherlands). The study design and characteristics of the 
cohort have been described in detail.14,15 Between September 1997 and September 1999, 
Chapter 4
68
705 people in the 1912–1914 birth cohort reached the age of 85 years and were eligible to 
participate in the study. No exclusion criteria were used. Fourteen people died before 
enrolment; a total of 599 (87%) people gave informed consent and were enrolled. Of 
the 599 participants enrolled in the study at age 85 years, 295 died before the age of 90, 
and 37 refused further participation or refused blood sampling. Thus, for the present 
study, ‘baseline measurements at age 90 years’, including systolic blood pressure and 
NT-proBNP levels, were available for 267 participants, all ‘included’ between 2002 and 
2004. Participants were visited by a research nurse at their place of residence to collect 
information on socio-demographic characteristics, as well as a venous blood sample. 
The Medical Ethics Commission of the Leiden University Medical Center approved the 
study, and all participants gave informed consent. The investigation conforms with the 
principles outlined in the Declaration of Helsinki.
Blood pressure and blood pressure categories
At age 90, blood pressure was measured twice with an interval of 2 weeks. Blood pres-
sure was measured using a mercury sphygmomanometer, in the seating position after 
at least 5 min rest without having performed vigorous exercise during the preceding 30 
min. The systolic value was measured at the onset of phase 1 of the Korotkoff sounds. 
For the analysis, we used the mean of the two systolic values at age 90 years.
Systolic blood pressure values were divided into two categories, ‘low’ and ‘high’ 
systolic blood pressure. Low systolic blood pressure was defined as a systolic blood 
pressure ≤ 150 mmHg, and high systolic blood pressure was defined as a systolic blood 
pressure >150 mmHg. This cut-off was based on the target value used in studies assess-
ing the risks and benefits of treating hypertension in individuals aged ≥ 80 years.16
N-terminal pro brain natriuretic peptide and categories of heart failure
Serum levels of NT-proBNP were measured for all participants at age 90 in one batch us-
ing the NT-proBNP assay of Roche Diagnostics (Mannheim, Germany) on a Roche Modu-
lar E-17 automated immunoanalyser. The within-run coefficient of variation was ≤ 2% 
and total variation was ≤ 6% at all levels measured (400–13 500 pg/mL). Low levels of NT-
proBNP can be used to rule out the diagnosis of heart failure.10-12 Since clinical cut-offs 
for NT-proBNP in very old age are still the subject of debate,12 in the present study we 
used gender-specific tertiles of NT-pro-BNP levels. Heart failure was considered absent 
in all participants in the lowest NT-proBNP tertile (NT-proBNP <284 pg/mL for women 
and <306 pg/mL for men). Heart failure was considered to be probably present in the 
participants in the middle and highest NT-proBNP tertile (NT-proBNP ≥ 284 pg/mL for 
women and ≥ 306 pg/mL for men).
69
Low blood pressure, heart failure and increased mortality
Other clinical characteristics
Each participant’s general practitioner (or, if applicable, nursing home physician) was 
interviewed annually about the participant’s medical history, using standardized 
questionnaires, including questions on present and past cardiovascular17 and non-
cardiovascular morbidities.
Mortality
All participants were followed for mortality from age 90 years onwards. Dates of death 
were obtained from municipality records, with the censoring date 31 December 2009 
(until ages 95–97 years). Specific data on cause of death were obtained from Statistics 
Netherlands, where all national death certificates are coded according to the Interna-
tional Classification of Diseases and Related Disorders, 10th revision (ICD-10).18 Causes of 
death were divided into two groups: cardiovascular mortality (ICD codes I00–I99) and 
non-cardiovascular mortality (all other ICD codes).
Statistical analysis
Participants were divided into two groups based on the NT-proBNP levels (lowest 
gender-specific tertile vs. middle and highest gender-specific tertile). Baseline sum-
mary characteristics are reported as mean with standard deviation (SD) for continuous 
variables and as numbers with percentage for categorical variables. Distributions of 
categorical clinical characteristics were compared using X2 tests, and continuous data 
were compared using independent t-tests. Time to event curves were constructed with 
the Kaplan–Meier method and compared using log rank test. Hazard ratios (HR) and 
corresponding 95% confidence intervals (CIs) were calculated with Cox proportional 
hazard models. The analysis of the mortality risk for the lowest tertile NT-proBNP com-
pared with the middle/highest tertiles NT-proBNP was adjusted for the continuous 
systolic blood pressure value. The analysis of the mortality risk for low systolic blood 
pressure compared with high systolic blood pressure was adjusted for the continuous 
NT-proBNP value. The HRs for the two NT-proBNP groups were calculated with Cox pro-
portional hazard models, containing the systolic blood pressure category (low or high) 
as a categorical variable. These HRs were adjusted for sex only, because the present 
study focused on the question of whether the predictive value of low systolic blood 
pressure for mortality in very old age is dependent on the presence of (subclinical) 
heart failure and not on in-depth aetiology.19 All participants were 90 years of age, so 
no adjustment for age was made. HRs per increase in SD for systolic blood pressure at 
age 90 years and NT-proBNP at age 90 years, respectively, were also analysed with Cox 
proportional hazard models. In the additional model, the HRs were adjusted for the use 
of antihypertensive medication and history of diabetes, cardiac morbidity, other vascu-
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lar morbidity, non-cardiovascular morbidity (including history of COPD, malignancies, 
arthritis, Parkinson’s disease, and hip fracture), and hypertension. To explore whether 
the predicted difference in mortality risk was attributable to terminally ill patients, 
participants who died within 3 months after baseline were excluded in an additional 
sensitivity analysis. To evaluate the influence of the choice to combine the middle and 
highest tertile of NT-proBNP in the analyses, the analyses were repeated including only 
the lowest and highest tertile of NT-proBNP in the analyses.
Data analysis was performed using SPSS 17 for Windows (SPSS Inc., Chicago, IL, USA).
results
Study population
Table 1 presents the baseline characteristics according to NT-proBNP values. At age 90 
years, < 30% of the participants were male, and almost 40% of the participants were 
institutionalized. Half of the study population had a history of cardiac morbidity, and 
almost half of the population used antihypertensive drugs. At age 90, mean systolic 
blood pressure was 152 mmHg (range 105–203 mmHg). There was no difference in sys-
tolic blood pressure at age 90 between participants with high NT-proBNP and those 
with low NT-proBNP. Participants with high NT-proBNP more often had a history of car-
diac disease compared with those with low NT-proBNP (56% vs. 36%, P = 0.002). There 
were no differences in other clinical and socio-demographic characteristics between 
participants with low and high NT-proBNP (P ≥0.05).
Mortality
During maximal follow-up of 7.2 years (median 3.6), 212 (79%) of the 267 participants 
died from age 90 years onwards. Participants with high NT-proBNP had a 2.9 increased 
mortality risk (95% CI 2.1–4.0) compared with those with low NT-proBNP, adjusted for the 
continuous systolic blood pressure value at age 90 years (HR 2.5, 95% CI 1.7–3.5 when ad-
justed for the use of antihypertensive medication and concomitant diseases mentioned 
in Table 1). A 1 SD increase in NT-proBNP (1915 pg/mL) was associated with an increased 
mortality risk (HR 1.39, 95% CI 1.25–1.55). Participants with low systolic blood pressure had 
a 1.6-fold increased mortality risk (95% CI 1.2–2.1) compared with participants with high 
systolic blood pressure, adjusted for the continuous NT-proBNP value at age 90; and 
HR 2.0 (95% CI 1.4–2.7) when adjusted for the use of antihypertensive medication and 
concomitant diseases mentioned in Table 1. A 1 SD increase in systolic blood pressure (18 
mmHg) was associated with a decreased mortality risk (HR 0.77, 95% CI 1.25–1.55).
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Figure 1 presents the Kaplan–Meier analysis of time to all-cause mortality depending 
on the systolic blood pressure at age 90 years for those in the low and high NT-proBNP 
category. It shows that low systolic blood pressure was associated with an increased cu-
mulative all-cause mortality compared with high systolic blood pressure, in both the low 
and high NT-proBNP categories. In participants with low and in participants with high 
NT-proBNP, those with low systolic blood pressure had an increased all-cause mortality 
risk compared with participants with high systolic blood pressure (Table 2). The same 
was seen after analysis of the data with full adjustments for the use of antihypertensive 
medication and a range of concomitant diseases (HR 2.6, 95% CI 1.3–5.3 in participants 
with low NT-proBNP and low systolic blood pressure compared with those with low 
NT-proBNP and high systolic blood pressure, and HR 2.1, 95% CI 1.5–3.1 in participants 
with high NT-pro-BNP and low systolic blood pressure compared with those with high 
NT-proBNP and high systolic blood pressure). When the same analysis was carried out 
table 1. Baseline sociodemographic and clinical characteristics at age 90 years, according to N-terminal 









Male (%) 73 (27%) 25 (28%) 48b (27%)
Institutionalized (%) 100 (38%) 32 (36%) 68b (38%)
Primary school only (%) 167 (63%) 55 (61%) 112b (64%)
State pension only (%) 41 (15%) 10 (11%) 31b (18%)
Systolic blood pressure (SD) 152 (18) 152 (17) 151c (18)
History of (non)cardiovascular comorbidity
Cardiac morbidityd (%) 131 (49%) 32 (36%) 99e (56%)
Other vascular morbidityf (%) 44 (17%) 15 (17%) 29b (16%)
Non-cardiovascular morbidityg (%) 170 (64%) 55 (61%) 115b (65%)
Hypertension (missing n=5) (%) 145 (55%) 44 (50%) 101b (58%)
Use of antihypertensive drugs
(missing n=46) (%)
104 (47%) 30 (41%) 74b (50%)
Diabetes 47 (18%) 11 (13%) 36 b (21%)
SD, standard deviation.




d Presence of a medical history of myocardial infarction, angina pectoris, arrhythmias, or heart failure.
e X2 P = 0.002.
f Including history of stroke and peripheral arterial disease.
g Including history of chronic obstructive pulmonary disease, malignancies, arthritis (including arthrosis, rheumatoid ar-
thritis and polymyalgia rheumatica), Parkinson’s disease, and hip fracture.
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High  systolic blood pressure (n=49) 
Low systolic blood pressure (n=41) 
Age (years) 
Participants at risk 
High  systolic blood pressure (n=49) 
Low systolic blood pressure (n=41) 
Age (years) 
Participants at risk 
Figure 1. Cumulative all-cause mortality depending on the systolic blood pressure at age 90 years for (a) 
participants from age 90 years onwards with low NT-proBNP(<284 pg/mL for women and <306 pg/mL for 
men); and (b) for participants with high NT-proBNP (≥284 pg/mL for women and ≥306 pg/mL for men)
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for cause-specific mortality, the same risk patterns were observed for cardiovascular 
and non-cardiovascular mortality (Table 2).
When participants who died within 3 months after baseline were excluded, similar 
increased mortality risks were seen. In both those with low and those with high NT-
proBNP, low systolic blood pressure still predicted increased mortality risk (HR 1.9, 95% 
CI 1.0–3.3 and HR 1.6, 95% CI 1.1–2.2, respectively).
When the analyses were repeated including only the lowest and the highest NT-
proBNP tertile, the same results emerged (data not shown).
disCussion
This study shows that, in nonagenarians, low systolic blood pressure defined as ≤ 150 
mmHg is predictive for an almost doubled mortality compared with high systolic blood 
pressure, in those without (subclinical) heart failure based on low NT-proBNP levels as 
well as in those with high NT-proBNP levels. Therefore, we could not confirm the hy-
pothesis that impaired cardiac function with concomitant low systolic blood pressure, 
in part, underlies the association between low blood pressure and increased mortality. 
The potential clinical relevance of these findings, after replication in another cohort, 
table 2. Mortality in low/high N-terminal pro-brain natriuretic peptide categories, depending on systolic 




Low systolic blood 
pressurea
(93/113)b




Low NT-proBNPe 30/41 22/49 2.0 (1.1-3.4)
High NT-proBNPe 66/72 94/105 1.7 (1.2-2.3)
Cardiovascular mortality
Low NT-proBNP 9/40 6/49 2.5 (0.9-7.2)
High NT-proBNP 22/72 35/101 1.4 (0.8-2.4)
Non-cardiovascular mortality
Low NT-proBNP 20/40 16/49 1.7 (0.9 -3.3)
High NT-proBNP 44/72 58/104 1.8 (1.2 -2.6)
CI, confidence interval; HR, hazard ratio.
a Low systolic blood pressure ≤150 mmHg; high systolic blood pressure >150 mmHg.
b Number of deceased/total.
c Sex-adjusted hazard ratios (95% CI); hazard ratios express risk of mortality associated with low blood pressure compared 
to high blood pressure (as a reference category).
d Complete cause-specific mortality data were missing for five participants.




may become clearer when alternative explanations for the observed inversion of risk 
prediction of low systolic blood pressure in very old age have been studied.
Strengths and limitations of study
The use of tertiles of NT-proBNP could potentially introduce misclassification. At age 
90 years, heart failure was considered absent based on low NT-proBNP values, but, vice 
versa, no explicit diagnosis of heart failure was made based on higher NT-proBNP values. 
The level of the lowest tertile in the present study (<284 pg/mL for women and <306 pg/
mL for men) is, however, in line with cut-off points used to exclude heart failure in earlier 
studies.10,12,13 Also, there was no difference in the predictive value of low systolic blood 
pressure in the analysis adjusted for the continuous NT-proBNP value, confirming that 
the chosen cut-off value did not influence our results. Misclassification by using tertiles 
of NT-proBNP is therefore minimal.
We chose the cut-off value of 150 mmHg for high systolic blood pressure at age 90 
years. This could be seen as an arbitrary choice. However, this value is based on the 
target value of systolic blood pressure used in the 2011 revision of the Dutch Guideline 
on Cardiovascular Risk Management,20 as well as studies assessing the risks/benefits 
of treating hypertension in individuals aged  ≥  80 years,16 indicating that this cut-off 
value may be clinically more relevant than the formal cut-off value of 140 mmHg as 
incorporated in the World Health Organization (WHO) definition of hypertension.21 This 
was supported by the fact that there was no difference in the predictive value of high 
NT-proBNP in the analysis adjusted for the continuous systolic blood pressure value.
It may be considered a limitation of the present study that only participants aged 90 
years were evaluated. Since our study population was a selection of strong survivors, 
we cannot extrapolate our conclusions to younger people. Still, our general population-
based study is well suited to show the ‘proof of principle’ of our research question. 
Nevertheless, replication in other, preferably larger, study populations is warranted.
Comparison with other studies
The relationship between high NT-proBNP and increased mortality risk, as well as the 
relationship between low systolic blood pressure and increased mortality risk described 
in the present study are in line with earlier observational studies in the elderly popu-
lation showing that high (NT-pro)BNP22-25 and low systolic blood pressure2-4 are each 
associated with an increased mortality risk. The present study shows that, in nonagenar-
ians, low systolic blood pressure remains associated with a doubled mortality risk even 
when (subclinical) heart failure is ruled out and regardless of the use of antihypertensive 
medication and concomitant diseases. To our knowledge, no other study has analysed 
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the association between low systolic blood pressure and increased mortality in partici-
pants in whom heart failure was excluded based on their NT-proBNP level.
Implications
Although the present study was not aimed at investigating aetiological mechanisms 
behind the observed associations, it is tempting to hypothesize that the increased all-
cause mortality risk associated with low systolic blood pressure as well as the increased 
all-cause mortality risk associated with heart failure are two unrelated phenomena. This 
finding warrants additional studies on the underlying mechanism(s). Also, instead of fo-
cusing on a monocausal explanation (e.g. heart failure,5 atrophy of the brain, or chronic 
hypoperfusion), low systolic blood pressure in very old age could also be a marker of an 
underlying syndrome that is associated with increased mortality (such as general wast-
ing, inflammation, and sarcopenia). Also, the ‘inversion of risk prediction’ of high blood 
pressure in old age is not a unique phenomenon. In old age, high cholesterol26 and obe-
sity27 are no longer risk factors for mortality, and in some studies have even been shown 
to be associated with better survival. These paradoxical observations have also been 
referred to as ‘reverse epidemiology’, ‘inverse epidemiology’, or ‘risk factor paradox’. 
In chronic dialysis patients, the reverse epidemiology of high blood pressure,28 high 
body mass index,29 and high serum cholesterol or serum creatinine concentration29 has 
also been described. The same reverse epidemiology was observed in other chronic 
diseases such as chronic heart failure,30 advanced COPD,31 and rheumatoid arthritis.32
Conclusion
In conclusion, the present study shows that in very old age, low systolic blood pressure 
is associated with an almost doubled mortality risk, even when there is no evidence 
of underlying heart failure. Thus, heart failure does not underlie the ‘inversion of risk 
prediction’ of systolic blood pressure in very old age. Future studies are needed to 
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To evaluate the independent contributions of both the trend in SBP and the SBP value 
at age 90 to the prediction of mortality in nonagenarians.
Methods
The trend in SBP between 85 and 90 years and SBP at age 90 years were assessed in a 
population-based sample of 271 participants (74 men and 197 women) aged 90 years 
of the Leiden 85-plus Study, an observational population-based prospective follow-up 
study (started 1997). Primary endpoint, followed up over 5 years (median 3.6 years), was 
all-cause mortality.
Results
A decreasing trend in SBP between 85 and 90 years (decline ≥2.9 mmHg/year) was as-
sociated with increased mortality compared to an average SBP trend (hazard ratio 1.45, 
95% confidence interval 1.02–2.06), independent of SBP at age 90. The effect was stron-
ger in institutionalized participants compared to those living independently [hazard 
ratio 1.87 (1.10–3.19) and hazard ratio 1.30 (0.81–2.09)]. After analysis with a fully adjusted 
model, the estimate approached unity [hazard ratio 1.08 (0.60–1.86)]. Overall, 90-year-
old participants with SBP of 150 mmHg or less had a 1.62 times increased mortality risk 
compared to those with SBP more than 150 mmHg (1.21– 2.20), independent of the SBP 
trend in preceding years. This applied to those with and without antihypertensive drugs 
and those with and without history of cardiovascular disease or noncardiovascular dis-
ease. In the fully adjusted model, the estimate was 1.47 (0.90–2.40).
Conclusion
In very old age, both decreasing trend in SBP over the previous 5 years and the current 
SBP value independently contribute to prediction of all-cause mortality. Therefore, in 
individual patients, all available preceding SBP measurements should be taken into 
account.
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introduCtion
Hypertension is a common condition with increasing age,1,2 but, so far, data on the as-
sociation between a single blood pressure measurement and mortality in very old age 
are surprisingly conflicting.3-13 In a large meta-analysis of observational data from 61 
studies,3 both high SBP and DBP were independently predictive of cardiovascular mor-
tality in all age groups. However, this association attenuated considerably with age. In 
contrast, several observational studies in exclusively very old populations have shown 
that low, and not high blood pressure, is associated with increased mortality in very 
old age.4-13 Following a steady rise during earlier life, SBP decreases in very old age.5,14-17 
There is limited information about the clinical significance of this decreasing SBP in the 
individual over time. Decreasing trend in SBP in very old age has been associated with 
an increased mortality risk, but data from these studies are not consistent.5,14,15,17-19
In view of these conflicting data on the associations of different blood pressure 
values and trends over time with mortality, we investigated the association between 
SBP trends and mortality in a cohort of nonagenarians from the Leiden 85-plus Study. 
The present study evaluates the independent contributions of both current SBP value 




The Leiden 85-plus Study is a prospective population-based study among 85-year-old 
inhabitants of the city of Leiden (the Netherlands). Study design and cohort characteris-
tics have been described in detail.20,21 In brief, between September 1997 and September 
1999, 705 people in the 1912–1914 birth cohort reached the age of 85 years and were 
eligible to participate. No exclusion criteria were used. Fourteen people died before 
enrollment; a total of 599 (87%) people gave informed consent and were enrolled. At 
baseline and yearly up to the age of 90 participants were visited at their place of resi-
dence. Figure 1 presents the flowchart of the present study, approved by the Medical 
Ethics Commission of the Leiden University Medical Center.
In this study, the cohort of interest consists of all participants who were alive at age 
90 and for whom blood pressure was measured at age 90 years (n =271).
Blood pressure and blood pressure categories
Each year up to age 90 years blood pressure was measured twice with an interval of 2 
weeks. Blood pressure was measured using a mercury sphygmomanometer, in seating 
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position, after at least 5 min of rest without having performed vigorous exercise during 
the preceding 30 min. The systolic value was measured at the onset of phase 1 of the 
Korotkoff sounds. For the analysis, the mean of the two systolic values for each year was 
used.
As there was no evidence that the relation between SBP and mortality was U-shaped, 
the SBP values at age 90 years were dichotomized into categories, ‘low’ and ‘high’ SBP. 
Low SBP was defined as a SBP of 150 mmHg or less and high as a SBP more than 150 
mmHg. This cut-off was based on the target value used in studies assessing the risks and 
benefits of treating hypertension in individuals aged at least 80 years.22,23
Blood pressure trends
A linear regression of SBP against time was used to assess the individual regression 
coefficient (β) of the blood pressure trend over the 5 preceding years (90–85 years) for 
each participant. Participants were divided into tertiles based on the beta from their 
individual model to describe the trend in SBP. The lowest tertile was considered as a 
‘decreasing trend in SBP’; the highest tertile was considered as an ‘increasing trend in 
SBP’; and the average tertile was considered as an ‘average trend in SBP’.










30 missing data 
63 died 
25 missing data 
55 died 
24 missing data 
38 died 
22 missing data 
49 died 













Figure 1. Flowchart of participants in the Leiden 85-plus Study
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Mortality
All participants were followed for mortality for 5 years from age 90 years onward. Dates 
of death were obtained from municipality records.
Sociodemographic, functional, and clinical characteristics
At age 90 years, participants were visited at their place of residence for face-to-face 
interviews, to perform several tests24-27 and to collect information on sociodemographic 
characteristics. Each participant’s general practitioner (or, if applicable, nursing-home 
physician) was interviewed about the participant’s medical history, using standardized 
questionnaires, including questions on present and past cardiovascular28 (including 
presence of a medical history of myocardial infarction, angina pectoris, arrhythmias, 
or heart failure, or an ECG at age 90 revealing a prior myocardial infarction, atrial fibril-
lation or left ventricular hypertrophy, history of stroke, and peripheral arterial disease) 
and noncardiovascular morbidities (including history of chronic obstructive pulmonary 
disease, malignancies, arthritis, Parkinson’s disease, and hip fracture). Pharmacists pro-
vided detailed information on all medication used by participants.
Statistical analysis
Baseline summary characteristics at age 90 years are reported as medians with inter-
quartile ranges (IQRs) or means with standard deviation (SD) for continuous variables 
and as numbers with percentage (%) for categorical variables. A linear regression of SBP 
against time was used to assess the individual regression coefficient (β) of the blood 
pressure trend over the 5 preceding years (90–85 years) for each participant. Differences 
in change in SBP between men and women were compared using the Mann–Whitney 
U-test. Time-to-event curves were constructed with the Kaplan–Meier method. Haz-
ard ratios and corresponding 95% confidence intervals (CIs) were calculated in Cox 
proportional-hazard models, including the blood pressure category (low or high) or 
trend in SBP (average, decreasing, increasing) as a categorical variable. The independent 
contributions of both SBP value at age 90 and trend in preceding SBP measurements to 
the prediction of mortality were calculated in Cox proportional-hazard models, includ-
ing both blood pressure category (low or high) and category of trend in SBP (average, 
decreasing, increasing). In the sex-adjusted model, all hazard ratios were adjusted for 
sex only, because the present study focused on prediction29 and not cause. In the addi-
tional models, the hazard ratios were subsequently adjusted for baseline characteristics 
from Table 1. The fully adjusted model included adjustment for sex, place of residence 
(institutionalized or not institutionalized), level of education, income, Activities of Daily 
Living Score, history of noncardiovascular disease, Mini-Mental State Examination Score, 
Geriatric Depression Scale Score, Instrumental Activities of Daily Living Score, smoking 
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status, history of diabetes, history of hypertension, use of antihypertensive drugs, total 
plasma cholesterol, history of cardiac or other vascular morbidity,  hemoglobin and 
body weight, all at age 90 years, and SBP at age 85 and 90 years.
As sensitivity analysis, stratified analyses were performed for sex, place of residence 
(institutionalized or not institutionalized), use of antihypertensive drugs, history of 
cardiovascular disease, and history of noncardiovascular disease, all at age 90 years. To 
evaluate the influence of the arbitrary choice to use the blood pressure trend over the 
5 preceding years, the analyses with blood pressure trend were repeated over 1 (90–89 
years), 2 (90–88 years), 3 (90–87 years), and 4 years (90–86 years), respectively.




Of the initial cohort of 599 participants (87% response) at age 85 years, 304 individuals 
survived up to the age of 90 years. Blood pressure measurement at age 90 was miss-
ing for 33 (11%) participants. Therefore, the current analyses included 271 participants. 
Table 1 presents the baseline characteristics. At age 90 years, less than 30% of the par-
ticipants were men, and almost 40% of the participants were institutionalized. Median 
Mini-Mental State Examination Score was 25 points. More than 60% of the study popula-
tion had a history of cardiac morbidity, the majority had a history of hypertension (56%), 
and almost half of the population used antihypertensive drugs.
Blood pressure at age 90 and SBP trends between age 85 and 90 years
At age 90 years, median SBP was 153 mmHg. The number of participants with a low SBP 
(<150 mmHg) was 116 (42.8%); 155 (57.2%) had a high blood pressure.
Overall, the average change in SBP was -1.5 (SD 3.4) mmHg per year (-2.2 mmHg per 
year in men and -1.3 mmHg per year in women; P=0.060), resulting in a mean decrease 
in SBP per participant of 7.3 (SD 29.2) mmHg over the 5 years between the ages of 85 and 
90 years (range -10.8 mmHg to +7.5 mmHg per year). The tertile limits (33 and 67%) of the 
change in SBP were -2.9 and -0.09 mmHg/year.
Mortality
SBP trends between age 85 and 90 years related to mortality after 90
From age 90 years onward, 187 (69%) of the 271 participants died during a median follow-
up of 3.6 (range 0.04–5) years. Figure 2 presents the Kaplan–Meier analysis of time to all-
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table 1. Baseline characteristics of the participants at age 90 years (n=271a)









Men 74 (27.3) 33 (36.7) 22 (24.2) 19 (21.1)
Smoking 32 (11.9) 15 (16.9) 8 (8.9) 9 (10.0)
Institutionalized 101 (37.5) 42 (46.7) 33 (36.3) 28 (31.1)
Low level of education (primary 
school only)
167 (62.1) 56 (62.2) 52 (57.1) 60 (66.7)
Low income (state pension only) 41 (15.2) 15 (16.9) 12 (13.3) 14 (15.6)
Functional status
Mini-Mental State Examination score 
(range 0-30, 30 optimal)
25 (18-28) 22 (15-27) 26 (20-28) 25 (20-28)
Activities of daily living score 
(range 9-36, 9 optimal)
13 (9-21) 16 (10-25) 15 (9-20) 12 (9-20)
Instrumental activities of daily living 
score (range 9-36, 9 optimal)
29 (21-36) 31 (24-36) 30 (23-35) 26 (19-35)
Geriatric Depression Scaleb 
(range 0-15, 0 optimal)
2 (0-5) 2 (1-4) 3 (0-6) 1 (0-4)
(Non)cardiovascular comorbidity
History of cardiac morbidityc 165 (61.3) 59 (66.3) 57 (63.3) 49 (54.4)
History of other vascular morbidityd 43 (16.3) 17 (19.5) 14 (15.9) 12 (13.5)
History of non-cardiovascular 
morbiditye
171 (63.6) 50 (56.2) 57 (63.3) 64 (71.1)
History of diabetes 48 (18.3) 13 (15.1) 17 (18.9) 18 (20.7)
History of hypertension 147 (55.7) 59 (67.8) 44 (50.0) 44 (49.4)
Use of antihypertensive drugs 105 (46.7) 36 (48.6) 41 (51.9) 28 (38.9)
Total cholesterol 5.3 (1.1) 5.1 (0.9) 5.3 (1.1) 5.4 (1.1)
Hemoglobin 8.2 (0.9) 8.1 (0.9) 8.1 (1.0) 8.3 (1.0)
Body weight 66.3 (12.9) 65.4 (13.7) 66.8 (12.1) 66.4 (13.0)
SBP at age 85 years 157.7 (17.6) 165.9 (18.5) 156.8 (16.2) 150.4 (14.6)
SBP at age 90 years 151.4 (18.1) 141.9 (17.1) 150.7 (16.7) 161.5 (15.1)
IQR, interquartile range; SD, standard deviation.
aMissings range from n=0 to n=8, and n=46 for use of antihypertensive drugs.
bIn participants with Mini-Mental State Examination score >18, n=196.
cPresence of a medical history of myocardial infarction, angina pectoris, arrhythmias or heart failure, or an ECG at age 90 
revealing a prior myocardial infarction (Minnesota Code 1-1 or 1-2, excluding 1-2-8), atrial fibrillation (Minnesota Code 8-3-1) 
or left ventricular hypertrophy (Minnesota Code 310, 330 or 340).
dIncluding history of stroke and peripheral arterial disease.
eIncluding history of chronic obstructive pulmonary disease, malignancies, arthritis (including arthrosis, rheumatoid arthri-
tis and polymyalgia rheumatica), Parkinson’s disease, and hip fracture.
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cause mortality depending on the 5-year trend in SBP for the participants who survived 
up to the age of 90 years. It shows that a decreasing 5-year trend (≥2.9mmHg/year) was 
associated with an increased cumulative all-cause mortality compared to an increasing 
or average 5-year trend. Participants with a decreasing 5-year trend in SBP had a 1.5-fold 
increased all-cause mortality risk compared to those with an average SBP trend (hazard 
ratio 1.51, 95% CI 1.07–2.15). When excluding participants who died within 3 months of 
follow-up (to avoid this increased risk being a reflection of terminally ill patients only), 
this increased mortality risk remained unchanged (hazard ratio 1.53, 95% CI 1.07–2.18). To 
evaluate the independent contribution of the trend in the SBP measurements between 
age 85 and 90 years, we analyzed mortality risk of the trends in SBP over 5 years, adjusted 
for SBP at age 90. Participants with a decreasing 5-year trend in SBP had an increased 
all-cause mortality risk (hazard ratio 1.45, 95% CI 1.02–2.06) compared to those with an 
average SBP trend, adjusted for SBP at age 90. There was no difference in mortality risk 
between participants with an average SBP trend and those with an increasing 5-year 
trend in SBP (hazard ratio 1.04, 95% CI 0.72–1.50; hazard ratio 1.18, 95% CI 0.81–1.71 after 
adjustment for SBP at age 90). After analysis of the data with a fully adjusted model, 




Figure 2. Cumulative all-cause mortality depending on the 5-year trend in SBP for the participants from 
age 90 years onward (decreasing trend = -10.8 to -2.9 mmHg/year; average trend = -2.8 to -0.09 mmHg/
year; increasing trend = -0.08 to +7.5 mmHg/year). The number of participants alive at each year of age is 
represented by the n at risk
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ing 5-year trend in SBP versus average SBP trend was 1.08 (95% CI 0.60–1.86) and 0.79 
(95% CI 0.46–1.37) for increasing 5-year trend in SBP versus average SBP trend.
Low versus high SBP at age 90 years
Participants with a low SBP at age 90 had an increased all-cause mortality risk compared 
to those with a high SBP (hazard ratio 1.57, 95% CI 1.18–2.09). To evaluate the independent 
contribution of SBP at age 90 years, we analyzed mortality risk of low versus high SBP at 
age 90 years adjusted for SBP trends. Participants with a low SBP at age 90 had a 1.6-fold 
increased all-cause mortality risk compared to those with a high SBP, adjusted for SBP 
trends (hazard ratio 1.62, 95% CI 1.21–2.20). After analysis of the data with a fully adjusted 
model, including all baseline characteristics mentioned in Table  1 and SBP trends, 
participants with a low SBP at age 90 had a 1.5-fold increased all-cause mortality risk 
compared to those with a high SBP at age 90 years (hazard ratio 1.47, 95% CI 0.90–2.40).
SBP trends stratified by low and high SBP at age 90
To investigate the effect of the trend in SBP in conjunction with SBP at age 90, we ana-
lyzed mortality risk of the trends in SBP over 5 years dependent on SBP at age 90 years. 
Participants with a high SBP at age 90 and an average 5-year trend were considered the 
reference group. Participants with a low SBP at age 90 in combination with a decreas-
ing trend in SBP in the preceding 5 years had a more than doubled all-cause mortality 
risk compared to the reference group (sex-adjusted model hazard ratio 2.39, 95% CI 
1.48–3.88, fully adjusted model hazard ratio 1.62, 95% CI 0.74–  3.52; Table  2). This was 
most prominent in participants with an already low SBP at age 85 years, at the onset of 
the decrease in SBP (Appendix Table a1).
Sensitivity analyses
As sensitivity analyses for the association between a decreasing 5-year trend in SBP 
and mortality, the analyses were stratified for sex, place of residence, use of antihy-
pertensive drugs, history of cardiovascular disease, and history of noncardiovascular 
table 2. All-cause mortality risks for various 5-year trends in SBP, depending on SBP at age 90 years (n=271)
SBP at age 90 years
5-year trend in SBP
(between 85 and 90 years) High (>150mmHg) Low (≤150 mmHg)
Decreasing 1.44 (0.83-2.51) 2.39 (1.48-3.88)
Average 1 (Ref ) 1.68 (0.99-2.82)
Increasing 1.32 (0.82-2.13) 1.45 (0.70-3.02)
Data are presented as sex-adjusted hazard ratios (95% confidence interval).
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disease. Overall, decreasing 5-year trend in SBP predicted an increased mortality risk 
in the different subgroups (Table  3). The effect was stronger in women than in men 
(hazard ratio 1.67, 95% CI 1.08–2.58 and hazard ratio 1.18, 95% CI 0.66–2.11, respectively), 
although there was no significant interaction between the mortality risk associated 
with sex and the risk associated with the trend in SBP between the ages of 85 and 90 
years (P=0.12). The effect was stronger in participants who were institutionalized than in 
those living independently (hazard ratio 1.87, 95% CI 1.10–3.19 and hazard ratio 1.30, 95% 
CI 0.81–2.09). The interaction between mortality risk associated with place of residence 
and the risk associated with the trend in SBP between the ages of 85 and 90 years was 
significant (P=0.01). The average change in SBP was -1.1 mmHg for independently liv-
ing participants and -2.3 mmHg in those who were institutionalized (Mann–Whitney 
U-test, P=0.01). Although the average change in SBP was different between participants 
table 3. All-cause mortality risks for 90-year-old participants with a decreasing 5-year trend in SBP (n=90) 
compared to participants with average SBP (n=91) as well as 90-year-old participants with low SBP (≤150 










Overall 181 (90/91) 1.51 (1.07-2.15) 271 (116/155) 1.57 (1.18-2.09)
Sex
Men 55 (33/22) 1.18 (0.66-2.11) 74 (38/36) 1.65 (0.99-2.76)
Women 126 (57/69) 1.67 (1.08-2.58) 197 (78/119) 1.53 (1.08-2.17)
Place of residence
Institutionalised 75 (42/33) 1.87 (1.10-3.19)c 103 (65/38) 1.30 (0.82-2.07)
Not institutionalised 106 (48/58) 1.30 (0.81-2.09) 168 (51/117) 1.40 (0.94-2.10)
Use of antihypertensive 
drugs
Yes 77 (36/41) 1.46 (0.85-2.51) 105 (41/64) 1.76 (1.09-2.86)
No 76 (38/38) 1.75 (1.03-2.96) 120 (53/67) 2.09 (1.37-3.20)
History of cardiovascular 
disease
Yes 123 (63/60) 1.43 (0.94-2.16) 177 (82/95) 1.49 (1.04-2.11)
No 52 (24/28) 1.64 (0.82-3.27) 87 (29/58) 1.38 (0.81-2.38)
History of non-
cardiovascular disease
Yes 107 (50/57) 1.54 (0.98-2.42) 171 (66/105) 1.45 (1.01-2.08)
No 69 (39/30) 1.50 (0.84-2.67) 98 (48/50) 1.74 (1.06-2.85)
Data are presented as sex-adjusted hazard ratios [95% confidence interval (CI)] except the analysis of the subgroup ‘sex’.
aMissings range from n=0 to n=6, and n=28 for use of antihypertensive drugs.
bMissings range from n=0 to n=8, and n=46 for use of antihypertensive drugs.
cInteraction between mortality risk associated with place of residence and the risk associated with the trend in SBP be-
tween the ages of 85 and 90 years, p=0.01.
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without a history of cardiovascular disease and those with a history of cardiovascular 
disease (-0.9 and 1.8 mmHg, respectively; P=0.04), there was no difference in association 
between a decreasing 5-year trend in SBP and mortality. The same sensitivity analysis 
was performed for the association between low SBP and mortality. Low SBP at age 90 
predicted an increased mortality risk in all different subgroups (Table 3).
As an additional sensitivity analyses, we analysed mortality risks associated with 
trends in SBP over 1–4 years (average, decreasing, increasing). A decreasing trend in 
SBP in the preceding years was still associated with an increased all-cause mortality risk 
when the trend was assessed over 4 years, but not when they were assessed over 1, 2, 
or 3 years.
disCussion
In this prospective, population-based study in nonagenarians, we report a strong as-
sociation between decreasing 5-year trend in SBP and an increased all-cause mortality 
risk. This observation was more pronounced in institutionalized participants. Addition-
ally, we replicated the earlier observed association between low SBP at age 90 and an 
increased all-cause mortality risk. Both the 5-year trend in SBP measurements and the 
SBP value at age 90 contribute independently to the prediction of mortality. This ap-
plied to those with and without antihypertensive drugs at age 90 and in those with 
and without history of cardiovascular disease or noncardiovascular disease. The most 
striking observation is that a decreasing trend in SBP in the preceding 5 years in those 
participants with a low SBP at age 90 predicted a more than doubled mortality risk 
compared to participants with an average 5-year trend in SBP and high SBP at age 90. 
Therefore, repeated blood pressure measurement may contribute to identification of 
older people at risk. This implies looking at the global trend in SBP measurements over 
previous years when interpreting a single blood pressure measurement in very old 
persons in daily practice, and weighing both the absolute current value and the existing 
trend in SBP when making treatment or withdrawal decisions. The full potential clinical 
relevance of these findings may become clearer when biological explanations for the 
observed association have been studied.
The results of previous studies assessing the association between decreasing blood 
pressure and increased mortality risk in old age are not consistent.5,14,15,17-19 In the present 
study, decreasing 4-year and 5-year trend in SBP were associated with an increased mor-
tality risk, whereas, in contrast, there was no significant difference in all-cause mortality 
risk associated with shorter term trends (up to 3 years) in SBP. It has been suggested that 
declining blood pressure is associated with declining health.19 In the present study, the 
association between decreasing trend in SBP and increased mortality risk was stronger in 
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institutionalized participants, yet this association was equally present in participants with 
and without history of cardiovascular disease or noncardiovascular disease. The estimated 
mortality risk associated with the trend in SBP did not change after adjustment for SBP at 
age 90, sex, place of residence (institutionalized or not institutionalized), level of education, 
income, Activities of Daily Living Score, and history of noncardiovascular disease (data not 
shown). After additional adjustments for Mini-Mental State Examination Score, Geriatric 
Depression Scale Score, Instrumental Activities of Daily Living Score, smoking status, history 
of diabetes, history of hypertension, use of antihypertensive drugs, total plasma cholesterol, 
body weight, hemoglobin, SBP at age 85 and 90 years, and history of cardiac or other vascu-
lar morbidity, the estimates approached unity. Although this could indicate that declining 
cardiovascular and cognitive health are true confounders, it is more likely that the adjust-
ments for cardiovascular, cerebral, and cognitive characteristics were made within the causal 
pathway. Therefore, no interpretation regarding cause or causality was made in this study. 
This warrants additional studies on the underlying mechanisms. A new finding of the pres-
ent study is that in nonagenarians, both the trend in preceding SBP measurements and SBP 
value at age 90 independently contribute to the mortality risk; decreasing trend in SBP in the 
preceding 5 years with a low SBP at age 90 predicted the highest mortality risk. The observed 
association between low SBP and an increased mortality risk is in contrast with a large meta-
analysis of observational data from 61 studies;3 however, it is in line with earlier studies in 
exclusively very old populations.4-13,15 Some suggested that this association is caused by poor 
health status,4,5 whereas in the present study, the association between low SBP and increased 
mortality risk was equally present in participants with and without history of cardiovascular 
disease or noncardiovascular disease, as reported in other studies.8-12,15 After adjustment for 
the baseline characteristics in the fully adjusted model, the estimated mortality risk associ-
ated with low SBP remained similar (initial model hazard ratio 1.62, 95% CI 1.21–2.20 and fully 
adjusted model hazard ratio 1.47, 95% CI 0.90–2.40). The observed association between SBP 
at age 90 years and mortality in the present study is linear until it reaches a plateau from SBP 
160–170mmHg onward. Therefore, it seems that ‘the lower the SBP, the worse’ rather than ‘the 
higher the blood pressure, the better’. In addition to the association between a decreasing 
trend in preceding SBP measurements and increased mortality, there might also be a trend 
for increased mortality with an increasing trend in SBP, especially when SBP at age 85 years is 
low (appendix Table a1). This could indicate that variability in blood pressure is also associated 
with increased mortality. Previous studies showed that higher variability in blood pressure 
is associated with an increased risk of cardiovascular events and mortality in middle-aged 
individuals.30-32 Relevant data for older individuals on blood pressure variability are scarce; 
whether blood pressure variability is associated with increased mortality in very old age is, 
therefore, subject for further research.
A strength of the present study is that we used a population-based sample of nonagenar-
ians. There were no exclusion criteria for participation in the Leiden 85-plus Study: 87% of 
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the general population aged 85 years living in Leiden participated and there was a complete 
follow-up for mortality. Furthermore, a blood pressure pattern was established over 5 years, 
with annual per-protocol measurements within the study. Also, use of the mean SBP values 
of two separate measurements annually, reduced regression to the mean. The present study 
focuses on prediction in clinical practice; SBP, being the most used blood pressure value in 
clinical practice, is therefore, the relevant blood pressure value to investigate. The choice of 
a cut-off value used for SBP at age 90 and the use of tertiles to describe the trends in SBP can 
be considered arbitrary. However, as there are no clinical cut-offs for these values and trends 
in very old age, it seems sensible to adhere to the target value used in studies assessing the 
risks/benefits of treating hypertension in individuals aged at least 80 years.22,23 Furthermore, 
there was no evidence for a U-shaped relationship between mortality and SBP at age 90 years, 
indicating that dichotomization of the blood pressure range can be considered correct. In 
addition, our relatively small number of participants reduced the statistical power to detect 
differences in mortality risk in subgroup analyses, creating the possibility of type-II errors. 
Due to a lack of power, we were unable to analyze the effects of declining SBP and low SBP on 
cause-specific mortality. Finally, as our study population included only strong survivors, thus 
a selected study population, we cannot extrapolate our conclusions to younger age groups.
In conclusion, at age 90 years, both the trend in SBP over the preceding 5 years and 
current SBP value independently contribute to all-cause mortality risk; the combination 
of a decreasing trend in SBP in the preceding 5 years and low SBP at age 90 predicts the 
highest mortality risk. Therefore, in very old age, all available preceding SBP measurements 
contribute to a more accurate prediction of mortality and should be taken into account. In 
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table a1. All-cause mortality risks for various 5-year trends in SBP, depending on SBP at age 85 and 90 years 
(n=271)
SBP at age 90 years
5-year trend in SBP
(between 85 and 90 years) SBP at age 85 years High (>150mmHg) Low (≤150 mmHg)
Decreasing High (>150mmHg) 1.50 (0.85-2.64) n=33 1.98 (1.15-3.41) n=39
Low (≤150 mmHg) x 4.30 (2.32-7.96) n=11
Average High (>150mmHg) 1 (ref ) n=45 1.70 (0.83-3.49) n=16
Low (≤150 mmHg) 2.09 (0.49-8.89) n=2 1.78 (0.99-3.20) n=28
Increasing High (>150mmHg) 1.16 (0.67-2.00) n=48 x
Low (≤150 mmHg) 1.85 (1.02-3.36) n=27 1.56 (1.14-2.14) n=15
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To assess predictive values for recurrent cardiovascular disease, of models with age 
and sex, traditional cardiovascular risk markers, and SMART risk score, with and without 
N-terminal pro-B-type natriuretic peptide (NT-proBNP). To assess treatment effect of 
pravastatin across low and high risk groups identified by these models.
Methods and Results
Post-hoc analysis in participants (n=2348, age 70-82 years) with a history of cardiovascu-
lar disease within the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER), 
a randomized placebo-controlled study. Primary endpoint was recurrent cardiovascular 
event (myocardial infarction and/or stroke) or cardiovascular mortality. The models 
with age and sex, traditional risk markers and SMART risk score had comparable pre-
dictive values (area under the curve (AUC) 0.58, 0.61 and 0.59, respectively). Addition 
of NT-proBNP to these models improved AUCs with 0.07 (pdiff=0.003), 0.05 (pdiff=0.009) 
and 0.06 (pdiff  <0.001), respectively, and net reclassification improvements were 41% 
(p<0.001), 39% (p<0.001) and 25% (p=0.002), respectively. For the model with age, sex 
and NT-proBNP, the hazard ratio for the primary endpoint with pravastatin treatment 
compared to placebo was 0.67 (95%CI 0.48-0.96) for participants in the high third of 
predicted risk and 0.94 (0.65-1.36) in the low third, number needed to treat 16 (8.7-121) 
and 116 (17-∞), respectively.
Conclusion
In secondary cardiovascular prevention in old age predictive value of traditional risk 
markers and SMART risk score is poor. Addition of NT-proBNP improves prediction of 
recurrent cardiovascular disease and mortality. A minimal model including age, sex and 
NT-proBNP predicts as good as complex risk models including NT-proBNP.
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introduCtion
Persons with known cardiovascular disease are at high risk of recurrent events, and 
guidelines worldwide advise statins for secondary prevention,1-3 even in old age.4 Yet, 
prescription of secondary preventive treatment decreases with age.5,6 This might be 
caused by dilemmas regarding starting, continuing, or safely stopping preventive treat-
ment, as physicians have to weigh postponed benefit versus current harm and priorities 
of care in old age. As many more patients are surviving their initial cardiovascular event, 
prediction of recurrent events becomes increasingly important. Ideally, the risk markers 
or risk models used, not only predict recurrence risk, but predict treatment effect as 
well. In secondary prevention in old age, traditional cardiovascular risk markers loose 
predictive value7,8 and most risk scores are either too complex or only apply to restricted 
subgroups of hospitalized patients.9,10 To date, for the general older population, no 
risk scores for prediction of recurrence risk and/or treatment effect exist. Recently the 
SMART risk score was developed to predict recurrent cardiovascular events in a younger 
cohort of patients with a history of cardiovascular disease (mean age 60 years),11 but this 
risk score has not been validated in older age.
A new promising predictor of cardiovascular risk in old age is N-terminal pro-brain 
natriuretic peptide (NT-proBNP),8,12-15 a polypeptide released in reaction to myocardial 
wall stress or ischemia. Addition of NT-proBNP to a model with the traditional cardiovas-
cular risk markers or SMART risk score might improve predictive performance, especially 
in older patients.
Therefore, we first validated the SMART risk score in 1157 old subjects (mean age 75 
years, placebo group) with a history of cardiovascular disease participating in the PRO-
spective Study of Pravastatin in the Elderly at Risk (PROSPER).16 We compared the predic-
tive value for recurrent cardiovascular events and mortality of the SMART risk score, 
with a model with traditional cardiovascular risk markers and with a minimal model 
including only age and sex. Second, we investigated whether addition of NT-proBNP 
to these prediction models could improve prediction. Third, we studied whether treat-
ment effect of pravastatin was different across groups with low and high risk, calculated 
with the different models.
methods
Study design
Data in this study were obtained from the PROSPER study, a randomized, double-blind, 
placebo-controlled trial designed to investigate the effect of pravastatin in prevention 
of vascular events in older persons. Details of the design and outcome of PROSPER have 
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been published elsewhere.16-18 Between December 1997 and May 1999, a total of 5804 
individuals were screened and enrolled in Scotland, Ireland and the Netherlands. Men 
and women aged 70-82 years were recruited. A total of 2565 participants had a history of 
cardiovascular disease (including stable angina, intermittent claudication, stroke, tran-
sient ischemic attack, myocardial infarction and vascular surgery), and were included in 
the present study.
Individuals with congestive heart failure (New York Heart Association functional 
class III and IV) or poor cognitive function (Mini-Mental State Examination score  <24 
points) were excluded from PROSPER.18 Participants were randomized into a group who 
received 40 mg pravastatin a day and a control group receiving placebo and were fol-
lowed 3.2 years on average. Throughout the study, all study personnel was unaware of 
the allocated study medication status of the participants. The institutional ethics review 
boards of all centres approved the protocol and all participants gave written informed 
consent. The protocol adhered to the principles of the Declaration of Helsinki.
Traditional cardiovascular risk markers and SMART risk score variables
During the pre-randomization visits, baseline participant characteristics were col-
lected,17 including a detailed medical history with date(s) of last cardiovascular events, 
smoking status and current medication use. Participants weight, height and blood 
pressure were measured and fasting venous blood samples were taken including 
biobank samples. A history of diabetes was defined as a known diabetes mellitus or 
fasting blood glucose  >7 mmol/L. Baseline serum creatinine levels were measured at 
central laboratories. Estimated glomerular filtration rate (eGFR) was estimated using the 
Modification of Diet in Renal Disease equation19:
eGFR=186 x serum creatinine level (mg/dl)(-1.154) x age(-0.203) x 0.742 [if female]
Data of eGFR was missing for 5 included participants. High sensitivity C-reactive protein 
(hsCRP) levels were measured on stored K2EDTA (at -80ºC) baseline samples.20 Data of 
hsCRP was missing for 41 included participants due to technical problems. All laboratory 
analyses were conducted by technicians blind to the identity of samples and outcomes. 
Time since last cardiovascular event was calculated from the recorded date(s) of last 
cardiovascular event.
NT-proBNP measurements
Blood samples were taken at 6 months after baseline in EDTA tubes.18 The venous blood 
samples were stored in the biobank. From biobank samples NT-proBNP was determined 
using electrochemiluminescence immunoassay on a Roche Modulator E170. NT-proBNP 
measurements were missing for 167 participants due to technical problems.
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Outcomes
For the present study the primary outcome of the trial was used: the combination of 
definite or suspect death from coronary heart disease, non-fatal myocardial infarction 
and fatal or non-fatal stroke.18 The PROSPER Endpoints Committee assessed all end-
points. The Endpoints Committee was blinded for study medication, and for plasma 
levels of NT-proBNP.
Statistical analysis
From the 2565 participants with a history of cardiovascular disease, participants with 
coronary events or who died in the first 6 months of the study (n=50) and participants 
with missing NT-proBNP values at 6 months (n=167) were excluded. Baseline summary 
characteristics are reported as median with interquartile range (IQR) for continuous vari-
ables and as numbers with percentage (%) for categorical variables for all participants 
(n=2348) and for participants on placebo and those on pravastatin separately. Follow-up 
for the outcomes was calculated from 6 months onward up to a maximum of 2.5 years.
Calibration of the SMART risk score
For calculation of the SMART risk score the SMART formula11 was used (Supplement 1).
Calibration of the SMART risk score for the PROSPER trial population was investigated 
by comparing the predicted versus observed cardiovascular disease risks. Participants 
taking placebo were divided into five categories of 2.5-year predicted risk,  <10%, 10 
to <20%, 20 to <30%, 30 to <40%, and ≥40%. Within each category, predicted risk was 
compared to actual observed Kaplan-Meier cardiovascular disease free survival at 2.5 
year follow-up (Supplement 2). In addition, the fitted regression coefficient (beta) was 
assessed in a Cox proportional hazard model fit, using only the linear prognostic score 
(A) as variable.21 The continuous predictive SMART prognostic risk score was multiplied 
with the calculated regression coefficient to recalibrate the SMART risk score for the 
PROSPER population, as the calibrated regression coefficient significantly differed from 
1 (0.466, p<0.001).
Risk prediction with three models in the placebo group
The 2.5-year cardiovascular disease risk (%) was predicted for all participants using a 
Cox proportional hazards models (complete case analysis) fit based on 1) age and sex 
(minimal model); 2) age, sex, smoking, systolic blood pressure, high density lipoprotein 
and total cholesterol, history of diabetes, history of hypertension, history of myocardial 
infarction, history of stroke/transient ischaemic attack and history of surgery for periph-
eral artery disease (all as assessed at baseline; traditional model); and 3) recalibrated 
SMART risk score (SMART model). Using the continuous predicted risks from the three 
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models, area under the curves (AUCs) and receiver operating characteristic (ROC) curves 
with p-values (level of significance 5%) and 95% confidence intervals for difference were 
calculated.
Additional value of NT-proBNP in the placebo group
NT-proBNP was non-normally distributed and therefore log transformed. Cox propor-
tional hazards models for the occurrence of the primary endpoint were fitted based 
on three additional models including 1) minimal model plus NT-proBNP; 2) traditional 
model plus NT-proBNP; and 3) SMART model plus NT-proBNP. AUCs and ROC curves 
were calculated and compared to the reference models without NT-proBNP (STATA 12.1). 
Cross validation method was used for comparison of optimism-corrected estimates.22
Net Reclassification Improvement
We calculated the category-less Net Reclassification Improvement (NRI) for the primary 
endpoint with logistic regression, comparing the models including NT-proBNP to the 
reference models without NT-proBNP.23,24
Treatment effect comparing placebo and treatment group
Predicted risk for the primary endpoint was calculated for all participants using the 
regression coefficients from the models developed in the placebo group. The treatment 
effect of pravastatin according to the thirds of predicted risk for the primary endpoint of 
the three models including NT-proBNP was assessed in three ways. First, the presence of 
multiplicative interaction was tested by adding the interaction term ‘treatment x thirds 
of predicted risk’ in the Cox model. Second, per third of predicted risk, the absolute num-
bers of events in the pravastatin group and the placebo groups were calculated and the 
absolute risk reduction (ARR) by pravastatin was calculated using the life-table method. 
Differences in ARR between the thirds of predicted risk, were tested using a z-test. 
Numbers needed to treat (NNT) were calculated over 2.5 years based on the difference 
in cumulative proportion surviving in the pravastatin and placebo groups. Finally, the 
hazard ratio (HR) for the occurrence of cardiovascular events in the pravastatin group 
versus placebo group was calculated using the Cox proportional hazard model per third 
of predicted risk.
results
Table  1 presents the baseline characteristics for the participants. Of the 2348 partici-
pants 57% (n=1334) were men, 73% (n=1713) had a history of cardiac disease, 25% (n=594) 
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had a history of cerebrovascular disease and 17% (n=408) had a history of peripheral 
disease. The median NT-proBNP level was 176 ng/L (IQR 96-359).
Traditional cardiovascular risk markers and SMART risk score
During the maximum follow-up of 2.5 years, 16% (n=187) of participants in the placebo 
group (n=1157) developed a cardiovascular event or died of cardiovascular disease (pri-
mary endpoint). We calculated AUCs and created ROC curves for the minimal model, 
the traditional model and the SMART model, with the primary endpoint at 2.5-year 
(Figure 1). The three models had similar AUCs: 0.58 (95% CI 0.54-0.63) for the minimal 
model; 0.61 (95%CI 0.57-0.66) for the traditional model; and 0.59 (95% CI 0.54-0.63) for 
the SMART model (Table 2).







Age (years) 75 (73-78) 75 (73-78) 75 (73-78)
Male Sex 1334 (57) 658 (57) 676 (57)
Current smoker 427 (18) 214 (19) 213 (18)
Systolic blood pressure (mm Hg) 152 (138-168) 151 (136-168) 153 (138-168)
High-density lipoprotein cholesterol 
(mmol/L)
1.2 (1.0-1.4) 1.2 (1.0-1.4) 1.2 (1.0-1.4)
Total cholesterol (mmol/L) 5.6 (5.0-6.3) 5.6 (5.0-6.2) 5.6 (5.0-6.3)
History of diabetes mellitus 200 (9) 99 (9) 101 (9)
History of coronary artery diseasea 1713 (73) 831 (72) 882 (74)
History of myocardial infarction 701 (30) 365 (32) 336 (28)
History of cerebrovascular diseaseb 594 (25) 299 (26) 295 (25)
History of peripheral artery diseasec 408 (17) 204 (18) 204 (17)
History of surgery for peripheral artery 
disease
113 (5) 53 (5) 60 (5)
Time since first diagnose 6.0 (3.0-11.0) 6.0 (3.0-11.3) 7.0 (3.0-11.0)
Creatinine clearanced 52 (43-63) 52 (43-63) 52 (43-63)
High-sensitivity C-reactive protein (mg/L)e 3.1 (1.6-6.3) 3.1 (1.7-6.1) 3.2 (1.6-6.5)
N-terminal pro-brain natriuretic peptide 
(ng/L)f
176 (96-359) 174 (96-354) 177 (95-367)
Data are presented as median with interquartile range (IQR) for continuous variables and as numbers with percentage (%) 
for categorical variables.
a History of angina, myocardial infarction, coronary artery bypass surgery or percutaneous transluminal coronary angio-
plasty.
b History of transient ischemic attack or stroke.
c History of claudication or surgery for peripheral disease.
d Calculated with the Cockroft-Gault formula , missing n=5.
e Missing n=41.
f Measured at 6 months after study entrance.
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Figure 1. Receiver operating characteristic curves for three models without NT-proBNP (dotted lines) and 
with NT-proBNP (black lines) for cardiovascular events and cardiovascular mortality. Model with age and 
sex (top, minimal model) model with traditional risk markers (middle, traditional model) and model with 
SMART risk score (bottom, SMART model) (p Δ 0.003, 0.003 and< 0.001, respectively)
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Addition of NT-proBNP
Figure 1 shows that the addition of NT-proBNP improved the AUC of all three models 
similarly. Addition of NT-proBNP to the minimal model increased the AUC from 0.58 
to 0.65 (95% CI 0.6-0.70), Δ 0.07, p for difference (pdiff) =0.003. The increase in AUC was 
similar for both the traditional and the SMART model (Δ 0.05, pdiff=0.009 and Δ 0.06, 
pdiff<0.001, respectively) (Table 2).
The minimal model with addition of NT-proBNP performed similarly to the tradi-
tional model with addition of NT-proBNP (pdiff=0.26) as well as to the SMART model plus 
NT-proBNP (pdiff =0.87).
Cross validation of the minimal model led to an AUC of 0.56 (95%CI 0.52-0.61) and for 
the minimal model with addition of NT-proBNP to an AUC of 0.64 (95%CI 0.60-0.69). The 
difference between these two cross validated AUCs was 0.08 (p=0.0016). Cross valida-
tion of the other models showed similar results (data not shown).
table 2. Absolute number of events in tertiles of predicted risk of the different models, with area under 
the curve (AUC), delta AUC with addition of NT-proBNP, and category free net reclassification improvement 
(NRI) for the primary endpoint
Absolute numbers of events in 
tertiles of risk
Risk models Low Medium High AUC (95%CI) ΔAUC p Δ NRI (%) p value
Minimal model 43 (11.2) 68 (17.8) 76 (19.4) 0.58 (0.54-0.63)
Minimal model 
plus NT-proBNP
58 (14.8) 56 (14.4) 73 (19.4) 0.66 (0.61-0.70) 0.07 0.0026 41 <0.001
Traditional model 42 (11.0) 56 (14.6) 89 (22.7) 0.61 (0.57-0.65)
Traditional model 
plus NT-proBNP
35 (9.0) 54 (13.7) 98 (26.1) 0.66 (0.62-0.70) 0.05 0.0091 39 <0.001
SMART model 60 (15.8) 60 (16.0) 65 (16.9) 0.59 (0.54-0.63)
SMART model 
plus NT-proBNP
53 (14.4) 65 (16.0) 67 (18.3) 0.65 (0.61-0.70) 0.06 0.0006 25 0.002
Primary endpoint: 2.5-year risk for cardiovascular morbidity and mortality in the placebo group.
Minimal model including age and sex.
Traditional model including age, sex, smoking, systolic blood pressure, high density lipoprotein and total cholesterol, his-
tory of diabetes, history of hypertension, history of myocardial infarction, history of cerebrovascular disease and history of 
surgery for peripheral artery disease.
SMART model including age in years, age in years2, sex, sex, smoking, systolic blood pressure, histories of diabetes, coro-
nary artery disease, cerebrovascular disease, abdominal aortic aneurysm and peripheral artery disease, years since first 




The category-less NRI with addition of NT-proBNP to the minimal model was 41% 
(p<0.001, 57% of participants reclassified up, minus 43% reclassified down in the group 
that experienced the endpoint, plus 63% reclassified down, minus 37% reclassified up 
in the group that did not experience the endpoint). The category-less NRI with addition 
of NT-proBNP to the traditional model was 39% (p<0.001). Addition of NT-proBNP to the 
SMART model had an NRI of 25% (p=0.002) (Table 2).
Treatment effect
Overall, in the 2348 participants with a history of cardiovascular disease within the 
PROSPER study population, the ARR by pravastatin treatment was 3.6% for 2.5 year. 
After, the 2.5-year HR for the development of the primary endpoint was 0.77 (95% CI 
0.62-0.95) in the pravastatin group compared to the placebo group.
We divided participants according to thirds of predicted risk. Multiplicative interac-
tion between treatment and thirds of predicted risks of all models was not significant 
(all p>0.1). Table 3 shows the treatment effect (2.5-year) of pravastatin according to thirds 
of predicted risk of cardiovascular disease and mortality for three risk models, all with 
NT-proBNP, including number of events (primary endpoint), ARR and HR. The ARR in 
primary endpoint with 2.5-year pravastatin treatment in the low predicted risk group of 
the minimal model plus NT-proBNP was 0.86% (95% CI -4.1-5.9) and in the high predicted 
risk group 6.2% (95% CI 0.8-11.5), difference=5.3% (95% CI 2.0-12.6, p diff=0.07). (Figure 2) 
In this model, participants with the highest predicted risk (highest third) and pravas-
tatin treatment had a HR of 0.67 (95% CI 0.48-0.96) for the development of the primary 
endpoint compared to those on placebo. The NNT during 2.5 years with pravastatin was 
16 (95% CI 8.7-121). HR for participants in the lowest third of predicted risk was 0.94 (95% 
CI 0.65-1.36), with a NNT of 116 (95% CI 17-∞).
disCussion
This study shows that the predictive value of traditional cardiovascular risk markers and 
the (recalibrated) SMART risk score is poor in older people with a history of cardiovas-
cular disease, and comparable to prediction with a model including only age and sex. 
Addition of NT-proBNP improved prediction of recurrent cardiovascular disease and 
mortality. We observed that a model with age, sex and NT-proBNP predicts as good as 
more complex risk models including NT-proBNP. Moreover in high risk individuals as 
identified by age, sex plus NT-proBNP level, NNT for 2.5-year pravastatin treatment was 
16, whereas, in patients with a low predicted risk in this model, NNT was 116. As many 
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more patients are surviving their initial cardiovascular event, prediction and prevention 
of recurrent events becomes increasingly important and according to our study NT-
proBNP is a promising risk predictor in old age.
Comparison with the literature
The combination of prediction of recurrent events and treatment effect has seldom 
been examined in secondary cardiovascular prevention. Our findings contrast with 
the findings in the CORONA and Heart Protection Study in patients with chronic heart 
failure, where the benefit of rosuvastatin was higher in the low NT-proBNP group. How-
ever, this relationship might have been modified by other patient characteristics in this 
specific population of ischemic heart failure patients.25
Previously, Sattar et al. have investigated within the entire PROSPER study popula-
tion whether hsCRP could predict treatment effect and they observed that hsCRP did 
not predict response to statin therapy.20 In contrast, Drewes et al. found a positive rela-
tion of homocysteine levels with treatment effect.26 However, physicians are perhaps 
table 3. Treatment effect after 2.5-year of treatment with pravastatin according to tertiles of predicted risk 
of cardiovascular disease and mortality for three risk models including NT-proBNP
Events in 
pravastatin group








Low 54 (13.9) 58 (14.8) 0.86 (-4.14-5.86) 0.94 (0.65-1.36)
Medium 41 (10.3) 56 (14.4) 4.2 (-0.48-8.86) 0.70 (0.47-1.05)
High 55 (13.5) 73 (19.4) 6.2 (0.83-11.54) 0.67 (0.48-0.96)
Traditional model 
plus NT-proBNP
Low 26 (6,6) 35 (9.0) 2.5 (-1.28-6.33) 0.73 (0.44-1.20)
Medium 45 (11.6) 54 (13.7) 2.0 (-2.73-6.77) 0.83 (0.56-1.24)
High 79 (19.4) 98 (26.1) 7.2 (1.18-13.29) 0.71 (0.53-0.95)
SMART model 
plus NT-proBNP
Low 45 (11.3) 53 (14.4) 3.0 (-1.86-7.78) 0.78 (0.52-1.15)
Medium 42 (11.6) 65 (16.0) 4.5 (-0.43-9.45) 0.72 (0.49-1.06)
High 60 (14.9) 67 (18.3) 4.0 (-1.45-9.43) 0.78 (0.55-1.11)
Minimal model including age and sex.
Traditional model including age, sex, smoking, systolic blood pressure, high density lipoprotein and total cholesterol, his-
tory of diabetes, history of hypertension, history of myocardial infarction, history of cerebrovascular disease and history of 
surgery for peripheral artery disease.
SMART model including age in years, age in years2, sex, sex, smoking, systolic blood pressure, histories of diabetes, coro-
nary artery disease, cerebrovascular disease, abdominal aortic aneurysm and peripheral artery disease, years since first 
diagnosis of vascular disease, estimated glomerular filtration rate and high sensitive C-reactive protein.
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more inclined to determine serological biomarkers that have a direct association with 
cardiac strain such as NT-proBNP.
With regard to prediction of recurrent events, the predictive value of NT-proBNP has 
been described in primary as well as in secondary prevention,12 even in very old age8,13,15 
and in persons with27 and without clinical heart failure.28 In the literature, addition of 
NT-proBNP to traditional cardiovascular risk markers results in an improvement of the 
AUC ranging from 0.01-0,1.8,12,29 The HOPE study findings29 showed that of all biomarkers 
added to traditional risk markers in secondary prevention, NT-proBNP was the strongest 
(increase in AUC 0.05 as compared to traditional risk markers, p<0.001). This is consistent 
with the present study in a secondary prevention population. The SMART risk score, 
which includes hsCRP, was not superior to the model including age and sex. This might 
be explained by the decreasing predictive value of hsCRP with age,30,31 as our study 
population was older by around 15 years on average, than the population in which the 
original SMART risk score was developed. Also, even if the true risks are the same in 
both populations, shrinkage can be expected when a prediction model is validated in 
a different population.
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Figure 2. Absolute risk reduction (ARR) and number needed to treat to benefit (NNTB) and number needed 
to harm (NNTH) with pravastatin for 2.5 years, according to tertiles of predicted risk, p-value of difference 
between lowest and highest predicted risk group for NNTB, estimated using z-test
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Implications for clinical practice and future research
In our cohort of older persons the SMART risk score had to be recalibrated as it overes-
timated actual risk for recurrent cardiovascular disease and cardiovascular mortality, 
especially in persons assigned to the high risk category. Physicians should be aware of 
the derivation cohort characteristics, before applying new risk scores to their patients.
Our result suggest than in secondary cardiovascular prevention in old age, measuring 
NT-proBNP helps physicians and patients better estimate recurrence risk. A more complex 
model including traditional cardiovascular risk markers including the history of cardiovas-
cular disease, or the SMART risk score, is not required as predictive value was the same in a 
model with age and sex only. However this requires further validation and then evaluation 
of clinical impact, especially regarding treatment effect, before it can be implemented. 
Nevertheless, the wide availability of NT pro-BNP assays in routine laboratories means 
clinical translation is ultimately possible, although current assays remain expensive.
Strengths and limitations
To analyse NT-proBNP levels in the well-defined secondary prevention population 
within the PROSPER study population, and to calculate treatment effect accordingly, 
was a tempting opportunity, since placebo controlled RCT’s concerning treatment ef-
fect of statins are ethically impossible to perform in the present era.
PROSPER is a randomised controlled trial, therefore, the participants were selected 
using more strict criteria than in a cohort study, like the SMART study. The observed 
risks could have been influenced. NT-proBNP was measured at 6 months, not at baseline 
due to limited plasma availability in latter. Therefore, follow-up was calculated form 6 
months onward. Pravastatin treatment had no effect on NT-proBNP levels in the first 6 
months, which is in line with previous studies.32 Since NT-proBNP was measured at 6 
months from baseline, we had to exclude participants that already died or experienced 
a cardiac event in the first 6 months of the study. As these participants are likely to be 
high risk individuals in the models, exclusion may have led to an underestimation of the 
true magnitude of predictive value of the models. Finally, the relatively low AUCs might 
be considered as a limitation. However, an AUC between 0.65 and 0.70 is common in 
studies in older populations.8,33
Conclusions
Due to increased survival following an acute cardiovascular event, prediction of recur-
rent events is becoming increasingly important and according to our study NT-proBNP 
is a promising risk predictor. Addition of NT-proBNP to (traditional) risk models improves 
prediction in old age and a minimal model with age, sex and NT-proBNP is as good as 
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2.5-year cardiovascular disease risk (%) = (1- 0.9488765exp[A + 2.099]) x 100%
Where A is the prognostic risk score:
A = -0.0850 x age in years + 0.00105 x (age in years)2 + 0.156 [if male] + 0.262 [if current 
smoker] + 0.00429 x systolic blood pressure in mmHg + 0.223 [if diabetic] + 0.140 [if 
history of coronary artery disease] + 0.406 [if history of cerebrovascular disease] + 0.558 
[if abdominal aortic aneurysm] + 0.283 [if peripheral artery disease] + 0.0229 x years 
since first diagnosis of vascular disease - 0.426 x HDL-cholesterol in mmol/L + 0.0959 x 
total cholesterol in mmol/L - 0.0532 x eGFR in mL/min/1.73m² + 0.000306 x (eGFR in mL/






















Predicted risk with the SMART risk score  
Figure 1. Calibration plot of 2.5-year predicted risk with the SMART risk score versus observed risk of cardio-
vascular events and cardiovascular mortality in PROSPER study participants
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The impact of renal function and its changes and the occurrence of cardiovascular 
events on changes in N-terminal pro-brain natriuretic peptide levels (NT-proBNP) is 
unknown in very old age.
Objective
To assess whether increase in NT-proBNP levels over time is still associated with cardiac 
disease and mortality in very old age, independent of renal function.
Methods
Changes in NT-proBNP levels between age 85 and 90 years and their associations with 
incident cardiac disease, (cardiovascular) mortality and renal function were assessed in 
252 nonagenarian participants from a population-based sample of the Leiden 85-plus 
Study.
Results
Median NT-proBNP increase over five years was 154 pg/mL (inter-quartile range: 29-549), 
while in the same period estimated glomerular filtration rate (eGFR) decreased by 5.8 
mL/min/1.73m2 (standard deviation 7.5). Participants with increasing NT-proBNP levels 
more frequently developed heart failure and atrial fibrillation (Odds Ratio 2.79, 95% 
confidence interval (CI) 1.11-7.02 and 2.63, 95% CI 1.02-6.79, respectively, adjusted for eGFR 
at age 85 and change in eGFR) between age 85 and 90 years. Increasing NT-proBNP 
between age 85 and 90 years was associated with an increased cardiovascular mortality 
risk after age 90 years compared to not-increasing NT-proBNP levels (hazard ratio 1.62, 
95% CI 1.04-2.51, adjusted for eGFR at age 90 years and change in eGFR).
Conclusion
In the oldest old, increase in NT-proBNP is associated with incident heart failure and 
atrial fibrillation and risk for cardiovascular mortality, independent of decreasing renal 
function.
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introduCtion
Brain natriuretic peptide (BNP) and N-terminal pro-BNP (NT-proBNP) are the two frag-
ments of the prohormone proBNP, which is released by ventricular myocytes in reaction 
to ventricular wall stress and hypoxia,1-3 and by the atrial myocytes in reaction to highly 
frequent atrial myocyte contraction in atrial fibrillation.4 Thus, natriuretic peptide levels, 
especially NT-proBNP levels, are diagnostic blood-based biomarkers for heart failure, 
but also prognostic markers for incident cardiovascular morbidity and mortality in 
middle-aged 5-7 and older persons.8-11
Few studies are available on the course of the NT-proBNP levels over time, their 
association with cardiovascular risk and the underlying conditions related to changes 
in NT-proBNP in older age, although not in the oldest old.12,13 One prospective observa-
tional cohort study of cardiovascular disease in older people (mean age 73 years) found 
that NT-proBNP levels frequently change over time, reflecting a dynamic change in 
subsequent cardiovascular risk concordant with the direction of change of NT-proBNP.13 
Moreover, a community-based study of subjects aged 70 years and over, found that 
not only single NT-proBNP levels, but also their changes over time, are predictive of 
all-cause and cardiovascular mortality.12 Changes in NT-proBNP levels were associated 
with cardiovascular risk indicators such as male gender, ischemic electrocardiogram 
(ECG) changes, renal dysfunction, and lower left ventricle ejection fraction, together 
with intercurrent cardiovascular events.12
NT-proBNP levels increase with age, even in the absence of heart failure or cardio-
vascular disease.14 NT-proBNP is mainly cleared through renal excretion.15 Impaired renal 
function, which is common in old age and is a strong predictor for cardiovascular dis-
ease as well, is associated with higher levels of NT-proBNP.16 Therefore, declining renal 
function could, at least in part, underlie the increase in NT-proBNP over time. There are 
currently no studies available that address this hypothesis in the oldest old. It has been 
suggested that, besides symptoms, signs and patients’ history, decline in renal function 
should also be considered when interpreting NT-pro-BNP values in old age.16,17
We hypothesized that an increase in NT-proBNP level still reflects cardiac morbid-
ity and risk for cardiovascular mortality in old age, independent of decreasing renal 
function. Therefore, we assessed whether 1) increase of NT-proBNP levels over five years 
is associated with incident cardiovascular disease during these five years; 2) whether 
this association is independent of the renal function; and 3) whether persons with an 
increase in NT-proBNP over five years have a higher mortality risk after these five years. 
Our analyses were performed in a population-based cohort of nonagenarians of the 
Leiden 85-plus Study, where NT-proBNP levels and estimated glomerular filtration rate 





The Leiden 85-plus Study is a prospective population-based study in 85-year-old inhab-
itants of the city of Leiden, the Netherlands.18 Between September 1997 and September 
1999, 705 people in the 1912-14 birth cohort reached the age of 85 years and were eligible 
to participate in the study. No exclusion criteria were used. Fourteen people died before 
enrolment; a total of 599 (87%) people gave informed consent and were enrolled. The 
Medical Ethics Commission of the Leiden University Medical Center approved the study 
and all participants gave informed consent.
Characteristics
Participants were visited yearly by a research nurse at their place of residence until death 
or the age of 90. During these visits information on sociodemographic characteristics 
was collected and participants underwent face to face interviews, blood sampling and 
electrocardiography.19
Of the 599 participants enrolled in the study at age 85 years, 295 died before the age 
of 90, and 32 refused blood sampling. An additional 20 participants missed creatinine 
clearance values at age 85 and/or 90 years. Thus, for the present study NT-proBNP levels 
and creatinine clearance at age 85 and 90 years were available for 252 participants (Flow 
chart Supplemental Figure 1).
NT-proBNP
Non-fasting blood samples were drawn before 11 a.m. Plasma samples were stored at 
−80°C. Serum levels of NT-proBNP were measured for all participants at age 85 and 90 
years using the NT-proBNP assay of Roche Diagnostics (Mannheim, Germany) on a Roche 
Modular E-17 automated immunoanalyzer. Predefined change patterns were used to 
analyse the change in NT-proBNP levels from 85 to 90 years. These change patterns 
were defined considering the biological variability of NT-proBNP in healthy populations 
and were based on change patterns used in previous studies:12,20 1) increasing: change 
in NT-proBNP levels ≥ +100% [i.e. NT-proBNP level at least doubled]; or 2) not-increasing: 
change in NT-proBNP levels < +100%.
Renal function
Plasma creatinine concentrations were measured according to the Jaffe method using a 
fully automated Hitachi 747 analyzer (Hitachi, Tokyo, Japan). Creatinine clearances were 
estimated using the Cockcroft–Gault formula.21
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Incident cardiovascular events
Incident cardiovascular events were recorded between the age of 85 and 90 years. Each 
participant’s general practitioner (or, if applicable, nursing home physician) was inter-
viewed annually about the participant’s medical history. ECGs were recorded yearly. 
Incident atrial fibrillation was defined as the appearance of Minnesota Code 8-3-1 on 
the ECG. Incident myocardial infarction was defined by newly diagnosed myocardial 
infarction according to the general practitioner and incident myocardial infarction on 
the ECG. Information about incident stroke and heart failure was collected from the 
general practitioner.
Mortality
All participants were followed for mortality from age 90 years onwards. Dates of death 
were obtained from municipality records, with censoring date 31 December 2011 (until 
ages 97 – 99 years). Specific data on cause of death were obtained from Statistics Neth-
erlands, where all national death certificates are coded according to the International 
Classification of Diseases and Related Disorders, 10th revision (ICD-10).22 Causes of death 
were divided into two groups: cardiovascular mortality (ICD codes I00–I99) and non-
cardiovascular mortality (all other ICD codes).
Statistical analysis
Summary characteristics are reported as mean with standard deviation (SD) or median 
with interquartile range (IQR) for continuous variables and as numbers with percentage 
(%) for categorical variables. Relations between the two groups of NT-proBNP change 
and various clinical characteristics were explored using chi-squared tests and indepen-
dent t-test as appropriate.
Differences in incident events that occurred between age 85 and 90 years between 
the two groups of NT-proBNP change were analysed using logistic regression analysis. 
We performed our analysis in three steps. First, crude analyses were performed. Second, 
we added eGFR at age 85 years. Third, change in eGFR between age 85 and 90 years was 
added. For incident atrial fibrillation and heart failure, subjects with a history of this 
event at age 85 years where excluded in this analysis.
For mortality after age 90, time to event curves were constructed with the Kaplan-
Meier method, adjusted for competing risks. Hazard ratios (HR) and corresponding 95% 
confidence intervals (CIs) were calculated with Cox proportional-hazard models. We 
performed our analyses in four steps. First, crude analyses were performed. Second, 
we added eGFR at age 85 years. Third, the change in eGFR between age 85 and 90 years 
was added. Furthermore, in a fully adjusted model we also added sex, smoking, total 
cholesterol and high-density lipoprotein cholesterol, systolic blood pressure, hyperten-
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sion, body mass index, plasma creatinine, history of diabetes, myocardial infarction, 
stroke, atrial fibrillation and heart failure and the use of antihypertensive medication, 
loop diuretics and/or digoxin. All participants were 90 years of age, so no adjustment 
for age was made.
Data analysis was performed using SPSS 20 for Windows (SPSS Inc., Chicago, IL, USA).
Sensitivity analysis
First, analyses were performed excluding all participants with atrial fibrillation and/or 
heart failure at baseline (n=38). Second, analyses for mortality after age 90 were repeated 
excluding participants with atrial fibrillation and/or heart failure at baseline, or incident 
atrial fibrillation and/or heart failure between the age of 85 and 90 years, since these 
incident events could have influenced both the change in NT-proBNP as well as the 
mortality risk from age 90 years onwards. Third, to evaluate the additional value of the 
use of serial NT-proBNP values, analyses were adjusted for NT-proBNP levels at baseline. 
Fourth, analyses were performed in a subsample of participants with an eGFR >30 mL/
min/1.73m2 at age 90 years and in a subsample of participants with a decrease in eGFR 
of less than 15% over five years (< one SD of change in eGFR between 85 and 90 years 
compared to eGFR at age 85 years). Finally, to evaluate the influence of the choice to use 
two categories of change, the analyses with change in NT-proBNP were repeated using 
four categories of change in NT-proBNP (reduction in NT-proBNP, rise by 0-50%, rise by 
50-100% and rise by more than 100%), respectively.
results
Study population
Change in NT-proBNP and eGFR levels was available for 252 nonagenarian participants, 
67 (26.6%) men and 185 (73.4%) women. Median NT-proBNP increase over five years was 
154 pg/mL (IQR 29-549). Participants were divided into two groups based on the NT-
proBNP change pattern (increasing levels n=119 and not-increasing levels n=133).
Renal function decreased between the age of 85 and 90 years, with a mean eGFR 
decrease of 5.6 mL/min/1.73m2 over five years (SD 7.5).
Table  1 shows the relations between the two change patterns of NT-proBNP and 
various clinical characteristics. History of hypertension and lower eGFR at age 85 years 
were associated with an increasing NT-proBNP level over time (p=0.025 and p=0.023, 
respectively). Participants with atrial fibrillation on the baseline ECG (n=17) had higher 
median levels of NT-proBNP at age 85 years compared to those without atrial fibrillation 
on the baseline ECG (1228.4 pg/mL [751.1-1673.8] and 225.8 pg/mL [134.5-391.1], respec-
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tively, p<0.001). However, participants with an increasing NT-proBNP level less often had 
atrial fibrillation on the ECG at age 85 years (p=0.011).
table 1. Characteristics at age 85 and 90 years dependent on NT-proBNP change pattern (85-90 years) 
(n=252)







Men (%) 67 (26.6) 38 (31.9) 29 (21.8) 0.069
Characteristics at age 85
Smoking (%) 27 (10.7) 10 (8.4) 17 (13.0) 0.551
Systolic blood pressure (mmHg) 157.9 (17.3) 158.7 (18.0) 157.2 (16.7) 0.498
Diastolic blood pressure (mmHg) 78.5 (8.6) 78.4 (9.0) 78.6 (8.1) 0.845
Hypertensiona (%) 152 (60.3) 81 (68.1) 71 (54.2) 0.025
Diabetes Mellitusb (%) 34 (13.5) 24 (20.2) 10 (7.6) 0.004
Body mass index (kg/m2) 27.4 (4.5) 27.2 (4.4) 27.6 (4.5) 0.452
History of myocardial infarction 
(clinical or on ECG) (%)
26 (10.3) 15 (12.6) 11 (8.3) 0.267
History of heart failure (%) 21 (8.3) 13 (10.9) 8 (6.0) 0.165
History of arrhythmia (%) 41 (16.3) 18 (15.1) 23 (17.3) 0.741
History of stroke (%) 15 (6.0) 5 (4.2) 10 (7.5) 0.274








Estimated glomerular filtration rate 
(mL/min/1.73m2)
46.7 (10.5) 45.1 (9.7) 48.1 (11.0) 0.023
Total cholesterol (mmol/L) 5.8 (1.0) 5.8 (1.0) 5.9 (1.0) 0.266
High-density lipoprotein 
cholesterol (mmol/L)
1.4 (0.4) 1.3 (0.4) 1.4 (0.4) 0.046
C-reactive protein (mg/L) 3.0 (1.0-5.0) 3.0 (1.0-5.0) 3.0 (0.25-6.0) 0.819








Estimated glomerular filtration rate 
(mL/min/1.73m2) at age 90 years
40.7 (11.7) 38.3 (11.0) 42.9 (11.9) 0.002
Change in NT-proBNP (pg/mL) 








Change in estimated glomerular 
filtration rate (mL/min/1.73m2) 
(between 85 and 90 years)
-5.6 (7.5) -6.7 (8.4) -5.0 (6.6) 0.078
Categorical data are presented as frequencies (%); continuous data as mean (SD) or median (IQR). Missings n=0-6.
aHistory of hypertension and/or systolic blood pressure >160mmHg and/or antihypertensive medication.




Between age of 85 and 90 years a total of 23 participants (9.1%) had an incident myo-
cardial infarction. A total of 26 participants (11.1%) had incident atrial fibrillation, eleven 
participants (4.4%) experienced an incident stroke and 25 (10.9%) developed incident 
heart failure. Table  2 shows that increasing NT-proBNP was associated with incident 
atrial fibrillation (HR 3.11, 95% CI 1.25-7.70) and newly developed heart failure (HR 2.77, 
95% CI 1.14-6.71), but not with incident myocardial infarction or stroke. The adjustment 
for eGFR at age 85 years and the change in eGFR between age 85 and 90 years did not 
alter the observed associations. The sensitivity and specificity of increasing NT-proBNP 
in identifying participants with atrial fibrillation were 73% and 53%, respectively, with 
a positive predictive value of 16.4% and a negative predictive value of 94.1%. For the 
identification of participants with heart failure, sensitivity of increasing NT-proBNP was 
68% and specificity 57%, with a positive predictive value of 16.0% and a negative predic-
tive value of 93.5%.
Time to death from age 90 years onwards by NT-proBNP change pattern is shown in 
Figure 1. Participants with an increasing NT-proBNP level over five years had an 1.6 fold 
increased all-cause mortality risk compared to those with an not-increasing NT-proBNP 
level when adjusted for eGFR at age 90 years and change in eGFR between age 85 and 
90 years (HR 1.57, 95% CI 1.20-2.05) (Figure 1a). Increasing NT-proBNP level over five years 
table 2. NT-proBNP change pattern and incident cardiovascular events
NT-proBNP change pattern 




(n=133) Crude Model 2a Model 3a
























For incident heart failure and incident atrial fibrillation, subjects with a history of the relevant event where excluded in 
this analysis .
a Model 2 adjusted for eGFR at age 85 years; model 3 adjusted for eGFR at age 85 years and change in eGFR over five years.
b Data from general practice (or, if applicable, nursing home physician) and ECG recordings.
c Missing n=1.
d Excluded n= 17; missing n=1.
e Excluded n=21; missing n=1.
f Missing n=11.
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HR 1.7 (95% CI 1.3-2.2) 
NT-proBNP change pattern 
increasing 
not-increasing 
HR 1.9 (95% CI 1.3-3.0) 
 
HR 1.6 (95% CI 1.1-2.2) 
 
Figure 1. Cumulative mortality from age 90 years onward in relation to the relative change in NT-proBNP levels 
(n=252) a.) all-cause mortality; b) cardiovascular mortality; c) non-cardiovascular mortality
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was associated with an increased cardiovascular mortality risk (HR 1.62, 95% CI 1.04-2.51) 
(Figure 1b) and non-cardiovascular mortality risk (Figure 1c). The same trend was seen 
for the fully adjusted model (Supplemental Table 1).
Sensitivity analysis
First, when the analyses where repeated in a subgroup of participants without heart 
failure or atrial fibrillation at baseline (n=252-38=214), the same results emerged (data 
not shown). Second, after exclusion of participants with atrial fibrillation and/or heart 
failure at baseline or incident atrial fibrillation and/or heart failure between the age 
of 85 and 90 years, the association of increasing NT-proBNP with higher mortality re-
mained similar (all-cause mortality HR 2.02, 95% CI 1.39-2.92; cardiovascular mortality 
HR 1.93 95% CI 1.04-3.58; non-cardiovascular mortality HR 1.99 95%CI 1.24-3.20). Third, 
when the analyses were adjusted for NT-proBNP levels at baseline, the results did not 
materially changed (data not shown). Fourth, in participants with relatively normal and 
stable renal function (eGFR >30 mL/min/1.73m2 at age 90 years and a decrease in eGFR 
of less than 15% over five years, respectively), increasing NT-proBNP level over five years 
was still associated with an increased cardiovascular mortality risk compared to an not-
increasing NT-proBNP level (data not shown). Finally, we analysed the association of 
incident cardiovascular events and mortality risks with four categories of change in NT-
proBNP (reduction in NT-proBNP, rise by 0-50%, rise by 50-100% and rise by more than 
100%). Participants with a rise by >100% more frequently had incident atrial fibrillation 
and heart failure compared to the other change categories (data not shown). Finally, 
only participants with a rise by >100% had an increased cardiovascular mortality risk (HR 
2.03, 95% CI 1.04-3.94), adjusted for eGFR at age 90 years and change in eGFR between 
age 85 and 90 years, compared to participants with a reduction in NT-proBNP.
disCussion
This study shows that in the oldest old an increase in NT-proBNP level, as compared to 
a not-increasing NT-proBNP level, is predictive for an increased cardiovascular mortality 
risk, independent of (change in) renal function. An increase in NT-proBNP in this group 
is also associated with incident atrial fibrillation and newly developed heart failure, 
irrespective of the renal function. Thus, interpretation of NT-proBNP and NT-proBNP 
changes over time in the oldest old is challenging, as they do not only reflect parallel 
changes in renal function.
In line with the literature, we found a predictive value of increasing NT-proBNP levels 
for increased mortality risk. This has been reported earlier in two observational studies 
in an elderly population.12,13 As described previously, NT-proBNP levels were found to 
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increase with advancing age.5,12,14,23 Present study investigates two possible biological 
pathways related to increasing NT-proBNP levels over time in old age: 1) decreasing 
renal function and 2) cardiovascular pathology. There is some evidence in the literature 
suggesting that, in old age, decreasing renal function could, in part, underlie increasing 
NT-proBNP levels over time.16 In an observational study among subjects aged 70 years,12 
increasing NT-proBNP levels were associated with lower eGFR. In line with these finding, 
the present study found that, in the oldest old, lower eGFR is related to increase in NT-
proBNP levels over time. However, in line with the second possible pathway, the present 
study found that incident atrial fibrillation is independently related to increasing NT-
proBNP levels over time in the oldest old. This concords with a study by Patton et al.24 
that reported that NT-proBNP is a remarkable predictor of incident atrial fibrillation. In 
the present study atrial fibrillation at baseline was inversely associated with increasing 
NT-proBNP levels. This is probably due to already higher baseline levels in participants 
with atrial fibrillation compared to those without atrial fibrillation. When the level of 
NT-proBNP is already high, this value is less likely to double (increase of  ≥100%). It is 
known from literature that patients with atrial fibrillation have markedly higher levels 
of NT-proBNP.24,25
This study provides insight into the biology and clinical applicability of NT-proBNP in 
very old age. To our knowledge, ours is the first to evaluate the relation between increas-
ing NT-proBNP levels and cardiac morbidity and mortality independent of the change 
in renal function in the oldest old. We show that an increase in NT-proBNP of at least 
100% is driven by cardiac abnormalities causing increased wall stress or highly frequent 
atrial contraction, in the oldest old mainly heart failure and atrial fibrillation, and that this 
association is independent of renal function. Although a decline in renal function should 
still be considered when interpreting NT-pro-BNP values in old age, our results call for the 
awareness of physicians to consider the presence of (so far unrecognized) atrial fibrillation 
and/or heart failure when observing an increase in NT-proBNP in the oldest old. Future 
studies are needed to evaluate the appropriate time intervals for NT-proBNP testing, to 
evaluate the clinical thresholds for changes in NT-proBNP levels over time and to evaluate 
the use of NT-proBNP in risk assessment in the oldest old in clinical practice, as well as its 
cost effectiveness.
This study has several strengths: a large group of oldest-old individuals who were 
recruited from the general population without exclusion criteria, complete long-term 
follow-up for cause-specific mortality and a low attrition rate. Nevertheless, this study has 
a number of limitations. We included a specific population in our cohort, namely partici-
pants with NT-proBNP measurements at both age 85 and 90 years, a selection of strong 
survivors. There was a significant difference in almost all baseline characteristics between 
participants alive at age 90 years and those who died between ages 85 and 90 years 
(Supplemental Table 2). Participants alive at age 90 years and included in our analyses less 
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frequently had a history of cardiovascular disease and had higher systolic and diastolic 
blood pressure and total cholesterol, all factors associated with better survival in very 
old age.26-28 Persons with serious heart failure at age 85 were likely to have died before 
they could reach the age of 90 years, and were therefore not included in our study. The 
selection of strong survivors has most likely led to an underestimation of the found asso-
ciation (odds ratios) between the increase in NT-proBNP and incident events. Second, the 
diagnosis of heart failure and myocardial infarction in the present study was based solely 
on the information from the participant’s general practitioner and electrocardiography, 
respectively. No echocardiography was available to confirm the diagnosis of heart failure. 
Misclassification may have played a role. However, this is a representation of routine clini-
cal practice during the time the study was conducted. Still, our general population-based 
study is well suited to show the determinants associated with changes in NT-proBNP in 
the oldest old and therefore generalizable to the older population.
In conclusion, the present study shows that in the oldest old, an increase in NT-proBNP 
is associated with incident heart failure and atrial fibrillation, independent of changes is 
renal function. Also, this increase still reflects increased risk for (cardiovascular) mortal-
ity, independent of decreasing renal function.
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supplemental Figure 1. Flow chart
aPPendix
supplemental table 1. Hazard ratio for mortality for participants with increasing NT-proBNP (n=119) compared to 






Unadjusted 1.7 (1.3-2.2) 1.9 (1.3-3.0) 1.6 (1.1-2.2)
Adjusted for sex and eGFR at age 90 1.6 (1.2-2.1) 1.6 (1.1-2.5) 1.5 (1.1-2.2)
Adjusted for sex, eGFR at age 90 and 
change in eGFR between 85 and 90 
years
1.6 (1.2-2.1) 1.6 (1.0-2.5) 1.5 (1.1-2.2)
Adjusted for sex, renal function and risk 
factors for and history of cardiovascular 
diseasea
1.8 (1.3-2.3) 1.8 (1.1-2.9) 1.7 (1.2-2.5)
Hazard Ratio and corresponding 95% confidence intervals.
a Risk factors for and history of cardiovascular disease include smoking, total cholesterol and high-density lipoprotein cho-
lesterol, systolic blood pressure, hypertension, body mass index, plasma creatinine, history of diabetes, myocardial infarc-
tion, stroke, atrial fibrillation and heart failure and the use of antihypertensive medication, loop diuretics and/or digoxin.
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supplemental table 2. Baseline characteristics for participants that reached the age of 90 years and those 
who died before they could reach the age of 90 years
Reached the age of 90 years
Characteristics at age 85 years Yes (n=252) No (n=308) P value
Men (%) 67 (26.6) 120 (39.0) 0.002
Smoking (%) 27 (10.7) 58 (18.8) 0.006
Systolic blood pressure (mmHg) 157.9 (17.3) 152.9 (19.6) 0.001
Diastolic blood pressure (mmHg) 78.5 (8.6) 75.3 (10.1) <0.001
Hypertensiona (%) 152 (60.3) 172 (55.8) 0.238
Diabetes Mellitusb (%) 34 (13.5) 56 (18.2) 0.134
Body mass index (kg/m2) 27.4 (4.5) 26.9 (4.5) 0.191
History of myocardial infarction (clinical or on 
ECG) (%)
26 (10.3) 65 (21.1) <0.001
History of heart failure (%) 21 (8.3) 49 (15.9) 0.007
History of arrhythmia (%) 41 (16.3) 75 (24.4) 0.021
History of stroke (%) 15 (6.0) 41 (13.3) 0.004
Atrial fibrillation on ECG (%) 17 (6.7) 39 (12.7) 0.019
NT-proBNP (pg/mL) 239 (141-429) 461 (192-1320) <0.001
Creatinine (umol/L) 92.8 (19.9) 103.5 (41.4) <0.001
Estimated glomerular filtration rate (mL/
min/1.73m2)
46.7 (10.5) 44.3 (12.3) 0.019
Total cholesterol (mmol/L) 5.8 (1.0) 5.6 (1.2) 0.017
High-density lipoprotein cholesterol (mmol/L) 1.4 (0.4) 1.3 (0.4) 0.003
C-reactive protein (mg/L) 3.0 (1.0-5.0) 5.0 (2.0-10.0) 0.003
Categorical data are presented as frequencies (%); continuous data as mean (SD) or median (IQR).
Missings n=0-17.
a History of hypertension and/or systolic blood pressure >160mmHg and/or antihypertensive medication.











The studies presented in this thesis address new possibilities in cardiovascular risk 
prediction in old age. This general discussion describes the context of cardiovascular 
risk prediction and prevention, research among an older population and important 
epidemiological themes emerging from this thesis, then makes recommendations for 
future research and, finally, highlights key points arising from this thesis.
1.  CardiovasCular risk PrediCtion and Prevention
Cardiovascular disease already has a substantial impact in old age and will probably 
have an even greater impact on society due to the projected increase in the prevalence 
of cardiovascular disease in the coming decades. To manage the expected epidemic of 
cardiovascular disease, it is essential to study (prediction) models that identify those in-
dividuals at highest or lowest (relative) risk and, when preventive strategies are proven 
effective, that these strategies be implemented, especially in older populations.
1.1 Prevention paradox
The prevention paradox, first formally described in 1981 by Sir Geoffrey Rose, describes 
the apparently contradictory situation where the majority of cases of cardiovascular 
disease occur among the population with mild to moderate increased risk, and only a 
minority of cases come from the minority of people at high risk.1 This should be taken 
into account when considering primary prevention of cardiovascular disease, because 
it leads to the use of two distinct and complementary strategies: the ‘low-risk popula-
tion approach’ and the ‘high-risk individual approach’. Interventions with the goal to 
improve health at the population level aim to produce small changes in a large number 
of people and have relatively little influence on the health of the majority of people. 
That is, for one person to benefit, many people have to change their behavior even 
though they receive no benefit. These interventions include, for example, promoting 
non-smoking, a healthy diet and physical exercise, and are usually implemented by the 
public health sector. No studies have focused on the effect of these interventions in the 
older population. However, prevention by promoting a healthy lifestyle starting early in 
life remains important.
The high-risk approach aims to identify individuals at highest risk, followed by 
appropriate interventions that may lowetr individual risk. However, this strategy has 
limited potential for population health improvement; moreover, focusing exclusively 
on those at high absolute risk overlooks the burden of events that will occur among 
the average majority. The Dutch Guideline Cardiovascular Risk Management more or 
less recommends screening for individuals at high cardiovascular risk.2 However, there 
is no evidence that this approach is effective in old age. The first step in this high-risk 
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approach in old age is to identify new possibilities in cardiovascular risk prediction in 
order to select high-risk older individuals - as described in this thesis.
1.2 Use of classic and new cardiovascular risk predictors in old age
The risk of cardiovascular disease is considered to be multifactorial. However, in 
older people, established classic risk factors and corresponding risk scores, such as the 
Framingham Risk Score and the SCORE risk function, do not qualify for adequate risk 
prediction. The Leiden 85-plus Study showed that the Framingham Risk Score in no way 
predicts cardiovascular risk in persons aged 85 years and over.3 Therefore, the study on 
classic and new cardiovascular risk predictors in old age, as described in this thesis, is 
a first step to optimize risk stratification and subsequent prevention of cardiovascular 
disease in older persons.
Part 1 of this thesis shows that the use of multiple blood pressure measurements, 
expressed as variability in blood pressure or trend in blood pressure, can identify older 
persons at high risk for (cardiovascular) mortality (Chapters 2 and 4). Blood pressure is 
one of the most frequently recorded measurements in the medical file, at least in general 
practice. Therefore, the use of multiple blood pressure measurements in cardiovascular 
risk prediction is expected to be easy to implement. Additional research is needed to 
assess whether risk stratification based on multiple blood pressure measurements is 
effective and whether additional benefit might be obtained from reducing variability 
in blood pressure. Identifying the association between inflammation (evidenced by 
higher levels of interleukin-6) and blood pressure variability (Chapter 3) might help to 
elucidate the underlying mechanisms of variability in blood pressure. Observational 
studies in exclusively older populations have shown that not high, but low systolic 
blood pressure predicts increased mortality.4-6 It is suggested that low blood pressure 
is merely a proxy for heart failure and is, therefore, associated with increased mortal-
ity. If that is the case, then it is better to evaluate the absence or presence of heart 
failure when assessing cardiovascular risk, rather than (low) blood pressure. Low blood 
pressure, however, does predict increased mortality in very old age even without heart 
failure (Chapter 4).
Part 2 of this thesis addresses the use of N-terminal pro-brain natriuretic peptide 
(NT-proBNP) in old age. NT-proBNP has predictive value in cardiovascular prevention in 
old age.7-11 In older patients with a history of cardiovascular disease, NT-proBNP not only 
predicts recurrent cardiovascular disease and cardiovascular mortality, but also predicts 
treatment effect of pravastatin (Chapter 6).
Risk prediction based on (risk prediction models including) serological biomarkers 
such as homocysteine12 and NT-proBNP, in combination with statin treatment in persons 
with high levels of these serological biomarkers, is likely to result in better targeting 
of preventive medication in older people with truly increased risks of cardiovascular 
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disease (Chapter 6). General practitioners may be more inclined to determine serologi-
cal biomarkers linked to cardiac damage, such as and NT-proBNP and troponin T. These 
markers of cardiac damage provide more information for the general practitioner, in ad-
dition to the cardiovascular risk prediction. For NT-proBNP it was shown that the change 
in NT-proBNP can also be informative. Changes in NT-proBNP do not merely reflect 
changes in renal function; an increase in NT-proBNP is associated with incident heart 
failure and atrial fibrillation, as well as a risk for cardiovascular mortality, independent of 
decreasing renal function (Chapter 7).
1.3 Treatment-risk paradox in the prevention of cardiovascular risk
Research has shown a treatment-risk paradox for primary and secondary prevention of 
cardiovascular disease.13,14 Patients become less likely to receive appropriate treatment 
the older they get. For example, in a study from Ontario in secondary prevention, the 
likelihood of a statin prescription was 6% lower for each year of increase in age.13 A 
study from the United Kingdom showed that in primary prevention for people aged 75 
years and older, the odds of receiving a statin prescription decreased every five-year 
increment in age and that many older people did not receive anti-hypertensive drugs.14 
Both polypharmacy and underprescribing are common among older people.15 It is dif-
ficult to determine whether there is a true under-utilisation of preventive treatment in 
older people; whether low use of preventive treatments in older people is just or unjust. 
Not prescribing these drugs might reflect a considered decision, taking into account 
factors associated with age such as multiple comorbidities, polypharmacy, cognitive 
decline, drug-drug interactions and side-effects such as serious fall injuries associated 
with antihypertensive medications16 and musculoskeletal pain associated with statin 
use17; all of these can make the physician reluctant to prescribe preventive drugs. The 
patient’s choice also plays a role. Nevertheless, there is a striking contrast between 
use of statins and use of antihypertensive drugs in older people, which does indicate a 
possible underuse of statins.14 This could reflect the limited evidence for a benefit from 
the use of statins in the oldest old. The treatment-risk paradox highlights the need for 
a stronger evidence base and clearer guidelines for older people, especially for those 
aged 75 years and over.
1.4 Cardiovascular preventive strategies in old age
With the increasing proportion of older persons in the population, physicians will be 
increasingly challenged to make therapeutic decisions about cardiovascular risk and 
cardiovascular disease in old age. When older patients at high predicted cardiovascular 
risk are identified, physicians need to decide whether or not to advise preventive medi-
cation to their older high-risk patients. The evidence for cardiovascular risk reduction 
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in the oldest old is sparse. Therefore, more research involving the oldest old is needed 
before evidence-based recommendations can be formulated.
Lifestyle changes like dietary changes, exercise and smoking cessation, can be seen 
as individual or population-based preventive strategies. There is little evidence for the 
benefit of these lifestyle changes in the oldest old in the reduction of cardiovascular 
risk. However, there are benefits beyond cardiovascular disease risk, e.g. the benefits 
of exercise with regard to osteoporosis, quality of life and fall prevention18 and the 
benefits in relation to pulmonary diseases. Reports on centenarians have shown that 
a healthy lifestyle initiated at young age, including caloric restriction, abundant intake 
of vegetables rich in antioxidants and moderate intake of alcohol, is associated with 
longevity.19
The evidence supporting prescription of antihypertensive drugs in older patients 
is relatively well established, although few studies have focused on the outcomes of 
control of hypertension in old age compared to middle-aged. Antihypertensive drugs 
are generally considered safe and effective in older patients when aiming for a systolic 
blood pressure of no less than 150 mmHg. The HYVET study showed that antihyper-
tensive treatment with a target systolic blood pressure of 150 mmHg in independently 
living patients over the age of 80 years with or without previous cardiovascular disease 
reduces risk of cardiovascular events and increases life expectancy with a benefit of 
treatment in the first year.20 This is indirectly supported by another study that showed 
no evidence of a J-shaped increased risk at lower blood pressure in old age in patients 
without a history of cardiovascular disease.21
The effect of high blood pressure does vary by cardiovascular endpoint. Heart fail-
ure contributed to a substantial part of the estimated loss of years free of cardiovascular 
disease associated with hypertension. One study discussed whether a blood pressure 
target below 150 mmHg, but not less than 140 mmHg, could be of potential benefit.22 
However, the reduction in cardiovascular events associated with antihypertensive treat-
ment is most likely driven by the decrease in blood pressure and not by achieving the 
target blood pressure of less than 150 mmHg.23 A meta-analysis of individual patient data 
showed that lowering blood pressure provides similar relative protection at all levels of 
baseline cardiovascular risk, but provides greater absolute risk reductions as baseline 
risk increases.24 Nevertheless, when deciding to initiate or continue antihypertensive 
treatment, the potential harms and benefits should be weighed. In another study anti-
hypertensive drugs were associated with an increased risk of serious fall injuries.16
The evidence for use of statins in older persons is less clear. There is insufficient evi-
dence regarding statin treatment beyond the age of 85 years. A statin trial in the oldest 
old is needed.25 Lipid lowering for those with a history of cardiovascular disease and 
high risk of cardiovascular events can be advised up to the age of 85 years. In this thesis 
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it was shown that older persons identified as high risk benefit the most from pravastatin 
treatment (Chapter 6).
Due to the increasing heterogeneity, it is essential to consider each person as an 
individual when decisions are made regarding initiating risk prediction and when 
preventive strategies are made. Patients’ wishes and individual preferences, functional 
status, cognition, comorbidities, goal of care, possible side-effects, and the likelihood 
and duration of the preventive treatment to benefit need to be incorporated in decision-
making, as well as the risk factors. The relatively new risk factor trends and variability 
in blood pressure and/or (change in) NT-proBNP can be useful regarding prediction of 
cardiovascular risk and treatment effect - as described in this thesis.
2. researCh among an older PoPulation
Research among an older population has important theoretical and methodological 
characteristics that need to be recognized and addressed.
2.1 What is ‘old age’?
The term ‘old age’ has a broad interpretation. Traditionally, one is considered old when 
reaching the age of 65 years, reflected in multiple domains of society and economics. 
In PubMed, a database for healthcare literature, the MeSH (Medical Subject Headings) 
-term ‘aged’ is used for persons 65 through 79 years of age. For a person older than 79 
years, the term ‘aged, 80 and over’ is used. However, references to older people may 
range from 60 up to 100 years. Increasing heterogeneity in medical complexity, func-
tion and cognition, one of the most striking features of ageing, may not be apparent 
in the word ‘elderly’ or ‘old’. The introduction of sub-populations like the terms used 
in PubMed, or the three subpopulations ‘young old’ for those aged 65-74 years; ‘old’ for 
those 75-84 years and ‘oldest old’ for those aged 85 years and over can help to describe 
distinct populations. Nowadays, subgroup analyses for age groups are used more 
frequently in healthcare literature, however, most literature still summarizes results for 
those aged 65 years and older using the term ‘elderly’ or ‘old’. Some of the terms used to 
describe an older population have a negative connotation. The use of the term ‘elderly’ 
is considered most undesirable.26 The use of the term ‘older’ is preferred by both older 
people themselves27 and the Human Rights Commission of the United Nations.28
2.2 Heterogeneity in an older population
Even if subgroups on age are being considered, heterogeneity still plays a role. Many 
80-year-old individuals are healthy, while others have serious medical issues and dis-
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abilities. Take, for example, a vigorous 80-year-old person who is an informal caregiver, 
independently living and swimming three times a week; compared with an 80-year-old 
person living in a long-term care facility with severe dementia and wheelchair-bound 
due to a stroke; and, again, an 80-year-old person with a life expectancy of less than 
one year due to metastasized cancer. Whereas a generalized approach is suitable for 
25-year-old individuals who are physiologically relatively similar, it is clear from these 
three examples that in older age a different, individual approach is needed. Subgroups 
within the same age group of, for example, multiple comorbidities might be the next 
step - like the sensitivity analyses described in various chapters of this thesis.
2.3 Generalizability of study results
Oldest old (aged 85 years and over) is the fastest-growing segment of the total popula-
tion. The proportion of the population aged 85 years and older is projected to increase 
to 151% by 2030.29 However, the evidence base for the older population is sparse when 
compared to younger populations. It can be said that with increasing age, less evidence-
based decisions can be made. The most conclusive evidence for the effectiveness of 
preventive risk stratification and preventive risk factor modifications is derived from 
randomized controlled trials. It is important to note that most of the randomized trials 
exclude older individuals, especially individuals with complex and multiple chronic 
conditions.30 With increasing age the number of comorbidities increases and therefore 
especially the oldest old are underrepresented in these trials.
Nevertheless, results from these trials are being extrapolated to older individuals, 
assuming that the same risk reduction applies to the older population. This assump-
tion implies that older people, for example, experience the same treatment response 
as younger adults. However, it is known that most older people experience a change 
in physiology and have multiple chronic conditions that may affect pharmacokinetics 
and pharmacodynamics. Polypharmacy is most common in older persons and the use 
of multiple ‘other’ treatments may also affect treatment response due to drug-drug 
interactions. In addition, the presence of one disease may lessen the effect of prevent-
ing another. For example, the functional benefit of preventing a stroke through blood 
pressure control might be compromised by the presence of advanced multiple sclero-
sis. Therefore, we cannot assume that the same risk reduction would apply to an older 
population. The same applies to preventive risk stratification. Therefore, extrapolating 
evidence from younger populations to older populations is probably not appropriate.
Thus, although there is an urgent need for research in the older population, there are 
some difficulties concerning inclusion of the oldest old in clinical research. As mentioned 
before, comorbidities make it difficult to include older individuals in trials. The capacity 
to give informed consent with an increasing prevalence of cognitive impairment in the 
oldest old raises ethical dilemmas. Also, older people may have difficulty complying 
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with study requirements. This can, however, often be overcome by (for example) making 
home visits instead of requesting visits at the research center. Alternatives for random-
ized controlled trials, such as observational studies of representative populations with 
complete health records could provide useful information. The Leiden 85-plus Study is a 
good example of such an observational population-based study (Chapters 4, 5 and 7).
2.4 Competing risk
The statistical analysis of the data of an old age population also raises several meth-
odological issues, such as ‘competing risk’. Survival analysis provides valuable insight 
into how the risk of interest depends on time.31 When analysing survival data in which 
each patient can experience only one of several different types of events over follow-
up, e.g. cardiovascular mortality, the probabilities of the other events are referred to as 
‘competing risks’.32 The commonly used approach in healthcare literature is to consider 
all events of all other causes as censored, as well as the true censored observations due 
to end of the study or loss to follow-up. This assumes that all patients at risk at a certain 
point in time are representative for all patients alive at this point in time; censoring 
distribution is considered independent. In other words, the censoring is not associated 
with an altered chance of the event occurrence at any given moment.31 This assumption 
is questionable, other events might have occurred which prevents occurrence of the 
event of interest. When the event of interest is death due to cardiovascular disease, but 
the patient is censored due to death from another cause such as cancer, the chance of 
death is now zero, therefore the censoring assumption is violated. This is the compet-
ing risk problem; other risks are competing with cardiovascular disease to produce the 
event death.
The competing risk problem is especially true in old age where death from other 
causes plays a large role. However, we can never explicitly prove that competing risks 
are or are not independent. It cannot be determined whether a patient that died from 
cardiovascular disease would have died from e.g. cancer if he/she had not died from 
cardiovascular disease. Non-independent censoring can lead to biased results in a 
survival analysis. When competing risks are present, cause-specific hazard is interpre-
table but the interpretation of the survival curve for a cause-specific mortality may be 
difficult or questionable.32 A better approach is to acknowledge that patients may die 
from causes other than cardiovascular disease and adjust for the competing risks in the 
analysis - as described in Chapter 7. There is no clear cut-off point when you should 
adjust for competing risks. It is clear that when two unadjusted survival curves add up 
to > 100%, competing risk is definitely an issue in the analysis and direct interpretation 
of these curves is erroneous. The longer the follow-up and the higher the incidence of 
the competing risks, the more important the adjustment for competing risks will be.
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In conclusion, there is an urgent need for research among the older population. It is 
important to recognize the heterogeneity in this population regarding study design and 
the analysis, interpretation and extrapolation of the results. In addition, it is important 
to be aware of competing risks. This requires special research groups with experience, 
skills and interest in research among the older population.
3. ePidemiologiCal Considerations
Epidemiology studies the distribution and determinants of disease frequency in differ-
ent groups of people. Several epidemiological concepts are mentioned in this thesis 
or where considered in the analysis cited in this thesis. ‘Prediction’, ‘causation’ and 
‘confounding’ are some important concepts.
3.1 Prediction versus causation
Being able to predict future health is important for both patients and physicians. That 
is probably why there is increasing interest in (the methodology of) clinical prediction 
research. Prediction research includes both diagnostic prediction research and prog-
nostic research. Diagnostic prediction research investigates the ability of certain test 
results or variables to predict the presence or absence of a certain disease. Prognostic 
prediction research investigates the ability of various factors to predict a specific out-
come - as described in this thesis. Both types of prediction research may include a single 
variable/predictor or multiple variables/multiple predictors. Prediction studies aim to 
find (independent contributing) predictors or develop and validate prediction models. 
A prediction model does not infer causal relationships of the risk factors included with 
the outcome of interest.
A framework of four distinct but inter-related prognosis research themes have been 
proposed33:
1. Fundamental prognosis research: the course of health-related conditions in the 
context of the nature and quality of current care.
2. Prognostic factor research: specific factors (such as biomarkers) that are associ-
ated with prognosis.
3. Prognostic model research: the development, validation, and impact of statisti-
cal models that predict individual risk of a future outcome.
4. Stratified medicine research: the use of prognostic information to help tailor 




Chapters 2, 5 and 7 of this thesis can be considered as ‘prognostic factor research’. 
Variability in blood pressure over time, a decreasing trend in systolic blood pressure 
over time, and higher and increasing NT-proBNP levels are identified as predictors 
of cardiovascular mortality and morbidity in old age. ‘Prognostic model research’ is 
described in Chapter 6, in which prognostic models for cardiovascular morbidity and 
mortality are compared. Chapter 6 use prognostic information to help tailor treatment 
decisions and could therefore also be seen as ‘stratified medicine research’. Subgroups 
of older persons are identified who would benefit the most (or the least) from pravas-
tatin therapy to prevent (subsequent) cardiovascular events.
Etiologic epidemiologic research aims to find causal associations. It is research into 
the causes of a health outcome, i.e. to understand the factors that influence the incidence, 
distribution and control of certain diseases. In Chapter 3 of this thesis, factors associ-
ated with intra-individual variability in blood pressure are identified. The study design 
described in Chapter 3 does not allow to assess causal relationships, but is, however, 
a first step in elucidating the underlying mechanisms of variability in blood pressure 
and its association with cardiovascular morbidity, mortality and cognition. In the cur-
rent medical literature, etiologic and prediction research aims are frequently confused. 
Investigators tend to use principles from prediction research for their etiologic research 
questions, which results in misleading interpretation of risk factor findings at hand.
3.2 Confounding in prediction and etiologic research
Confounding is the ‘disturbance of the true effect’ and is a type of bias. Potential con-
founders may or may not distort the relationship between the determinant of interest 
and the outcome in the data, depending on the presence or absence of associations 
between these variables. If a factor is related to both the determinant and the outcome 
in an occurrence relation, the factor is a confounder. It should, however, not be a part 
of the causal relationship or causal chain between the determinant and the outcome.
In prediction research there is no central determinant for which the relationship to 
the outcome should be causally isolated from other outcome predictors as in causal 
research. Thus, confounding thus is not an issue in prediction research,34 and adjusting 
for confounding in prediction research is therefore erroneous. Nevertheless, multiple 
predictors can be analysed together to assess whether a predictor makes an indepen-
dent contribution.
In contrast, confounding plays an important role in etiological research. A determi-
nant is believed to be causally related to an outcome if the association remains when 
confounding is excluded. However, residual confounding by some unidentified factors 
needs to be excluded. A causal association is difficult to establish and is more probable 
when a large number of independent studies show consistent results; e.g. a temporal 
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relationship where the cause precedes the outcome; when there is a strong association; 
when there is a dose-response relationship; and when there is biological plausibility.35
3.3 Directed acyclic graphs
The structure of confounding can be represented by using causal diagrams or directed 
acyclic graphs (DAGs). A DAG is a graphical tool to represent qualitative expert knowl-
edge and a priori assumptions about the causal structure of interest and was first 
described by Judea Pearl in 2009.36 DAGs can be helpful in identifying confounding, 
selection bias, and strategies for the selection of variables of interest for e.g. regression 
analysis. A factor can be seen as a confounder that needs to be eliminated from a causal 
model, but may be an important component in a prediction model. In both cases, DAGs 
can be useful. Figure  1 shows three examples of DAGs. It is called ‘directed’ because 
the edges imply a direction. The arrow from, e.g., heart disease to aspirin (use) may 
cause aspirin use, but not the other way around. It is called ‘acyclic’ because there are 
no cycles: a variable cannot cause itself, either directly or through another variable.37 
Figure  1a shows an example of confounding. The effect of aspirin on the risk (reduc-
tion) of stroke is confounded if aspirin is more likely to be prescribed to individuals with 
heart disease that is both an indication for aspirin and a risk factor for stroke. Both heart 
disease and stroke are caused by atherosclerosis, an unmeasured variable. In this graph, 
heart disease is a confounder in the association between aspirin and stroke.
Causation and prediction can be linked. When it is known what causes a disease or 
event, it would be helpful in predicting its behavior. Causal thinking can help to develop 
accurate prediction models. However, a predictor does not have to be causally related 
to the outcome. An example may help to clarify this. In Figure  1b cigarette smoking 
has a causal effect on both nicotine-stained fingers and lung cancer. The absence of an 
arrow between nicotine-stained fingers and lung cancer indicates that having nicotine-
stained fingers does not have a causal effect on lung cancer. Nevertheless, nicotine-
stained fingers could still be a good predictor for lung cancer. Another example is the 
predictor homocysteine (Figure 1c). There is no causal relation between homocysteine 
and cardiovascular disease. Although the common factor is still unknown, homocyste-
ine is a good predictor for cardiovascular disease.12
In conclusion, prediction and etiologic research are two distinct but related fields of 
research in which different methodological aspects apply. Confounding is one of these 
aspects. DAGs can help to select important variables for both etiologic and prediction 
research. However, to avoid confusion and misinterpretation, it is of utmost importance 
to describe whether the research is aimed at identifying predictors (or prediction mod-
els) or identifying causal associations.
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4. reCommendations For Future researCh
There is a need for a stronger evidence base and clearer guidelines for older people as 
a whole, and for cardiovascular risk prevention in old age in particular. Future research 
among older people, especially involving people aged 75 years and older, is needed 
before evidence-based recommendations on cardiovascular risk prevention can be 
formulated for general practitioners and physicians in general.
Heart disease Stroke Aspirin 
Atherosclerosis 
Cigarette smoking Lung cancer Nicotine stained fingers 
Unknown common cause Cardiovascular disease Homocysteine 
Figure 1. Directed acyclic graphs
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With regard to cardiovascular risk prediction in old age, an important step is to 
develop and validate risk prediction models in the oldest old in order to select high-risk 
older individuals. The inclusion of (multiple) NT-proBNP measurements and possibly 
other emerging risk factors such as troponin T might be promising. Serological risk 
factors might be more relevant in an older population than imaging techniques that 
test for subclinical atherosclerotic disease, like the use of the calcium score which is 
generally not recommended older patients.38 More studies are needed to evaluate the 
appropriate time intervals for NT-proBNP testing, to evaluate the clinical thresholds 
for changes in NT-proBNP levels over time, and to evaluate the use of NT-proBNP in 
risk assessment in the oldest old. The second step is to study the effectiveness of the 
preventive strategies including the (new) risk prediction models in the older population 
and, when proven effective, to study how these strategies can be implemented.
With regard to the prevention of cardiovascular disease, future research on the ef-
fectiveness of statin therapy in the oldest old, and possibly also the differential effects of 
various antihypertensive drugs on variability in blood pressure and cardiovascular risk 
and mortality, is warranted. Besides the aim of lowering the level of blood pressure in 
hypertensive patients, additional benefit might be obtained from reducing variability 
in blood pressure. This requires additional studies on the underlying mechanisms of 
blood pressure variability; for this, the association between the trend in interleukin-6 
and variability in blood pressure could be a target for future research.
5. what does this thesis add?
By studying classical and new cardiovascular risk predictors in old age in an observational 
and a clinical trial, this thesis contributes to improved knowledge about cardiovascular 
risk prediction in old age. This can help to optimize risk stratification and subsequent 
prevention of cardiovascular disease in older persons. The use of multiple blood pres-
sure measurements in cardiovascular risk prediction and risk stratification in old age is 
promising. Not only low systolic blood pressure, but also a decreasing trend in systolic 
blood pressure independently contribute to a prediction of mortality in the oldest old. 
The association between low systolic blood pressure and increased mortality risk found 
in old age is not influenced by the absence or presence of heart failure. In addition, 
blood pressure variability is associated with increased risk for coronary heart disease 
and mortality in older high-risk populations. Since blood pressure is one of the most 
frequently recorded measurements in medical files, the use of multiple blood pressure 
measurements in cardiovascular risk prediction in old age is also feasible.
In addition, in old age, the serological biomarker NT-proBNP may play an important 
role in the prediction of cardiovascular events and mortality, as well as treatment ef-
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fect. The cardiovascular risk factors identified in this thesis can provide evidence-based 
information about cardiovascular risk factors and predicted treatment effect. This can 
help physicians (mainly general practitioners) in their discussions with patients on the 
cardiovascular risks and treatment benefits when considering the difficult decision to 
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Cardiovascular disease is the leading cause of death worldwide. With increasing age, 
incidence and prevalence of cardiovascular disease increase as well. Therefore, the 
impact of cardiovascular disease is high in old age. Due to the expected increasing 
longevity and the aging population in the Netherlands, the number of older persons 
and therefore the impact of cardiovascular disease is projected to raise even further. 
Therefore, focus on prevention and risk prediction of cardiovascular disease in old age 
is of interest. Many physicians face the dilemma whether or not to start preventive treat-
ment in old age, especially in primary prevention. To help physicians decide whether 
to advise preventive medication to their older patients, prediction of those at highest 
or lowest (relative) risk using (preferably) inexpensive and easy to use cardiovascular 
risk factors is important. However, in old age there is a lack of good cardiovascular risk 
predictors, as the classical cardiovascular risk factors tend to lose their predictive value. 
For many serological biomarkers the association with cardiovascular disease has been 
studied predominantly in middle age and not in old age. The use of multiple blood 
pressure measurements expressed in the variability or trends in blood pressure and the 
serological biomarker N-terminal pro-B-type natriuretic peptide (NT-proBNP) could be 
interesting candidates in cardiovascular risk prediction in old age. Selection of high risk 
blood pressure patterns or high risk NT-proBNP levels in old age could be an important 
and easily available step in the successful prediction of mortality and cardiovascular 
morbidity in this age group. Therefore, the general aim of this thesis is to study classical 
and new cardiovascular risk predictors in old age, in order to optimize risk stratification 
and subsequent prevention of cardiovascular disease in older persons (Chapter 1).
Part 1 Multiple blood pressure measurements in cardiovascular risk 
prediction in old age
Variability in blood pressure predicts cardiovascular disease in young- and middle-
aged subjects, but relevant data for older individuals are sparse. Therefore, Chapter 2 
studied the impact of visit-to-visit variability in blood pressure in older patients. We ex-
amined the association between visit-to-visit variability in blood pressure and incident 
cardiovascular disease in the PROSPER study. Higher visit-to-visit variability in systolic 
blood pressure, diastolic blood pressure and pulse pressure was associated with an 
increased long-term risk of (vascular) death, even after adjustment for respective mean 
blood pressure levels, the use of antihypertensive medication and other risk factors. 
Persons with higher variability in diastolic blood pressure also had an increased risk 
for coronary events and hospitalization for heart failure. Variability in pulse pressure 
(but not diastolic blood pressure or systolic blood pressure) was somewhat associated 
with long-term risk of stroke. The principal finding of this study was that in old age, 
variability in diastolic blood pressure is more strongly associated with incident cardio-
vascular disease and (vascular) death than systolic pressure variability. To elucidate the 
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underlying mechanisms of variability in blood pressure in old age, Chapter 3 studies 
the association between biological factor(s) and variability in blood pressure. Markers 
of inflammation, endothelial function, renal function and glucose homeostasis were 
included in the analysis. Inflammation (as evidenced by higher levels of interleukin-6) at 
baseline was consistently associated with higher variability in systolic blood pressure, 
diastolic blood pressure, and pulse pressure, even when adjusted for cardiovascular risk 
factors. Markers of endothelial function, renal function and glucose homeostasis were 
not or to a minor extent associated with blood pressure variability.
Observational studies have shown that not high, but low systolic blood pressure pre-
dicts increased mortality in old age. A plausible explanation is that (subclinical) heart 
failure may, at least pertly, underlie this ‘inversion of risk prediction’. The aim of Chapter 
4 was to investigate whether low systolic blood pressure is predictive for increased risk 
of death in the oldest old without heart failure, defined by low levels of NT-proBNP, 
as well as in the oldest old with high levels of NT-proBNP. This study was performed 
within the Leiden 85-plus Study, but restricted to the nonagenarian participants. We 
compared differences in risk of death between 90-year old persons with low systolic 
blood pressure and high systolic blood pressure for persons with low NT-proBNP (i.e. 
without heart failure) and for persons with high NT-proBNP. Persons with low systolic 
blood pressure had a two-fold increased risk of death compared to persons with high 
systolic blood pressure, both in the group with low NT-proBNP and in the group with 
high NT-proBNP. The main finding of this study was that in the oldest old, the absence or 
presence of heart failure does not influence the prognostic value of low systolic blood 
pressure regarding risk of death.
In Chapter 5 the use of multiple blood pressure measurements to assess the trend in 
systolic blood pressure in cardiovascular risk prediction in the oldest old was studied in 
the Leiden 85-plus Study. We examined the association between the trend in systolic 
blood pressure between the age of 85 and 90 years, and systolic blood pressure at age 
90 years and risk of death. The role of comorbidities and the use of antihypertensive 
medication in these associations were also investigated. Participants who had a de-
creasing trend in systolic blood pressure had a higher risk of death, independent of their 
blood pressure at age 90 years. Participants with low systolic blood pressure at age 90 
years also had an increased risk of death, independent of the preceding trend in systolic 
blood pressure. Both for participants with and without antihypertensive medication 
and with or without (cardiovascular) comorbidities. Therefore, it was concluded that, in 
very old age, both decreasing trend in systolic blood pressure over the previous 5 years 




Part 2 N-terminal pro-brain natriuretic peptide levels in cardiovascular risk 
prediction in old age
As many more patients are surviving their initial cardiovascular event, prediction of re-
current events becomes increasingly important. However, no risk scores for prediction 
of recurrence risk and/or treatment effect exist for the general older population. There-
fore, the aim of Chapter 6 was to assess predictive values for recurrent cardiovascular 
disease, of models with age and sex, traditional cardiovascular risk markers, and SMART 
risk score, with and without NT-proBNP in old age. Also, to assess treatment effect of 
pravastatin across low and high risk groups identified by these models. This study was 
again performed within the PROSPER study, but restricted to those participants with 
a history of cardiovascular disease at baseline. The models with age and sex, tradi-
tional risk markers and SMART risk score had comparable predictive values. Addition 
of NT-proBNP to these models improved area under the curves, and net reclassification 
improvements were 41%, 39% and 25%, respectively. For the model with age, sex and 
NT-proBNP, the absolute risk reduction in cardiovascular morbidity and mortality was 
0.86% (number needed to treat 116) in the low third of predicted risk and 6.2% (number 
needed to treat 16) in the high third of predicted risk. The principal finding of this study 
was that NT-proBNP is a promising cardiovascular risk predictor in old age. A minimal 
model with age, sex and NT-proBNP improves prediction of recurrent cardiovascular 
disease and mortality, and is as good as complex risk models including NT-proBNP.
An increase of NT-proBNP over time is further studied in Chapter 7. The aim of this study 
was to assess whether an increase in NT-proBNP lever over time is still associated with 
cardiac disease and death in very old age, independent of (a change) in renal function. 
Within the Leiden 85-plus Study changes in NT-proBNP levels between age 85 and 90 
years and their associations with incident cardiac disease, risk of (cardiovascular) death 
and renal function was studied. Participants with increasing NT-proBNP levels more 
frequently developed heart failure and atrial fibrillation between the age of 85 and 90 
years, even when adjusted for renal function. Increasing NT-proBNP level between age 
85 and 90 years was also associated with and increased risk of (cardiovascular) death 
after the age of 90 years, even when adjusted for renal function. In conclusion, in the 
oldest old, increase in NT-proBNP is associated with incident heart failure and atrial 
fibrillation, independent of renal function. Also, this increase still reflects increased risk 
of (cardiovascular) death, independent of decreasing renal function.
Chapter 8 is a general discussion and describes the context of cardiovascular risk pre-
diction and prevention and highlights the themes discussed in this thesis. Due to the 
increasing heterogeneity, it is essential to consider each person as an individual when 
decisions are made regarding initiating risk prediction and when preventive strategies 
are made. The risk factors described in this thesis can be useful. Next, research among 
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an older population is discussed including its challenges resulting in a recommendation 
for special research groups with experience, skills and interest in research among the 
older population. In addition, important epidemiological themes emerging from this 
thesis, including the differences between prediction and causation and the concept 
of confounding, are explored. Prediction and etiologic research are two distinct but 
related fields of research in which different methodological aspects apply. To avoid 
confusion and misinterpretation, it is of utmost importance to describe whether the 
research is aimed at identifying predictors (or prediction models) or identifying causal 
associations. After the recommendations for future research, which highlights the need 
for a stronger evidence base and clearer guidelines for older people as a whole, and for 








Hart- en vaatziekten zijn doodsoorzaak nummer één wereldwijd. Met het stijgen van 
de leeftijd, stijgt ook het aantal nieuwe en bestaande gevallen van hart- en vaatziekten 
waardoor de impact van hart- en vaatziekten op hoge leeftijd groot is. Door de te ver-
wachten toenemende vergrijzing, zal ook in Nederland het aantal (oudste) ouderen met 
hart- en vaatziekten toenemen en zal de impact hiervan alleen maar groter worden. 
Aandacht voor preventie en risicopredictie van hart- en vaatziekten is daarom zeker ook 
op hoge leeftijd van belang. Er bestaat bij veel (huis)artsen een dilemma om al dan niet 
te starten met preventieve medicatie bij oudere patiënten, zeker als het gaat om oudere 
patiënten die geen hart- en vaatziekten hebben gehad (primaire preventie).
Het kennen van de mate van risico (risicopredictie) kan (huis)artsen ondersteunen in 
hun keuze om al dan niet preventieve medicatie te adviseren aan hun oudere patiënten. 
Het voorspellen van patiënten met het hoogste of juist laagste (relatieve) risico op het 
krijgen van hart- en vaatziekten is hierbij belangrijk. Het ontbreekt echter aan goede 
risicofactoren op hoge leeftijd. De erkende klassieke risicofactoren verliezen hun voor-
spellende waarde bij het stijgen van de leeftijd. De nieuwe risicofactoren zijn vooral 
onderzocht op middelbare leeftijd en niet op hoge leeftijd. Dit betekent dat het op dit 
moment niet goed mogelijk is om het risico op hart- en vaatziekten voor ouderen in te 
schatten. Interessante potentiële nieuwe risicofactoren op hoge leeftijd zijn het gebruik 
van meerdere bloeddrukmetingen uitgedrukt in bloeddrukvariabiliteit of bloeddruk-
patroon en het gebruik van N-terminaal pro-‘brain natriuretic peptide’ (NT-proBNP). 
Selectie van hoog risico patiënten door gebruikmakend van deze nieuwe risicofactoren 
kan een belangrijke stap zijn in de succesvolle voorspelling van toekomstige hart- en 
vaatziekten (hoofdstuk 1).
Het doel van dit proefschrift is het bestuderen van klassieke en nieuwe risicofactoren 
voor hart- en vaatziekten op hoge leeftijd, ten einde de risicostratificatie en daarmee 
uiteindelijk ook preventie van hart- en vaatziekten op hoge leeftijd te verbeteren.
Deel 1 Gebruik van meerdere bloeddrukmetingen in de cardiovasculaire 
risicopredictie op hoge leeftijd
De ‘bezoek-tot-bezoek’-bloeddrukvariabiliteit is een risicofactor voor hart- en vaatziek-
ten bij jongeren en personen van middelbare leeftijd. Het was onbekend of dit ook 
geldt op hogere leeftijd, daarom was het doel van hoofdstuk 2 om te onderzoeken 
of ‘bezoek-tot-bezoek’-bloeddrukvariabiliteit voorspellend is voor hart- en vaatzieken 
en/of sterfte aan hart- en vaatziekten op hoge leeftijd. De associatie tussen ‘bezoek-
tot-bezoek’-bloeddrukvariabiliteit en incidente hart- en vaatziekten werd onderzocht 
in de PROSPER studie. Hogere ‘bezoek-tot-bezoek’-bloeddrukvariabiliteit in systolische 
bloeddruk, diastolische bloeddruk en polsdruk was op lange termijn geassocieerd met 
een hoger risico op sterfte (aan hart- en vaatziekten), ook na correctie voor gemiddelde 
Chapter 10
166
bloeddruk, gebruik van bloeddrukverlagende medicatie en andere risicofactoren. 
Deelnemers met een hogere variabiliteit in diastolische bloeddruk hadden daarnaast 
ook een hoger risico op het krijgen van een hartinfarct en ziekenhuisopname voor hart-
falen. De belangrijkste bevinding van dit onderzoek was dat variabiliteit in diastolische 
bloeddruk op hoge leeftijd sterker geassocieerd is met hart- en vaatzieken en/of sterfte 
aan hart- en vaatziekten dan variabiliteit in systolische bloeddruk.
Om de onderliggende mechanismen van bloeddrukvariabiliteit op te helderen werden 
in hoofdstuk 3 de associaties tussen biologische factoren en bloeddrukvariabiliteit 
onderzocht. Markers van ontsteking, endotheelfunctie, nierfunctie en de glucose 
homeostase werden geïncludeerd in de analyses. Ontsteking (gemeten door hogere 
niveaus van interleukine-6) bij aanvang van de studie was consequent geassocieerd 
met hogere variabiliteit in systolische en diastolische bloeddruk en polsdruk, ook wan-
neer werd gecorrigeerd voor klassieke risicofactoren voor hart- en vaatziekten. Markers 
van endotheelfunctie, nierfunctie en de glucose homeostase waren niet of slechts in 
geringe maten geassocieerd in bloeddrukvariabiliteit.
In tegenstelling tot in jongere leeftijdsgroepen is op zeer hoge leeftijd niet een hoge, 
maar juist een lage systolische bloeddruk geassocieerd met verhoogd sterfterisico. 
Mogelijk is (subklinisch) hartfalen verantwoordelijk voor deze ‘omdraaiing van risico-
predictie’. Het doel van hoofdstuk 4 was om te onderzoeken of lage systolische bloed-
druk voorspellend is voor een hoger risico op sterfte bij de oudste ouderen, ook als er 
geen sprake is van hartfalen, blijkend uit een laag-normaal NT-proBNP. De studie was 
onderdeel van de Leiden 85-plus Studie, maar beperkte zich tot de 90-jarige deelne-
mers. Wij vergeleken het sterfterisico van 90-jarigen met een lage systolische bloed-
druk met het sterfterisico van 90-jarigen met een hoge systolische bloeddruk, zowel in 
de groep deelnemers met een laag-normaal NT-proBNP (waarbij hartfalen uitgesloten 
kon worden) als in de groep met een hoog NT-proBNP. Negentigjarige deelnemers met 
een lage systolische bloeddruk hadden een twee maal verhoogd sterfterisico ten op-
zichte van 90-jarigen met een hoge systolische bloeddruk, zowel in de groep met een 
laag-normaal NT-proBNP als in de groep met een hoog NT-proBNP. Concluderend kan 
worden gesteld dat ook als er geen sprake is van hartfalen een lage systolische bloed-
druk geassocieerd is met een verdubbeld sterfterisico bij de oudste ouderen. De aan- of 
afwezigheid van hartfalen beïnvloedt de prognostische waarde van lage systolische 
bloeddruk wat betreft sterfterisico niet.
Het doel van hoofdstuk 5 was om bij 90-jarigen in de Leiden 85-plus Studie na te gaan 
of het gebruik van een 5-jaars patroon van metingen van de systolische bloeddruk 
toegevoegde waarde heeft voor de voorspelling van de sterfte in vergelijking met 
een enkelvoudige bloeddrukmeting op de leeftijd van 90 jaar. Wij onderzochten de 
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associatie tussen systolische bloeddruk op 90 jaar en de vijf voorafgaande jaren (bloed-
drukpatroon 85-90 jaar) en het sterfterisico. De mogelijke invloed van comorbiditeit en 
gebruik van bloeddrukverlagende medicatie op deze associaties werd ook onderzocht. 
Negentigjarige deelnemers met een dalende systolische bloeddruk hadden een hoger 
sterfterisico in vergelijking met deelnemers met een stabiele systolische bloeddruk 
over 5 jaar, onafhankelijk van hun systolische bloeddruk op 90 jaar. Een lage bloeddruk 
op 90 jaar was ook geassocieerd met een hoger sterfterisico, ongeacht het bloeddruk-
patroon in de vijf voorgaande jaren. Dit gold voor zowel deelnemers met en zonder 
bloeddrukverlagende medicatie, en voor deelnemers met en zonder comorbiditeit. De 
belangrijkste bevinding van dit onderzoek was dat zowel een dalende systolische bloe-
ddruk over vijf jaar als de huidige systolische bloeddruk beiden onafhankelijk bijdragen 
aan de voorspelling van het sterfterisico op zeer hoge leeftijd.
Deel 2 N-terminaal pro-‘brain natriuretic peptide’ in de cardiovasculaire 
risicopredictie op hoge leeftijd
Steeds meer patiënten zullen hun eerste hart- of vaatziekte overleven, daarom wordt het 
voorspellen van herhaalde hart- of vaatziekte en sterfte steeds belangrijker. Er is voor 
ouderen met een voorgeschiedenis van hart- en vaatziekten echter geen gevalideerde 
risicoscore voor herhaalde hart- en vaatziekte en/of sterfte. Mogelijk is NT-proBNP hierin 
bruikbaar. Daarom werd in hoofdstuk 6 onderzocht in hoeverre modellen met leeftijd 
en geslacht, traditionele risicofactoren en de SMART risicoscore herhaalde hart- en 
vaatziekten adequaat voorspellen op hogere leeftijd. Daarnaast werd onderzocht of de 
voorspellende waarde van deze modellen verbetert door het toevoegen van NT-proBNP 
aan deze modellen. Tot slot werd onderzocht of deze modellen ook het behandeleffect 
met pravastatine voorspellen. Deze studie was onderdeel van de PROSPER studie, maar 
beperkte zich tot de deelnemers met een voorgeschiedenis van hart- en vaatziekten bij 
aanvang van de studie. De modellen met leeftijd en geslacht, traditionele risicofactoren 
en de SMART risicoscore hadden vergelijkbare voorspellende waarden. Het toevoegen 
van NT-proBNP aan deze modellen verbeterde de voorspellende waarde. Voor het 
model met leeftijd, geslacht plus NT-proBNP was de absolute risicoreductie in hart- en 
vaatziekten en sterfte 0,86% in het laagste tertiel van voorspeld risico en 6,2% in het 
hoogste tertiel. Dat betekent dat 16 mensen met een hoog voorspeld risico behandeld 
moeten worden (‘number needed to treat’) met pravastatine gedurende 2.5 jaar om één 
hart- en vaatziekte of sterfte te voorkomen. Om ditzelfde resultaat te behalen moeten 
in de groep met een laag voorspel risico 116 mensen 2.5 jaar behandeld worden met 
pravastatine. Deze studie liet zien dat NT-proBNP een veelbelovende risicopredictor is 
op hoge leeftijd Een eenvoudig model met leeftijd, geslacht plus NT-proBNP presteert 
net zo goed als meer complexe modellen met NT-proBNP.
Chapter 10
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In hoofdstuk 7 werd bestudeerd of een stijging in NT-proBNP over tijd geassocieerd is 
met totale en oorzaakspecifieke sterfte en incidente hart- en vaatziekten bij de oudste 
ouderen. Hierbij was een belangrijke vraag wat de rol is van (verandering in) nierfunctie. 
Binnen de Leiden 85-plus Studie werden de veranderingen in NT-proBNP tussen de 
leeftijd van 85 en 90 jaar en de associaties met het optreden van hart- en vaatziekten, 
sterfte en nierfunctie onderzocht. Deelnemers met een stijgend NT-proBNP over 5 jaar 
ontwikkelden vaker hartfalen en atriumfibrilleren tussen 85 en 90 jaar, ook wanneer 
gecorrigeerd werd voor de nierfunctie. Een stijging in NT-proBNP tussen 85 en 90 jaar 
was ook geassocieerd met een hoger sterfterisico na 90 jaar, zelfs na correctie voor de 
nierfunctie. Concluderend kan worden gesteld dat een stijging in NT-proBNP is geas-
socieerd met incident hartfalen en atriumfibrilleren, onafhankelijk van de nierfunctie. 
Daarnaast is een stijging in NT-proBNP ook op zeer hoge leeftijd nog steeds voor-
spellend voor een hoger sterfterisico, onafhankelijk van de (verandering in) nierfunctie.
hoofdstuk 8 is een algemene discussie waarin de belangrijkste thema’s worden be-
sproken die uit dit proefschrift naar voren kwamen. Het beschrijft de context van de 
predictie en preventie van hart- en vaatziekten op hoge leeftijd. Door de toename van 
heterogeniteit met het toenemen van de leeftijd is het essentieel om iedere persoon als 
individu te beschouwen en te behandelen als het gaat om beslissingen rond risicopre-
dictie en preventieve behandeling. De risicofactoren zoals beschreven in dit proefschrift 
kunnen hierbij een rol spelen. Vervolgens wordt het doen van wetenschappelijk onder-
zoek in een oudere populatie in zijn algemeenheid besproken. Er is dringend behoefte 
aan onderzoek binnen de oudere populatie. Onderzoek naar en binnen deze doelgroep 
brengt uitdagingen met zich mee, wat resulteert in een aanbeveling voor specifieke 
onderzoeksgroepen met ervaring, vaardigheden en interesse in het onderzoek doen 
binnen een oudere populatie. Aansluitend worden belangrijke epidemiologische 
thema’s die uit dit proefschrift naar voren komen besproken, waaronder het verschil 
tussen predictie-onderzoek, waarbij je onderzoekt of je met bepaalde metingen iets kan 
voorspellen, en etiologisch onderzoek, waarbij gezocht wordt naar een onderliggende 
oorzaak. Predictie-onderzoek en etiologisch onderzoek zijn twee verschillende, maar 
gerelateerde onderzoeksgebieden waarbij verschillende methodologische aspecten 
van belang zijn. Om misverstanden te voorkomen is het belangrijk om te beschrijven of 
een onderzoek als doel heeft om voorspellers òf oorzakelijke factoren te identificeren. 
Daarnaast worden aanbevelingen gedaan voor vervolgonderzoek op het gebied van 
hart- en vaatziekten bij ouderen, waarin het belang van een sterkere empirische onder-
bouwing van richtlijnen en duidelijkere richtlijnen benadrukt wordt voor ouderen in 
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Onderzoek doe je niet alleen. Zonder de steun, inspiratie en kritische blikken van velen 
om mij heen was dit proefschrift nooit tot stand gekomen. Dit dankwoord geeft mij de 
gelegenheid iedereen te bedanken die op enige wijze bij dit onderzoek betrokken is 
geweest.
Naast het eigenlijke werk tijdens het promotietraject is de plek waar je werkt voor mij 
minstens zo belangrijk gebleken. Daarom wil ik ook alle collega’s van de afdeling Public 
Health en Eerstelijnsgeneeskunde van het LUMC bedanken voor de fijne werksfeer, 
inspirerende gesprekken, hun enthousiasme en hun betrokkenheid. Een aantal mensen 
wil ik nog in het bijzonder noemen. Wendy, samenwerken aan TRUST gaf een andere di-
mensie aan het werk als onderzoeker. Wat een fijne collega was je en een lieve vriendin 
ben je. Jeanet, Petra en Yvonne, onderzoek op het gebied van cardiovasculaire ziekten 
bij ouderen leverde ons vanaf het begin een betekenisvolle band op, nu is er zo veel 
meer. Bedankt dat jullie er zijn.
De onderzoeksperiode in Glasgow heeft mijn wetenschappelijke blik verruimd. Dear 
David, thank you for your support to come to Glasgow. I am grateful for the opportunity 
to work with you and your team. Our collaboration was and is inspiring and intellectu-
ally stimulating for me.
Om een promotietraject tot een succesvol einde te brengen is een goede samenwerk-
ing met promotor en co-promotor essentieel. Jacobijn, jouw kritische wetenschap-
pelijke blik heeft mij gestimuleerd. Jij steunde mij niet alleen op wetenschappelijk, 
maar ook op persoonlijk vlak. Ik ben blij dat wij voorlopig nog samen kunnen blijven 
werken. Wouter, wat heb jij mij veel geleerd de afgelopen jaren. Mijn promotietraject 
in combinatie met de huisartsopleiding vergde hier en daar behoorlijk wat flexibiliteit 
en jij steunde mij daarin. Door jou ben ik de afgelopen jaren gegroeid in mijn werk als 
onderzoeker. Jouw enthousiasme voor het vak is aanstekelijk. Mijn ‘ex-promotor’ Pim 
wil ik ook bedanken. Jouw visie op de huisartspraktijk was een aanvulling tijdens het 
begin van mijn promotietraject.
Daarnaast wil ik mijn dank betuigen aan de leden van mijn promotiecommissie prof. dr. 
Yvo Smulders, prof. dr. Theo Stijnen en dr. Eric Moll van Charante voor de tijd die zij vrij 
wilden maken om mijn proefschrift te beoordelen en met mij van gedachten te willen 
wisselen tijdens de verdediging ervan.
Al mijn opleiders, huisartsbegeleiders en gedragswetenschappers van de huisartsoplei-
ding wil ik bedanken voor de ruimte die zij mij hebben gegeven om naast mijn opleiding 
ook mijn promotieonderzoek voort te zetten. In het bijzonder wil ik Paul Jonas en Ans 
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van der Salm bedanken. Paul, aan het einde van mijn eerste jaar in de huisartsenoplei-
ding heb jij mij het laatste zetje gegeven te gaan solliciteren voor de AIOTHO plek. 
Ans, bij jou in de praktijk ben ik echt de huisarts-onderzoeker geworden die ik nu ben. 
Daarnaast wil ik de SBOH bedanken voor de mogelijkheid mijn promotieonderzoek te 
combineren met de opleiding tot huisarts.
Antonette, wat bijzonder dat ik jouw paranimf mocht zijn en wat fijn dat jij mijn para-
nimf wilt zijn op deze dag. Wat hebben wij samen gezwoegd op ‘onze kamer’. Bedankt 
voor alles.
Lieve Yorick, ik ben blij dat jij mij als paranimf bij wilt staan. Ik ben er trots op jouw zus te 
zijn. Wij steunen elkaar door dik en dun en dat vind ik heel bijzonder. Bedankt voor het 
mooie ontwerp van de omslag van mijn proefschrift, dit betekent veel voor mij.
Lieve pap en mam, dank voor jullie onvoorwaardelijke steun en vertrouwen. Jullie heb-
ben mij altijd gestimuleerd om mijn ambities waar te maken. Wat fijn om te beseffen dat 
ik uit zo´n warm nest kom. Bedankt dat jullie er altijd voor mij zijn.
Familie en vrienden, bedankt voor jullie interesse, steun en vertrouwen. Bij jullie vond 
ik de ontspanning en het klankbord dat ik nodig had. Oma’s en opa, wat bijzonder dat 
jullie dit nog mee mogen maken.
En ten slotte natuurlijk Remco, wat een geluk dat jij in mijn leven bent gekomen. Be-
dankt voor jouw steun, betrokkenheid en de ruimte die jij mij geeft mijn ambities waar 
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